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“We sift over our fingers the first grains of this great 
outpouring of information and say to ourselves that 
the world be helped by it.“ 
(Margaret Oakley Dayhoff in 1968 about the first Atlas of 
Protein Sequence and Structure) 
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Introduction 
Human beings are remarkable machines. Zoom in on cellular processes and you will be stunned by 
the amount of activities performed to keep a cell in good shape: energy metabolism, production of 
new proteins, transfer of signals, defense against pathogens, growing and dividing, etc. Nearly all 
these processes, from cell-growth to cell-death, are carried out by proteins, the work horses in your 
body. The fact that proteins are important for almost every biological process is the reason that lots 
of research is focused on proteins, their functions, their pathways, and their interactions. Different 
fields of research are looking at different features of these proteins. Research in the field of cell 
biology or physiology, for example, is often focused on the behavior of a complete protein(complex) 
during cellular processes, whereas research in the field of organic chemistry  tries to manipulate the 
protein at the atomic level in order to stimulate a specific reaction. Structural bioinformaticians 
usually study the protein’s structure in detail at the atomic level; trying to understand its 
mechanism, the binding of ligands or the effect of mutations. They use computers and specialized 
software to visualize, study, and manipulate the protein’s structure, function, and dynamics in silico. 
In this thesis we show that the study of a protein’s 3D-structure can contribute to lab-research by 
providing basic understanding of the proteins, answers to biomedical questions, and ideas for new 
experiments. In the recent years, the use of Next Generation Sequencing (NGS) has rapidly changed 
the ways research was done in many areas of the life-sciences field. In contrast to studies that look 
at the behavior of a mutated protein in context of the whole cell, NGS makes it possible to perform a 
very detailed study of these mutations on the DNA-level. This requires the use of specialized tools 
and software that are often not easily available to every life-scientist, making it necessary for them 
to collaborate with bioinformaticians in even the smallest project.  
 The work described in this thesis aims to make bioinformatics more well-known, more 
accessible, and more understandable. Our approach culminated in Project HOPE, a system that 
makes the analyses of molecular phenotypic effects of mutations easily available and 
understandable for everyone working in the field of (bio)medical science. The results of our 
collaborations with (bio)medical scientists are described in chapter 5 and provide nice examples of 
translational science. During the numerous projects carried out in collaboration with medical 
scientists we found that we sometimes literally had to make translations in the communication 
between the lab and bioinformatics. Therefore, we set up a bioinformatics-wiki as an online 
dictionary that explains difficult bioinformatics keywords using as much as possible the jargon of life-
sciences. We hope that our work helps bioinformatics to become a standard tool in everyday lab-
research and that together we can push forward the limits of our research. We truly believe that in 
translational science 1+1=3.  
 
Figure 1.1a: The basic structure of amino acids consists of a central carbon atom connected to a proton (H), an 
amino-group (red), a carboxyl-group (cyan) and a side chain (purple). It is the side chain that gives each amino 
acid its unique properties. In the case of proline, the side chain connects to the central carbon atom instead of 
the proton resulting in a rigid ring-structure. Figure 1.1b: The amino acids in a protein are connected to each 
other via a peptide bond. This bond connects the carboxyl-group to a residue with the amino group of the next 
residue.  
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Proteins & amino acids: building blocks of life 
Over 50% of the mutations known in the Human Gene Mutation Database involve a mutation that 
affects the protein structure1. Therefore, the central subject of human genetics bioinformatics is 
proteins, or more precise, the 3D-structure of proteins. Proteins consist of smaller building blocks 
called amino acids or residues. In general, the proteins in the human body consist of 20 different 
types of amino acids. Nine of these amino acids are essential for a normal healthy adult, meaning 
that our body cannot synthesize these residues and therefore we need to include them in our diet. 
The other amino acids (and their derivatives) normally can be produced in our body.  
The amino acids are all built up according to similar structural layout. The central carbon 
atom (Cα) is connected to four different chemical groups: an amino (NH2)-group, a carboxyl (COOH)–
group, a hydrogen (H)-atom and one variable group known as the side chain or R-group. This is 
illustrated in figure 1.1a. All amino acids have this same basic structure, but their side chains differ. 
In a protein, amino acids are connected to each other through a peptide bond. The carboxyl-group 
of one amino acid is connected to the amino-group of the next amino acid. As a result, a protein 
contains a ‘backbone’ in which we can find the amino-group, the central carbon atom, and the 
carboxyl-group (carbonyl-group now) of a residue.   
As illustrated in figure 1.1b, the side chains of the amino acids are pointing away from this 
backbone. The side chain gives each amino acid its own unique properties like hydrophobicity 
(tendency to hide from water), aromaticity (structure that contains a flat ring with special chemical 
properties), size, and charge. In the case of cysteine the sulfur atom in the side chain can participate 
in a disulfide bond with another cysteine. This property of cysteine is often related to the stability of 
the protein. The side chain of glycine consists of just one hydrogen-atom, making glycine the most 
flexible residue of all because there is no side chain that sterically limits the conformations of the 
backbone. Glycine is often found at positions in the protein structure where a certain amount of 
flexibility is required or where unusual torsion angles are needed. Figure 1.2 shows the structure of 
all 20 amino acids. 
It is these differences between the amino acids that form the basis of Richard Grantham’s 
amino acid substitution matrix. Grantham scored each amino acid on its composition (c), volume (v) 
and polarity (p)2. He reasoned that two amino acids can be substituted for another when they have 
similar c, p, and v scores. The Grantham score is still used a lot nowadays to score the severity of 
newly found point mutations. 
 
During protein production, the amino acids are all linked together in a long chain that is not 
functional yet. This chain needs to fold into the correct conformation to become a functional 
protein. Protein folding is dictated by interactions between the amino acids; hydrophobic side chains 
want to sit in the core of the protein to avoid contact with water, charged residues will attract an 
opposite charge, and proline and glycine will facilitate sharp turns where required. Directed by these 
forces, and helped by chaperones when needed, a protein will eventually fold into a conformation in 
which it can fulfill its function. 
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Figure 1.2: The 20 different amino acids. The backbone is coloured red and shown here as fully protonated. 
The side chains are coloured black and shown in their neutral form. The residues are labeled with their 1-letter 
code, 3-letter code and full names. 
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The structure of a protein can be described at four different levels: 
 Primary Structure: This is simply the order of amino acids in the protein, also known as the 
protein sequence. For instance, the protein in figure 1.3 has the sequence “AEMLHDILQ”. 
The primary structure is often used in databases and software using the 1-letter code and 
can be represented as simple text.  The order of amino acids is encoded in our DNA.  
 Secondary Structure: When a protein starts folding, it will first form small local structures. 
We can recognize two common regular structures: the α-helix (a corkscrew-like structure) 
and the β-strand (the fully extended polypeptide chain that can interact via hydrogen bonds 
with other β-strands thereby forming a β-sheet). These structures are linked with residues in 
turns and irregular structures, often indicated as random coils or, more correctly, as loops. 
Both the α-helix and the β-sheet are shown in figure 1.3. 
 Tertiary Structure: The local structures interact with each other to form the actual protein 
conformation. Nature uses a limited number of folds for the tertiary structures of proteins. 
Databases such as CATH3 or SCOP4 classify proteins based on their structure. The 
combination of a six parallel β-sheet alternated by two pairs of α-helices, for example, is 
known as the Rossman fold5, and 8 β-sheets surrounded by 8 α-helicest is known as a TIM-
barrel6.  
 Quaternary Structure: Proteins often need to interact with other proteins or co-factors to 
fulfill their task. Such a complex of interacting proteins is called the quaternary structure. 
Haemoglobine, for instance, is only functional as a complex of 2 α-chains and 2 β-chains, 
each containing a haem-molecule and a series of buried water molecules.  
 
In this thesis we will mainly use the tertiary and quaternary structure of a protein to study the 
effects of mutations on the function of the protein. We know that the structure and function of a 
protein are inseparable and that the protein must be properly folded to perform its function. It is the 
structure that enables the potassium channel to allow passage of potassium-ions only. It is the 
structure that enables topoisomerases to open and close around a DNA-strand. And in numerous 
proteins it is the structure of the substrate binding site that makes sure only the correct ligand binds 
to the protein. None of these proteins could perform their function would they have a different 
structure. Of course, when looking at protein structures we will have to keep in mind that a protein 
structure is dynamic. Movement is required for a protein to fulfill its function. For instance, ion-
channels should be able to adopt an open or closed formation when needed, and oxygen-binding in 
one haemoglobin-subunit triggers a conformation-change in the subunits making it easier for the 
other subunits to bind oxygen. When studying a mutation in a protein we need to consider these 
movements.  
Figure 1.3: The four different levels to describe a protein structure. Primary = the 1-letter code of the protein 
sequence, secondary = local structures like the α-helix and β-sheet, tertiary = completely folded chain, 
quaternary = completely functional protein complex with all chains and co-factors. 
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Every active protein has a 3D-structure, and this structure is important for the function. However, 
the 3D-structure is known for only 20% of all the 23.000 known human protein sequences. Why only 
20%? Determining the protein conformation is difficult and hard lab work. The primary structure of 
proteins can be determined by a method called ‘sequencing’.  In the past this has been a laborious 
but rather straightforward process. Nowadays, the always ongoing improvement in technology 
enables us to sequence the DNA of a whole person quickly using next-generation sequencers. It has 
become rather simple to determine the sequence of a protein. However, defining the 3D-structure 
of that same protein still requires a more laborious approach for which two main methods exist: X-
ray crystallography and Nuclear Magnetic Resonance (NMR).  
 
 X-ray:  Structure determination by X-ray requires that crystals are grown of the molecule of 
interest. These crystals are subjected to X-rays (röntgen radiation). The regular nature of the 
crystal causes the diffracted X-rays to form distinct patterns on a röntgen sensitive film or 
nowadays normally a specialized röntgen radiation detector. From these patterns the 
coordinates of the atoms can be calculated.  Unfortunately, not every protein will easily 
form crystals. Especially, transmembrane domains are notoriously problematic in forming 
crystals and therefore many membrane proteins are often solved without their 
transmembrane domain. Nevertheless, X-ray is still the first choice when determining a 
protein structure. 
 NMR: Every atom has a nucleus, the core of the atom, and every atomic nucleus has a so-
called spin. Using strong magnetic fields and radio pulses, certain spins can be manipulated. 
The spins of nuclei that are close to each other in space influence each other. Some of these 
interactions can be measured, and from that data it is possible to get a rough estimate of 
interatomic distances, torsion angles, etc. This information can be used to calculate atomic 
coordinates. The result of an NMR experiment is a collection of structures, in contrast to the 
single structure that is produced by an X-ray experiment. No crystal is needed for an NMR-
experiment. 
 
Both methods result in a structure that is stored in a so-called PDB-file in the Protein Data Bank 
(PDB)7. PDB-files contain, among other information, the X, Y, and Z coordinates of every atom in the 
protein. PDB-viewers can read these files and visualize the protein on your computer screen. Smart 
PDB-viewers allow you to manipulate this protein in silico and to use it to study the protein and its 
mutations. The process from NMR/X-ray experiment to 3D-visualisation is illustrated in figure 1.4.  
It sounds simple enough, but in contrast to sequencing, both NMR and X-ray require lots of 
work and time and the resulting structures are not without errors. For instance, the tight crystal 
packing needed for X-ray crystallization can force residues and loops at the surface of the protein in 
a conformation that differs from the biological one. It also occurs that a protein is solved in a 
crystallization-multimer that differs from the biologically relevant one. NMR is in general less 
accurate and we often see undetermined regions in NMR structures. It is important to keep all these 
problems in mind when analyzing a protein structure.  
Solving a protein structure is not easy and therefore many more proteins sequences are 
known than structures. In the future, the gap between known sequences and their corresponding 
solved protein structure will only grow. The latest technological developments resulted in machines 
that can sequence the complete human genome in only a fraction of the time that was needed 
before. So, whereas the sequencing process is speeding up, the process of solving a 3D-structure is 
still slow and time-consuming. 
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Figure 1.4: Process of protein structure determination and visualization. The experimental NMR and X-ray 
techniques result in coordinates of the atoms in a structure. These coordinates are stored in a PDB-file in the 
Protein Data Bank from where they can be downloaded and used for visualization using a PDB-viewer. Shown 
here, is a screenshot of YASARA, our choice in protein-visualization software. 
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Homology modeling 
In case the 3D-structure of the protein of interest is not known yet, we can try to predict it. This 
process is known as ‘homology modeling’. Proteins that are homologs (i.e. have a common 
evolutionary ancestor) often have similar features such as the topology, the location of the active 
site, residue types in the active site, etc. Structural principles are often conserved and re-used in 
nature. It is therefore possible to use one protein structure as a template to predict the structure of 
a homologous protein. To determine whether two proteins are homologous, we compare the 
sequences of these proteins in a process called ‘aligning’. While making an alignment, we assume 
that the two sequences have a common ancestor and that all differences between the two 
sequences are caused by mutations, insertions and deletions in this common ancestor sequence. 
The two sequences are arranged in such a way that the minimum number of substitutions is 
required to change one sequence into the other. This means that we place residues originating from 
the same ancestor underneath each other; identical residues are aligned, the other residues are 
aligned with residues that have similar properties as much as possible. The two sequences can have 
different lengths caused by the introduction or deletion of residues. These insertions/deletions are 
shown as gaps in the alignment, often indicated with ‘-‘.  
We can use the alignment of two sequences to determine whether the proteins are 
homologous. Sander & Schneider8  defined a formula that indicates homology depending on the 
number of aligned residues and the length of the alignment. A graph that results from this formula is 
shown in figure 1.5. Any two aligned sequences for which the percentage identical residues fall 
above the threshold are thought to adopt a similar structure. In the other case the proteins might 
still be homologous, but that cannot be identified by a simple alignment.  
 
 
Figure 1.5: This plot indicates the safe homology modeling threshold. When the values for the length 
(horizontal axis) and percentage identity (vertical axis) fall above the line we can assume the two sequences to 
be homologous. For example: 25% of sequence identity is required for two aligned sequences of 80 amino 
acids length to be considered homologous. (Figure after Sander and Schneider8.) 
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Homology modeling is based on two important assumptions: 
 
 The function of a protein is facilitated by the structure. Nature is very good in re-using ideas 
that work and, therefore, we can find similar structural motifs (sometimes with slight 
adaptations) in large protein-families. For instance, the active site of a serine protease 
consists of serine, histidine, and aspartic acid and is conserved throughout the family of 
serine proteases, and even beyond this family. The structure and function of a protein are 
closely associated.  
 During evolution structures are more conserved than their sequences. Because some amino 
acids have the same or similar properties it is possible to change one amino acid into the 
other without changing the structure or function of that protein, as long as essential active 
site residues remain unchanged. However, the specificity for substrates or the regulation of 
the protein often changes during evolution.   
As soon as computers became widely available people started using software to build models in 
silico9. The first programs were only able to change the amino acid side chains one by one without 
further adaptions in rotamers or the backbone. Since then, homology modeling has come a long 
way. Nowadays, everyone can use online web servers that cannot only change the residue side 
chains, but can also deal with insertions/deletions, model loops, do rotamer predictions, and 
perform energy minimizations. Many servers exist that produce fairly good models (Robetta10, 
ITasser11, etc). A bi-annual protein prediction contest investigates the results of these servers and 
provides the user with a nice overview of the best web servers for protein modeling. This so-called 
CASP12 competition not only shows us the progress in protein structure and function prediction, but 
also indicates the problems and possible points for improvement. Chapter 3 is an extensive 
investigation of the method and current possibilities of homology modeling. 
 
Bioinformatics  
According to the Wikipedia we can describe the term bioinformatics as “The application of statistics 
and computer science to the field of molecular biology.“ The fact that we can nowadays use a 
system like Wikipedia indicates how much we rely on computers and the World Wide Web for our 
information. We cannot imagine our lives without a computer or without internet. The same holds 
for science in general, and for bioinformatics in particular.   
 The term bioinformatics was coined by Paulien Hogeweg in 1978 for the study of informatic 
processes in biotic systems13. In the last few decades the development of the bioinformatics field has 
gone hand-in-hand with technological developments. Bigger and faster computers made it possible 
to store and search through the enormous amount of available data that has been generated, for 
example, by the human genome project. In a similar way it became much easier to store atomic 
coordinates from protein 3D-structure nicely as one file instead of a few boxes with punched-cards, 
as illustrated in figure 1.6. In fact, protein 3D-structures are so easy to use nowadays that a wide 
variety of research projects is now depending on in silico structure analyses. Take, for example, the 
development of new medicines. Instead of simply trying every new drug compound in the lab, we 
can perform in silico drug docking first. This will limit the number of lab-experiments and this will in 
turn save time and money. On the other hand, we can use the computer to compare already known 
drugs with new target proteins. This so-called ‘drug repositioning’ can result in a much more time 
and cost-efficient drug developing and marketing process because the drug is already approved for 
use in human patients. This makes drugs repositioning the most promising path towards medication 
for the 5000-7000 orphan diseases14, such as the many genetic disorders described in this thesis. 
Until recently, these diseases have been neglected by the big pharmaceutical companies because 
worldwide only a few people are affected by it so that the enormous investments involved in 
designing a medicine ab initio would never pay off. However, using techniques such as in silico 
experiments and drug repositioning can finally make it cost-efficient to develop medicines for 
orphan diseases. 
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Figure 1.6: Improvement in computer data storage. In the past, storing coordinates of one protein could cost 
many punched cards. Nowadays, we can store the complete PDB (>70.000 proteins) on one USB-stick. 
We can say that bioinformatics has become one of the basic needs for every life science researcher, 
but bioinformatics would not be possible without the lab-experiments. Data that result from these 
experiments need to be analyzed and the latest developments in life science technology demand a 
variety of bioinformatics skills. It is, for instance, impossible to manually analyze the output from a 
next generation sequencer, or to make sense of the data generated in a micro-array experiment. 
That is why bioinformatics and lab-work need each other. The ever growing heap of data must be 
collected in databases; smart algorithms like BLAST15 have been invented to search these databases 
and protocols like SOAP16 and DAS17 enable us to extract from local and remote sources exactly that 
piece of information that is useful for us. Our in-house developed search and retrieval system MRS18 
is a typical example of an application that became both possible and necessary by the enormous 
increase in available biological data. This software provides simple and rapid access to a large series 
of biological data banks and presents this information in a human readable and cross-linked fashion. 
Currently, lots of biological data are stored in databanks and databases located on servers 
throughout the world and smart interfaces provide easy access to these information sources. 
Nowadays, every researcher needs bioinformatics as much as he/she needs lab work and it’s a good 
thing that (at least at the Radboud University) bioinformatics is part of the compulsory curriculum 
for molecular life sciences.  
We are interested in the effect of mutations on protein 3D-structures. This side of 
bioinformatics is called structural bioinformatics and focuses on the use, validation, and analysis of 
the 3D-structures of proteins. As mentioned before, almost every protein has a 3D-structure that 
facilitates the function. For example, the shape of the active site defines what substrate can fit, just 
like a key fits in a lock. Even a small change in this site can affect binding of the ligand and can 
thereby disturb the function of the protein. We call such a change a mutation. This thesis focuses on 
the effects of mutations on protein 3D-structure and function.  
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We recognize different types of mutations:  
 
 Nonsense: a mutation of an amino acid into a stop codon, this means that the protein is 
truncated. 
 Missense: one residue-type is mutated into another residue-type. This means in most cases 
(except when proline is involved) that only the side chain is changed while the backbone 
stays principally the same. For instance, a mutation from alanine to arginine means that the 
small, hydrophobic, and uncharged side chain is changed into a large, hydrophilic, and 
positively charged side chain. 
 Insertions/deletions: one or more residues are inserted in or deleted from the protein. This 
means that the length of the protein sequence changes. Normally, this occurs in irregular 
loops on the surface and does not have a severe effect, however, an insertion/deletion in 
secondary structure elements or in functional loops can be detrimental to the protein.  
 Frame-shifts: residues from a certain point are changed into another residue type, often 
leading to a premature stop and truncated protein. This is caused by a deletion or insertion 
at the DNA-level of a number of bases that is not a multiple of three. 
 
We are especially interested in the missense mutations, the mutation from one residue-type into 
another. Other mutation types are either very rare (insertions/deletions) or more often fatal for the 
protein (frameshifts/truncations). To study the effect of point mutations we need to visualize the 
proteins. We mainly use the program YASARA19 (Yet Another Scientific Artificial Reality Application) 
developed by Elmar Krieger. This, and other programs, can read the atom-coordinates in a PDB-file 
and show the protein in 3D (as shown in figure 1.4). The structure can be manipulated (zoom, rotate, 
etc) and this enables us to visualize the effects of mutations. YASARA is available in 4 stages of 
increasing complexity. YASARA View is the first stage and contains all options described above that 
enable the user to look at a 3D-structure.  The program is so easy and intuitive that it was even 
possible to incorporate it in a project called `the travelling DNA-labs´, a project in which students 
visit high schools to teach the pupils the first principles of protein structure analysis. The most 
complex YASARA stage has all  WHAT IF20 functionalities built in and contains everything you need 
for complex in silico experiments, such as building energy minimized homology models, validation of 
macromolecular structures, ligand docking, etc. In 2008, YASARA was one of the top-contenders in 
the aforementioned CASP competition and even ranked first overall in the ‘high-resolution server 
accuracy'-category. It is not surprising that we choose YASARA for our homology modeling 
experiments.  
 
Translational science: From bench-to-bedside (and back again) 
The term ”translational science” is defined as scientific research that is motivated by the need for 
practical applications that help people21. In other words, translational science is science that tries to 
develop methods, tools, and products that are directly useful. In medical science, for example, we 
can see the development of new drugs that will improve human health, and, therefore, this science 
is also described as ‘from bench to bedside’.  
The project described in this thesis not only runs in the ‘bench to bedside’ direction, but it 
also goes from ‘bedside to bench’. On one hand, our method of mutational analysis can provide a 
valuable contribution to the fundamental understanding of protein structures, which can lead to 
new ideas and experiments and, eventually, new medicines. On the other hand, our project connects 
the world of lab-experiments to find disease causing mutations with the world of in silico protein 
structure analyses that explain their effects. It translates questions that rise in the lab to a problem 
that can be approached bioinformatically. The answers of the analyses will be translated (using our 
bioinformatics-wiki) into bioinformatics-jargon free language in such a way that every (bio)medical 
scientist can understand the answer and use it to design new experiments or to publish the results in 
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an article. All together, we believe that this thesis describes examples of translational science, that 
sometimes are very literal. 
 
Several research departments in the academic hospital in Nijmegen are studying hereditary diseases. 
An extensive series of experiments can result in the knowledge that a certain mutation in a certain 
gene is causing a disease.  Such results are publishable and contribute to the fundamental 
knowledge about diseases. However, the molecular basis of the disease is then still unknown. We 
don’t know why, at a molecular level, that particular mutation causes the disease. Is the mutation 
disturbing the structure of the protein, or is it located at the surface where it can disturb 
dimerisation? We will not know until we closely study the 3D-structure of the protein in the light of 
all other knowledge about the molecule. Only when we understand the underlying molecular basis 
of the disease can we think of a reliable diagnostic test or a possible cure for the patient. The 
example in the next paragraph illustrates a protein study in which the structural analysis contributed 
significantly to the understanding of the disease and provided new ideas for experiments that 
eventually might lead to a cure for patients. 
 
Example: The department of human genetics studied a family of hereditary disorders causing various 
combinations of limb malformations in the split hand-split foot spectrum, orofacial clefting, and 
ectodermal dysplasia, including ‘Ectrodactylyl, Ectodermal dysplasia and Cleft lip syndrome’ (also 
known as EEC syndrome). Lab experiments resulted in the identification of mutations in the gene for 
p63, a transcription factor22. The mutations seemed to be scattered all over the protein. The 
identification of these mutations in itself was an important discovery, but the molecular mechanism 
of the diseases was not yet understood. After homology modeling of the protein structure it became 
clear that the disease-causing mutations were located in either the DNA-binding region, contacted a 
metal-ion, or were located at the dimerisation interface. Strikingly, the location of these mutations 
could be directly correlated to the different variants of the disease23. Researchers at the Swedish 
Karolinska institute took up the challenge to develop a medicine for this disease. They developed a 
small molecule named PRIMA-1 that can covalently bind to p53-family members (p63, p53, and p73) 
and stabilize the dimer. This partly restores the protein function because binding of PRIMA-1 
stabilizes the dimer and thereby simply makes sure that there is more active form of the protein 
available24-26. Hopefully, PRIMA-1 can be used as a lead compound to develop new therapies. Figure 
1.7 illustrates this process.  
 
 
 
 
Figure 1.7: Overview of the translational science process in the case of p63 starting with the identification of 
the syndrome, followed by the discovery of the mutations in the p63 gene, structural analysis of the homology 
model, and eventually the development of a therapeutic compound. 
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This example shows how protein 3D-structures can contribute to the understanding of processes in 
the human body in general, and hereditary diseases in particular, and can be used to develop cures 
or at least to design new experiments towards this goal. A part of this thesis consists of projects 
carried out in collaboration with life-science departments. In chapter 5 you will find a summary of 
the articles that were the results of these collaborations most of which have been published already. 
These articles investigated one or more point mutations that were found to cause a disease. Other 
projects have also been carried out, but they fall beyond the scope of this thesis because they do not 
include point mutations. The summaries show how protein structures can provide a serious 
contribution to the understanding of a disease mechanism and, in a way, provide the last piece of 
the molecular puzzle. 
 
HOPE: Have (y)Our Protein Explained 
Even though a structural analysis of a point mutation seems to be very valuable for further research, 
not every biomedical scientist has access to a bioinformatics department and not every scientist has 
the background to study proteins structures in depth. The aim of this PhD project was to bridge the 
gap between (bio)medical sciences and structural bioinformatics. Therefore, we developed Project 
HOPE: an online system that can analyze the structural effects of point mutations and explain them 
in a (bio)medically friendly way. HOPE gathers information about a protein from databases and 
servers located on computers in a wide range of countries. The name HOPE stands for: Have yOur 
Protein Explained, but also represents the fact that you can always hope that something more is 
known about your protein. With HOPE we hope to open the world of protein structures to everyone.  
 
Scope of this thesis 
This thesis focuses on protein 3D-structures and the effect of mutations on these structures. As 
mentioned previously, homology modeling is the only way to obtain a 3D-structure of your protein 
of interest when experimental techniques fail or simply have not yet been tried. A homology 
modeling experiment is a multi-step process. In chapter 2 we extensively describe each step and its 
underlying principles.  
In chapter 3 we describe homology modeling in the light of a series of recent developments, 
and an overview will be given of the problems and opportunities encountered in this field. The major 
topic, the accuracy and precision of homology models, will be discussed extensively. 
In chapter 4 we introduce Project HOPE, a fully automatic program that analyzes the 
structural and functional effects of point mutations. HOPE collects information from a wide range of 
information sources including the protein 3D-structure or homology model. These homology models 
are built according to the method described in chapter 2.    
Chapter 5 illustrates the use of protein 3D-structures in the field of life-sciences. In the 
recent years, we collaborated in many projects. We were often able to analyze the protein structure 
in order to provide insights in the effects of that mutation and to suggest new experiments. Many of 
these projects resulted in a publication which will be summarized in this chapter. 
We validated Project HOPE by analyzing a large series of mutations described in journals 
such as Nature Genetics and the American Journal of Human Genetics. We compared HOPE's 
predictions with the predictions described by the authors of these articles, with our own manual 
analyses, and with predictions by SIFT and PolyPhen, two other, commonly used packages for 
mutant structure prediction. We also compared mutations that we analyzed previously (chapter 5) 
with HOPE’s predictions. The results of these analyses are described in chapter 6 and 6a.  
Chapter 7 summarizes this thesis and provides insight in improvements and future 
perspectives. 
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A Toll-Like Receptor (TLR) – A class of receptor 
proteins that recognize a wide variety of 
structurally conserved molecules in microbes 
and therefore play an important role in the 
innate immune system. (PDB file 2z63) 
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Homology Modeling 
The goal of protein modeling is to predict a structure from its sequence with an accuracy that is 
comparable to the best results achieved experimentally. This would allow users to safely use in silico 
generated protein models in scientific fields where today only experimental structures provide a 
solid basis: structure-based drug design, analysis of protein function, interactions, antigenic 
behavior, or rational design of proteins with increased stability or novel functions. Protein modeling 
is the only way to obtain structural information when experimental techniques fail. Many proteins 
are simply too large for Nuclear Magnetic Resonance (NMR) analysis and cannot be crystallized for 
X-ray diffraction. Among the major approaches to 3D structure prediction homology modeling is the 
‘easiest’ approach based on two major observations: 
 
 The structure of a protein is uniquely determined by its amino acid sequence1, and therefore 
the sequence should, in theory, contain sufficient information to obtain the structure. 
 During evolution, structural changes are observed to be modified at a much slower rate than 
sequences. Similar sequences have been found to adopt practically identical structures while 
distantly related sequences can still fold into similar structures. This relationship was first 
identified by Chothia & Lesk2 and later quantified by Sander & Schneider3 as summarized in 
figure 2.1. Since the initial establishment of this relationship, Rost et al.4 was able to derive a 
more precise limit for this rule with accumulated data in the Protein Data Bank (PDB). Two 
protein sequences are highly likely to adopt a similar structure provided that the percentage 
identity between these proteins for a given length is above the threshold shown in the 
figure.  
 
 
Figure 2.1: The two zones of sequence alignments defining the likelihood of adopting similar structures. Two 
sequences are highly likely to fold into the same structure if their length and percentage sequence identity fall 
into the region above the threshold, indicated with the smiling icon (the ‘safe’ zone). The region below the 
threshold indicates the zone where inference of structural similarity cannot be made, thus making it difficult to 
determine if model building will be possible. (Figure after Sander and Schneider3) 
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The identity between the sequences can be obtained by doing a simple BLAST run with the sequence 
of interest, the model-sequence, against the PDB, see figure 2.2. The sequence that aligns with the 
model-sequence is called the ‘template’. When the percentage identity in the aligned region of the 
structure template and the sequences to be modeled falls in the safe modeling zone of figure 2.1, a 
model can be built.  
 
 
 
Figure 2.2: Typical blast output of a model-sequence run against the PDB sequences, where (Q) represents the 
model-sequence with unknown structure and (S) is the sequence for the PDB structure template. 
 
In figure 2.1 it is shown that the threshold for safe homology modeling can be as low as 25%, 
especially for longer sequences. However, the quality of the model is dependent on the sequence 
identity and should be considered since sequences with 25% sequence identity tend to yield poor 
structural models with high uncertainty in side chain positioning.   
The impact of identities between the model-sequence and the template on the process of 
protein homology modeling can be broken down as follows. At sequence identities greater than 75% 
protein homology modeling can easily be achieved requiring minor manual intervention. 
Consequently, the time needed to finalize such a model is limited only by the interpretation of the 
model to answer the biological question at hand, see figure 2.3. The level of accuracy achieved with 
these models is comparable to structures that were solved by NMR. For sequence identities 
between 50 - 75% more time is needed to fine-tune the details of the model and correct the 
alignment if needed. Between 25-50% identity obtaining the best possible alignment becomes the 
major concern in the process of homology modeling. Finally, sequence identities lower than 25% 
often mean that no template structure can be detected with a simple BLAST search thus requiring 
the use of more sensitive alignment techniques to find a potential template structure.  
 
 
 
Figure 2.3: The limiting steps in homology modeling as function of percentage sequence identity between the 
model-sequence and the sequence of the template. (Figure based on Rodriguez and Vriend5) 
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In practice, homology modeling is a multi-step process which can be summarized as follows: 
1: Template recognition and initial alignment 
2: Alignment correction 
3: Backbone generation 
4: Loop modeling 
5: Side chain modeling 
6: Model optimization 
7: Model validation 
8: Iteration 
These steps are all illustrated in figure 2.4 and will be discussed in detail in the rest of this chapter. 
 
Decisions need to be made by the modeler at almost every step of this model building process. The 
choices are not always obvious, thus subjecting model building to a serious thought about how to 
gamble between multiple seemingly similar choices. To reduce possible errors introduced by a 
subjective decision making process, algorithms have been developed to automate the model 
building process (see table 2.1). 
 
Table 2.1: A few examples of the online available homology modeling servers.  
Server name URL 
Automatic Homology Modeling Servers 
 
3D-Jigsaw http://www.bmm.icnet.uk/servers/3djigsaw/ 
CPHModels http://www.cbs.dtu.dk/services/CPHmodels/ 
EsyPred3D http://www.fundp.ac.be/urbm/bioinfo/esypred/ 
Robetta http://robetta.bakerlab.org/ 
SwissModel http://swissmodel.expasy.org/ 
TASSER-lite http://cssb.biology.gatech.edu/skolnick/webservice/tasserlite/index.html 
 
Semi-Automatically Homology Modeling Servers (provide your own alignment) 
 
HOMER 
 
http://protein.cribi.unipd.it/homer/help.html 
WHAT IF http://swift.cmbi.kun.nl/WIWWWI/ 
 
 
Current techniques allow modelers to construct models for about 25-65% of the amino acids coded 
in the genome, thereby supplementing the efforts of structural genomics projects6. This value differs 
significantly between individual genomes, and increases steadily with the continuous growth of the 
PDB. The remainder of these genomes have no identified template that can be used for homology 
modeling and therefore modelers will need to resort to fold recognition, ab initio structure 
prediction, or simply the traditional NMR or X-ray experiment to obtain structural data. While 
automated model building provides a high throughput-solution the evaluation of these automated 
methods during CASP indicated that human expertise is still helpful, especially if the sequence 
identity of the alignment is close to the zone of uncertainty regarding the feasibility of building a 
proper model (25%, see figure 2.1)7. The 8 steps of homology modeling will be discussed in more 
detail on the following pages. 
 
 
 
Next page: Figure 2.4: The process of building a ‘model’ by homology to a ‘template’. The numbers in the plot 
correspond to the step-numbers in the subsequent section.  
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Step 1 - Template Recognition and Initial Alignment 
Sequences in the safe homology modeling zone (figure 2.1) share a high percentage identity to a 
possible template and therefore can easily be paired with simple sequence alignment programs such 
as BLAST8 or FASTA9. To identify the template, the program compares the query sequence to all the 
sequences of known structures in the PDB using mainly two matrices: 
 
 A residue exchange matrix (figure 2.5). This matrix defines the likelihood that any two of the 
20 amino acids ought to be aligned. Exchanges between different residues with similar 
physico-chemical properties (for example Phe->Tyr) get a better score than exchanges 
between residues that widely differ in their properties. Conserved residues generally obtain 
the highest score. 
 An alignment matrix (figure 2.6). The axes of this matrix correspond to the two sequences to 
be aligned, and the matrix elements are simply the values from the residue exchange matrix 
(figure 2.5) for a given pair of residues. During the alignment process, one tries to find the 
best path through this matrix, starting from a point near the top left, and going down to the 
bottom right. To make sure that no residue is used twice, one must always take at least one 
step to the right and one step down. A typical alignment path is shown in figure 2.6. At first 
sight, the dashed path in the bottom right corner would have led to a higher score. However, 
it requires the opening of an additional gap in sequence A (Gly of sequence B is skipped). By 
comparing thousands of sequences and sequence families, it became clear that the opening 
of gaps is about as unlikely as at least a couple of non-identical residues in a row. The jump 
roughly in the middle of the matrix on the other hand is justified, because after the jump we 
earn lots of points (5,6,5) which otherwise would only have been (1,0,0). The alignment 
algorithm therefore subtracts an ‘opening penalty’ for every new gap and a much smaller 
‘gap extension penalty’ for every residue that is additionally skipped once the gap has 
already been made. The gap extension penalty is much smaller than the gap open penalty 
because one gap of three residues is much more likely than three gaps of one residue each. 
 
In practice, template structures can be easily retrieved by submitting the query sequence to one of 
the countless BLAST servers on the web, using the PDB as the database to search. Usually, the 
template structure with the highest sequence identity will be the first option, see figure 2.2, but 
other considerations should be made. For example, the conformational state (i.e. active or inactive), 
present co-factors, other molecules or multimeric complexes will have an impact on model building. 
Nowadays, the increasing amount of CPU power makes it possible to choose multiple templates and 
build multiple models giving the investigator the opportunity to select the best model for further 
study.  It has also become possible to combine multiple templates into one structure that is used for 
modeling. The online Swiss-Model10 and the Robetta servers11, for example, use this approach. 
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Figure 2.5: A typical residue exchange or scoring matrix used by alignment algorithms. Because the score for 
aligning residues A and B is normally the same as for B and A, this matrix is symmetric. 
 
 
 
Figure 2.6: The alignment matrix for the sequences VATTPDKSWLTV and ASTPERASWLGTA, using the scores 
from figure 2.5. The optimum path corresponding to the alignment on the right side is shown in gray. Residues 
with similar properties are marked with a star '*'. The dashed line marks an alternative alignment that scores 
more points but requires to open a second gap. 
 
Step 2 - Alignment Correction 
Having identified one or more possible modeling templates using the initial screen described above, 
more sophisticated methods are needed to arrive at a better alignment. 
Sometimes it may be difficult to align two sequences in a region where the percentage 
sequence identity is very low. A potential strategy is to use other sequences from other homologous 
proteins to find a solution. An example of using this strategy to address a challenging alignment is 
shown in figure 2.7. Suppose the sequence LTLTLTLT needs to be aligned with YAYAYAYAY. There are 
two equally poor possibilities, and the use of third sequence, TYTYTYTYT, that aligns easily to the two 
sequences can resolve the issue. 
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Figure 2.7: Addressing a challenging alignment problem with homologous sequences. Sequences A and B are 
impossible to align, unless one considers a third sequence C from a homologous protein. 
 
The example above introduced a very powerful concept called ‘multiple sequence alignment’. Many 
programs are available to align a number of related sequences, for example CLUSTALW12, and the 
resulting alignment contains a lot of additional information. For example, consider an Ala->Glu 
mutation. Relying on the matrix in figure 2.5, this exchange always gets a score of 1. In the three 
dimensional structure of the protein, it is however very unlikely to see such an Ala->Glu exchange in 
the hydrophobic core, but on the surface this mutation is perfectly normal. The multiple sequence 
alignment implicitly contains information about this structural context. If at a certain position only 
exchanges between hydrophobic residues are observed, it is highly likely that this residue is buried. 
To consider this knowledge during the alignment, one uses the multiple sequence alignment to 
derive position specific scoring matrices, also called ‘profiles’13; 14. During the last years, new 
programs like MUSCLE15 and T-Coffee16 have been developed that use these profiles to generate and 
refine the multiple sequence alignments. Structure based alignment programs, like 3DM, also 
include structural information in combination with profiles to generate multiple sequence 
alignments17. The use of 3DM on a specific class of proteins can result in entropy vs. variability plots. 
The location of a residue in this plot is directly related to function in the protein. This information 
can in turn be added to the profile and used to correct the alignment or to optimize position specific 
gap penalties.  
 
When building a homology model, we are in the fortunate situation of having an almost perfect 
profile: the known structure of the template. We simply know that a certain alanine sits in the 
protein core and must therefore not be aligned with a glutamate. Multiple sequence alignments are 
nevertheless useful in homology modeling, for example to place deletions or insertions only in areas 
where the sequences are strongly divergent. A typical example for correcting an alignment with the 
help of the template is shown in figures 2.8 and 2.9. Although a sequence alignment gives the 
highest score for alignment 1 in figure 2.8, a simple look at the structure of the template reveals that 
alignment 2 is actually a better alignment, because it leads to a small gap, compared to a huge hole 
associated with alignment 1. 
 
Template I C R L P G S A E A 
1: Model (bad) V C R M P - - - E A 
2: Model (good) V C R - - - M P E A 
 
Figure 2.8: Example of a sequence alignment where a three-residue deletion must be modeled. While 
alignment 1, red, appears better when considering just the sequences (a matching proline at position 5), a look 
at the structure of the template leads to a different conclusion (figure 2.9). 
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Figure 2.9: Correcting an alignment based on the structure of the modeling template (C-trace shown in 
black). While the alignment with the highest score (red, also in figure 2.8) leads to a big gap in the structure, 
the second option (blue) creates only a tiny hole. This can easily be accommodated by small backbone shifts.  
 
Step 3 - Backbone Generation 
When the alignment is ready, the actual model building can start. Creating the backbone is trivial for 
most of the model: one simply transfers the coordinates of those template residues that show up in 
the alignment with the model-sequence (see figure 2.2). If two aligned residues differ, the backbone 
coordinates for N, C, C and O and often also the Cβ can be copied. Conserved residues can be 
copied completely to provide an initial guess. 
Experimentally determined protein structures are not perfect (but still better than models in 
most cases). There are countless sources of errors, ranging from poor electron density in the X-ray 
diffraction map to simple human errors when preparing the PDB file for submission. A lot of work 
has been spent on writing software to detect these errors (correcting them is even harder), and the 
current count is at more than 25,000,000 errors in the approximately 50,000 structures deposited in 
the PDB by the end of 2007. The current PDB-redo18 and RECOORD19 projects have respectively 
shown that re-refinement of X-ray and NMR structures normally improves the quality of the 
structure, suggesting that re-refinement before modeling seems to be a wise option. 
A straightforward way to build a good model is to choose the template with the fewest 
errors (the PDBREPORT database20 at www.cmbi.ru.nl/gv/pdbreport can be very helpful). But what if 
two templates are available, and each has a poorly determined region, but these regions are not the 
same? One should clearly combine the good parts of both templates in one model - an approach 
known as multiple template modeling. (The same applies if the alignments between the model 
sequence and possible templates show good matches in different regions). Although this is a simple 
principle (and used by automated modeling servers like Swiss-Model10) it is hard in practice to 
achieve results that are closer to the true structure than all the templates. Nevertheless the 
feasibility of this strategy has already been demonstrated by Andrej Šali's group in CASP4.  
One extreme example of a program that combines multiple templates is the Robetta server 
(see table 2.1). This server uses several different algorithms to predict domains in the sequence. The 
regions of the model-sequence that contain a homologous domain in the PDB are modeled while 
those parts without homology are predicted de novo by using the Rosetta method. This method 
compares small fragments of the sequence with the PDB and inserts them with the same local 
conformation into the model. The Robetta server can generate models of complete sequences even 
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without a known template11. Skolnick’s TASSER follows a same strategy but combines larger 
fragments, found by threading, and folds them into a complete structure21. 
 
Step 4 - Loop Modeling 
For the majority of homology model building cases, the alignment between model and template 
sequence contains gaps. Either in the model sequence (deletions as shown in figures 2.8 and 2.9), or 
in the template sequence (insertions). Gaps in the model-sequence are addressed by simply omitting 
residues from the template, thus creating a hole in the model that must be closed. Gaps in the 
template sequences are treated by inserting the missing residues into the continuous backbone. 
Both cases imply a conformational change of the backbone. The good news is that conformational 
changes often do not occur within regular secondary structure elements. Therefore it is often safe to 
shift all insertions or deletions in the alignment out of helices and strands and place them in 
structural elements that can accommodate such changes in the alignment such as loops and turns. 
The bad news is that changes in loop conformation are notoriously hard to predict (a big unsolved 
problem in homology modeling). To make things worse, even without insertions or deletions a 
number of different loop conformations can be observed between the template and model. There 
are three main reasons for this difficulty5: 
 Surface loops tend to be involved in crystal contacts and therefore a significant 
conformational change is expected between the template in crystal form and the final 
structure modeled in the absence of crystallization constraints. 
 The exchange of small to bulky side chains underneath the loop induces a structural change 
by pushing it away from the protein.  
 The mutation of a loop residue to proline or from glycine to any other residue will result in a 
decrease in conformational flexibility. In both cases, the new residue must fit into a more 
restricted area in the Ramachandran plot, which normally requires a conformational change 
of the loop. 
 
There are three main approaches to model loops: 
 Knowledge based: a search is made through the PDB for known loops containing endpoints 
that match the residues between which the loop is to be inserted. The identified coordinates 
of the loop are then transfered. All major molecular modeling programs and servers support 
this approach (e.g. 3D-Jigsaw22, Insight23, Modeller24, Swiss-Model10 or WHAT IF25).  
 In between or hybrid: the loop is divided in small fragments that are all separately compared 
to the PDB. This strategy has been described earlier as implemented for the Rosetta 
method11. The local conformation of all small fragments results in an ab initio modeled loop 
but is still based on known protein structures. This method is reminiscent of the very old 
ECEPP software by the Scheraga group26.  
 Energy based: as in true ab initio fold prediction, an energy function is used to judge the 
quality of a loop. This is followed by a minimization of the structure, using Monte Carlo27 or 
molecular dynamics techniques28 to arrive at the best loop conformation. Often the energy 
function is modified (e.g. smoothed) to facilitate the search29. 
 
For short loops (up to 5-8 residues), the various methods have a reasonable chance of predicting a 
loop conformation close to the true structure. As mentioned above, surface loops tend to change 
their conformation due to crystal contacts. So if the prediction is made for an isolated protein and 
then found to differ from the crystal structure, it might still be correct. 
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Step 5 - Side Chain Modeling 
When we compare the side chain conformations (‘rotamers’) of residues that are conserved in 
structurally similar proteins, we find that they often have similar 1-angles (i.e. the torsion angle 
about the C-C bond). It has been shown by Summers et al. that in homologous proteins (over 40% 
identity) at least 75% of the Cγ occupy the same orientation30. It is therefore possible to simply copy 
conserved residues entirely from the template to the model (see also Step 3) and achieve a very 
good starting point for structure optimisation. In practice, this rule of thumb holds only at high levels 
of sequence identity, when the conserved residues form networks of contacts. When they get 
isolated (<35% sequence identity), the rotamers of conserved residues may differ in up to 45% of the 
cases31. 
In practice, all successful approaches to side chain placement are at least partly knowledge 
based. Libraries of common rotamers extracted from high resolution X-ray structures are often used 
to position side chains. The various rotamers are successively explored and scored with a variety of 
energy functions. Intuitively, one might expect rotamer prediction to be computationally demanding 
due to the combinatorial explosion of the search space - the choice of a certain rotamer 
automatically affects the rotamers of all neighboring residues, which in turn affect their neighbors 
and the effect propagates continuously. For a sequence of 100 residues and an average ~5 rotamers 
per residue, the rotamer space would yield 5100 different possible conformations to score. Significant 
research efforts have been invested to develop algorithms to address this issue and make the search 
through the rotamer conformation space more tractable32; 33. 
Aside from directly extracting conserved rotamers from the template, the key to handling 
the combinatorial explosion of conformational possibilities lies in the protein backbone. Instead of 
using a ‘fixed’ library that stores all possible rotamers for all residue types, an alternative ‘position 
specific’ library can be used. These libraries use information contained in the backbone to select the 
correct rotamer. A simple form of a position specific library classifies the backbone based on 
secondary structure since residues found in helices often favor a rotamer conformation that is not 
observed in strands or turns. More sophisticated position specific libraries can be built by classifying 
the backbone according to its Phi/Psi angles or by analyzing high resolution structures and collecting 
all stretches of 5 to 9 residues (depending on the method) with a reference amino acid at the center 
of the stretch. These collected examples in the template are superposed on the corresponding 
backbone to be modeled. The possible side chain conformations are selected from the best 
backbone matches34. Since certain backbone conformations will be strongly favored for certain 
rotamers to be adopted (allowing for example a hydrogen bond between side chain and backbone) 
this strategy greatly reduces the search space. For a given backbone conformation, there may be a 
residue that strongly populates a specific rotamer conformation and therefore can be modeled 
immediately. This residue would then serve as an anchor point to model surrounding side chains 
that may be more flexible and adopt a number of other conformations. An example of a backbone 
conformation that favors two different tyrosine rotamers is shown in figure 2.10. 
  
Figure 2.10: Example of a backbone-dependent rotamer library. The current backbone conformation favors 
two different rotamers for Tyrosine (shown as sticks) which appear about equally often in the database. 
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Position-specific rotamer libraries are widely used today for drug docking purposes to 
visualize all possible shapes of the active site35-37. The study by Chinea et al.34 shows that the search 
space is even considerably smaller than assumed by Desmet et al.32. 
Although search space for rotamer prediction initially presented a combinatorial problem to be 
explored exhaustively, it is far smaller than originally assumed as evidenced in a study conducted in 
2001 by Xiang and Honig who first removed a single side chain from known structures and re-
predicted it38. In a second step, they removed all the side chains and added them again using the 
same method. Surprisingly, it turned out that the accuracy was only marginally higher in the much 
easier first case. 
Rotamer prediction accuracy is usually quite high for residues in the hydrophobic core where 
more than 90% of all 1-angles fall within 20° from the experimental values, but much lower for 
residues on the surface where the percentage is often even below 50%. There are three reasons for 
this: 
 Experimental reasons: flexible side chains on the surface tend to adopt multiple 
conformations, which are additionally influenced by crystal contacts. So even experiments 
cannot provide a single correct answer. 
 Theoretical reasons: the energy functions used to score rotamers can easily handle the 
hydrophobic packing in the core (mainly Van der Waals interactions). The calculation of 
electrostatic interactions on the surface, including hydrogen bonds with water molecules 
and associated entropic effects, is more complicated. Nowadays, these calculations are 
being included in more force fields that are used to optimize the models39.  
 Biological reasons: loops on the surface often adopt different conformations as part of the 
biological function, for example to let the substrate enter the protein. 
It is important to note that the rotamer prediction accuracies given in most publications cannot be 
reached in real-life applications. This is simply due to the fact that the methods are evaluated by 
taking a known structure, removing the side chains and re-predicting them. The algorithms thus rely 
on the correct backbone, which is not available in homology modeling since the backbone of the 
template often differs significantly from the model structure. The rotamers must thus be predicted 
based on a ‘wrong’ backbone and reported prediction accuracies tend to be higher than what would 
be expected for the modeled backbone. 
 
Step 6 - Model Optimization 
The problem of rotamer prediction mentioned above leads to a classical ‘chicken and egg’ situation. 
To predict the side chain rotamers with high accuracy, we need the correct backbone, which in turn 
depends on the rotamers and their packing. The common approach to address this problem is to 
iteratively model the rotamers and backbone structure. First, we predict the rotamers, then remodel 
the backbone to accommodate rotamers, followed by a round of refitting the rotamers to the new 
backbone. This process is repeated until the solution converges. This boils down to a series of 
rotamer prediction and energy minimization steps. Energy minimization procedures used for loop 
modeling are applied to the entire protein structure, not just an isolated loop. This requires an 
enormous accuracy in the energy functions used, because there are many more paths leading away 
from the answer (the model structure) than towards it. This is why energy minimization must be 
used carefully. At every minimization step, a few big errors (like bumps, i.e. too short atomic 
distances) are removed while at the same time many small errors are introduced. When the big 
errors are gone, the small ones start accumulating and the model moves away from its correct 
structure, see figure 2.11.  
As a rule of thumb, today's modeling programs therefore either restrain the atom positions 
and/or apply only a few hundred steps of energy minimization. In short, model optimization does 
not work until energy functions (force fields) become more accurate. Two ways to achieve better 
energetic models for energy minimization are currently being pursued: 
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 Quantum force fields: Protein force fields must be fast to handle these large molecules 
efficiently; energies are therefore normally expressed as a function of the positions of the 
atomic nuclei only. The continuous increase of computer power has now finally made it 
possible to apply methods of quantum chemistry to entire proteins, arriving at more 
accurate descriptions of the charge distribution40. It is however still difficult to overcome the 
inherent approximations of today's quantum chemical calculations. Attractive Van der Waals 
forces are for example so hard to treat, that they must often be completely omitted. While 
providing more accurate electrostatics, the overall accuracy achieved is still about the same 
as in the classical force fields. 
 Self-parameterizing force fields: The accuracy of a force field depends to a large extent on 
its parameters (e.g. Van der Waals radii, atomic charges). These parameters are usually 
obtained from quantum chemical calculations on small molecules and fitting to experimental 
data, following elaborate rules41. By applying the force field to proteins, one implicitly 
assumes that a peptide chain is just the sum of its individual small molecule building blocks - 
the amino acids. Alternatively, one can just state a goal - e.g. improve the models during an 
energy minimization - and then let the force field parameterize itself while trying to 
optimally fulfill this goal42; 43. This leads to a computationally rather expensive procedure. 
Take initial parameters (for example from an existing force field), change a parameter 
randomly, energy minimize models, see if the result improved, keep the new force field if 
yes, otherwise go back to the previous force field. With this procedure, the force field 
accuracy increases enough to go in the right direction during an energy minimization (figure 
2.11). The YASARA software uses this technology for homology model optimization. The 
CASP 2008 experiment beautifully illustrates the enormous potential of this method. 
The most straightforward approach to model optimization is to simply run a molecular dynamics 
simulation of the model. Such a simulation follows the motions of the protein on a femtosecond (10-
15 s) timescale and mimics the true folding process. One thus hopes that the model will complete its 
folding and converges to the true structure during the simulation. The advantage is that a molecular 
dynamics simulation implicitly contains entropic effects that are otherwise hard to treat; the 
disadvantage is that the force fields are again not accurate enough to make it work. 
 
 
 
Figure 2.11: The average RMSD between models and the real structures during an extensive energy 
minimization of 14 homology models with two different force fields. Both force fields improve the models 
during the first ~500 energy minimization steps but then the small errors sum up in the classic force field and 
guide the minimization in the wrong direction, away from the real structure while the self-parameterizing 
force field goes in the right direction. To reach experimental accuracy, the minimization would have to 
proceed all the way down to ~0.5 Å which is the uncertainty in experimentally determined coordinates. 
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Different distributed computing projects (folding@home, Rosetta@home, Models@home), 
have been developed to use many personal computers in a network to run molecular dynamics 
simulations and to mimic protein folding. Model optimization becomes more and more important. 
Even the focus of the CASP competition is changing to a comparison of the optimization of initial 
models provided by these online servers instead of building the initial models from scratch. 
 
Step 7 - Model Validation 
Every protein structure contains errors, and homology models are no exception. The number of 
errors (for a given method) mainly depends on two values:  
 The percentage sequence identity between template and model-sequence. If the identity is 
greater than 90%, the accuracy of the model can be compared to crystallographically 
determined structures, except for a few individual side chains2; 44. From 50% to 90% identity, 
the root mean square error in the modeled coordinates can be as large as 1.5 Å, with 
considerably larger local errors. If the sequence identity drops to 25%, the alignment turns 
out to be the main bottleneck for homology modeling, often leading to very large errors 
rendering it a meaningless effort to model these regions, see also figure 2.3. 
 The number of errors in the template. Errors in the template structure can be reduced by 
an additional re-refinement of the template structure as mentioned earlier. Errors in a 
model become less of a problem if they can be localized. For example, a loop located 
distantly from a functionally important region such as the active site of an enzyme can 
tolerate some inaccuracies. Nevertheless, it is in the best interest to model all regions as 
accurately as possible since seemingly unimportant residues may be important for protein-
protein interactions or a yet unassigned function.  
 
There are two principally different ways to estimate errors in a structure: 
 Calculating the model's energy based on a force field: This checks if the bond lengths and 
bond angles are within normal ranges, and if there are lots of clashing side chains in the 
model (corresponding to a high Van der Waals energy). Essential questions like "Is the model 
folded correctly?" cannot yet be answered this way, because completely misfolded but well 
minimized models often reach the same force field energy as the correct structure45. This is 
mainly due to the fact that molecular dynamics force fields are lacking several contributing 
terms to the energy function, most notably those related to solvation effects and entropy. 
 Determination of normality indices: This describes how well a given characteristic of the 
model resembles the same characteristic in real structures. Many features of protein 
structures are well suited for normality analysis. Most of them are directly or indirectly 
based on the analysis of interatomic distances and contacts. Some published examples are:  
- General checks for the normality of bond lengths, bond- and torsion angles46,47 are good 
checks for the quality of experimentally determined structures, but are less suitable for 
the evaluation of models because the better model building programs simply do not 
make this kind of errors.  
- Inside/outside distributions of polar and apolar residues can be used to detect 
completely misfolded models48. 
- The radial distribution function for a given type of atom (i.e. the probability to find 
certain other atoms at a given distance) can be extracted from the library of known 
structures and converted into an energy-like quantity, called a ‘potential of mean 
force’49. Such a potential can easily distinguish good contacts (e.g. between a C of valine 
and a C of isoleucine) from bad ones (e.g. between the same C of valine and the 
positively charged amino group of lysine). 
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- The direction of atomic contacts can also be accounted for in addition to interatomic 
distances. The result is a three dimensional distribution of functions, that can also easily 
identify misfolded proteins and are good indicators of local model building problems50.  
 
Most methods used for the verification of models can also be applied to experimental structures 
(and hence to the templates used for model building). A detailed verification is essential when trying 
to derive new information from the model, either to interpret or predict experimental results or plan 
new experiments. 
 
Step 8 - Iteration 
When errors in the model are recognized and located, they can be corrected by iterating portions of 
the homology modeling process. Small errors that are introduced during the optimization step can 
be removed by running a shorter molecular dynamics simulation. An error in a loop can be corrected 
by choosing another loop conformation in the loop modeling step. Large mistakes in the backbone 
conformation sometimes require the complete process to be repeated with another alignment or 
even with a different template.  
 
In summary, it is safe to say that homology modeling is unfortunately not as easy as stated in the 
beginning. Ideally, homology modeling also uses threading to improve the alignment, ab initio 
folding to predict the loops and molecular dynamics simulations with a perfect energy function to 
converge into true structure. Doing all this correctly will keep researchers busy for a long time, 
leaving lots of fascinating discoveries. 
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Introduction 
Knowledge of the 3D structure of proteins is a prerequisite for much research in fields as diverse as 
protein engineering, human genetics, and drug design. Only two spectroscopic techniques, NMR and 
X-ray, can produce high resolution three dimensional coordinates of macromolecules. Most other 
spectroscopic techniques either add information to such three dimensional coordinates, or require 
these coordinates for the detailed interpretation of their results. NMR and X-ray are very elaborate 
techniques, and worldwide only about 30 protein structures are solved per day. In the time needed 
to read the text above, on the other hand, about 50 sequences were determined (worldwide) and 
deposited in international, freely and easily accessible sequence databases. Consequently, the 
necessity for homology modeling is only increasing. In its most elementary form, homology modeling 
involves calculating the structure of a protein for which only the sequence is known using its 
alignment with a homologous protein for which the structure is known. 
The first homology modeling articles were published already in the late 1970's1, and ever 
since we have kept using, and improving the same concepts as described in those ground-breaking 
articles. The process starts with the detection of a suitable template; an alignment is produced; 
insertions, deletions, and residue substitutions are performed; the model is optimized; and since the 
late 1990's we all agree that structure validation is needed to detect any, unavoidably made, errors 
in the final model.  
In the early 1990's many homology models were built (and unfortunately also published; also in EBJ) 
just for the sake of modeling, but since the mid 1990's homology models are considered tools that 
can aid with the design of experiments and with the interpretation of their results, albeit that 
occasionally things still can go very wrong in the literature.  
G protein-coupled receptors (GPCRs) are by far the most important target for the 
pharmaceutical industry, and due to the scarcity of GPCR structure data GPCRs are the most 
frequently modeled molecules ever. Until August 2000 GPCR models were either built ab initio, or 
using the non-homologous bacteriorhodopsin as a homology modeling template. In August 2000 the 
structure of bovine opsin became available2, and since that moment GPCR homology modeling is a 
serious possibility. GPCR models built before that historical moment are better forgotten3. 
Unfortunately, people kept building, using, and publishing ab initio models even after the bovine 
opsin structure was solved4. Today, four GPCR structures are available that can be used as template; 
figure 3.1 shows the principal differences between the bovine opsin structure and the structure of 
the beta-2 adrenergic receptor5, one of the recently resolved GPCR crystal structures. Long before 
August 2000 the importance of GPCR structure models for drug design triggered a very large number 
of spectroscopic experiments focussed on a variety of aspects.  
The following series of short paragraphs illustrate the mutual relation between spectroscopy 
and homology modeling. Most examples are drawn from the GPCR research field. These examples 
are just illustrations and neither imply a judgment nor pretend completeness. 
 
Exposed residue labeling 
In two studies Davidson and Findlay identified residues that were exposed to the membrane 
environment or the retinal binding site respectively, by labeling opsin with photoactivated l-azido-4-
[125]iodobenzene6; 7. This study was carried out long before the first crystal structure of any GPCR 
became available, and determining which residues were allowed Davison and Findlay to get a more 
complete picture of the three dimensional organization of the opsin molecule.  
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Figure 3.1: The most striking difference between the crystal structures of rhodopsin (PDBid 1f882) and the 
beta-2 adrenergic receptor (PDBid 2rh15) concerns the structure and location of the extracellular loop between 
helix IV and V. The loop IV-V in rhodopsin forms a β-sheet that folds into the binding pocket (yellow), whereas 
loop IV-V in the beta-2 adrenergic receptor forms an α-helix and extends towards the extracellular 
environment (purple) 
 
Site-directed spin labeling 
The group of Khorana used site-directed spin labeling to analyze structure and light-dependent 
changes of part of GPCRs8. The electron paramagnetic resonance (EPR) spectrum of each spin 
labeled mutant was analyzed in terms of residue accessibility and mobility.  In the article where they 
describe the region extending from helix VII to the palmitoylation sites in the rhodopsin molecule 
they concluded that this region had extensive tertiary interactions9. After Oliveira et al.10-correctly- 
modeled this region as a helix that runs parallel to the membrane, the interpretation of the EPR data 
could be extended significantly, indicating how modeling can help interpret spectroscopic 
measurements. 
 
Fluorescence resonance energy transfer 
Turcatti et al.11 studied ligand-receptor interactions in the neurokinin-2 receptor (NK2) using 
fluorescence resonance energy transfer (FRET). A fluorescent unnatural amino acid was introduced 
at known sites into NK2. Inter-molecular distances were determined by measuring the fluorescence 
resonance energy transfer between the fluorescent unnatural amino acids and a fluorescently 
labeled NK2 heptapeptide antagonist. A similar approach was used to measure distances between 
the cholecystokinin receptor and a natural agonist12 and between the secretin receptor and secretin 
analogues13. Distances obtained were used as constraints to improve models for ligand-receptor 
interactions. The NK2 results were interpreted in terms of an obviously very poor bacteriorhodopsin 
structure. Looking at their results more than 10 years later, and with four GPCR structures at hand, 
we can see that they located the NK2 ligand largely at the correct place. This tells us how to trust or 
distrust the secretin FRET results, and it illustrates how spectroscopy can help improve the modeling. 
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Fourier transform infrared spectroscopy  
Molecular models of rhodopsin based upon electron density projection maps that were constructed 
before the first crystal structure became available proposed a specific interaction between 
transmembrane (TM) helices III and V, which appeared to be mediated by amino acid residues 
Glu122 and His211 on TM helices III and V, respectively. Beck et al.14 used a combination of site-
directed mutagenesis and Fourier transform infrared spectroscopy (FTIR) to validate this hypothesis. 
 
Small angle scattering 
Small angle scattering has occasionally been used to assist with the homology modeling of water-
soluble proteins. Mascarenhas et al.15 studied crotoxin. The sequence identity with a template 
structure was generally high enough to build a good homology model, but the structure of one large 
loop remained highly ambiguous. Small angle neutron scattering data corresponded much better 
with one of the two models made, thus solving this problem. Comoletti et al.16 studied the structure 
of the neuroligins and their complex with neurexin using small angle neutron scattering and small 
angle X-ray scattering. A high-resolution structure of the neurexin was available but no structure was 
available of a neuroligin. However, the neuroligins have signiﬁcant sequence similarity with 
acetylcholine esterase making it possible to build a homology model. Scattering from neuroligin 
constructs was similar to that previously obtained from acetylcholine esterase structures17 indicating 
that the homology model was valid. 
 
Fluorescent ligands 
Turcatti et al.18 studied the NK2 receptor using a number of fluorescent ligands, differing only in the 
length of the spacer between the fluorescent probe and the peptide ligand. By analyzing the 
different levels of fluorescence related to the spacer lengths they found that the binding pocket of 
the NK2 receptor was buried at a depth of 5-10 Å.  
 
Modeling and spectroscopy of the M13 protein 
The final example to illustrate the never ending love story of modeling and spectroscopy was 
recently reviewed by the Hemminga group19. In a beautiful review article titled "From ‘I’ to ‘L’ and 
back again: the odyssey of membrane-bound M13 protein" they illustrate how a large series of 
spectroscopic techniques have been employed world-wide over a period of more than 20 years to 
continuously update the structure model of the M13 protein in its membrane-bound form. The 
(mainly spectroscopic) techniques used during this whole odyssey include NMR, site specific and 
other solid state NMR, X-ray fibre diffraction, cryo-electron microscopy, site directed spin-labeling 
and site directed introduction of fluorescence probes similar as described above for the GPCR 
studies, fluorescence energy transfer, site specific infrared dichroism, etc. Throughout this odyssey 
of Hemminga and others, homology modeling and spectroscopy were both applied. This example 
nicely illustrates the importance of homology modeling for spectroscopy, and vice versa. In some 
cases the spectroscopic results triggered the need to analyze the model, while in other cases the 
model suggested the spectroscopic experiments, and in some cases both went hand-in-hand. 
Throughout the odyssey the model improved and the spectroscopy got more sophisticated. 
The M13 odyssey also shows that spectroscopic techniques developed over the years, 
allowing for all the time more precise and more accurate measurements. In this same period 
homology modeling improved as well. In the next paragraphs we will discuss the latest 
developments in homology modeling and its remaining unsolved problems. We will also illustrate 
the usefulness of homology models, sometimes in combination with spectroscopic techniques, with 
a few real-world examples. 
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Method overview: the eight steps of homology modeling 
Homology modeling is usually described as a multi-step process in which the number of steps 
typically varies from X to Y. Here we use an eight step plan (figure 3.2). Over the years each of these 
eight steps has undergone extensive scrutiny and has been the topic of much research. 
Consequently, models built today with a fully automatic web server are considerably more accurate 
than the first model-approach four decades ago by Browne et al. using wire and plastic models of 
bonds and atoms20. Here, we will discuss the latest innovations and developments in each of the 
eight homology modeling steps. 
  
Step 1: Template recognition and initial alignment 
Traditionally, the modeling template is found by performing a BLAST21 search against the Protein 
Data Bank (PDB)22. This approach is often successful when the query is highly identical to structures 
in the database. In contrast, templates that are close to the possible homology modeling threshold 
are harder to find or may even remain undetected23. The development of PSI-BLAST24 and fold-
recognition methods25 improved the detection of these difficult-to-find templates because these 
methods use a profile instead of a single sequence to search the database. Furthermore, the growing 
number of structures collected in the PDB makes it every year easier to find a homologous one.  
 
 
 
Figure 3.2: The eight steps of homology modeling. The first step involves finding a suitable, homologous 
protein of which the structure can be used as modeling template, and generating the initial alignment 
between that template and the model sequence. In step 2 this alignment is refined using, for example, 
knowledge obtained from the template structure. In step 3 the backbone is generated and deletions are 
performed so that, temporarily forgetting insertions, the backbone of the template looks like that of the model 
as much as possible. In step 4 gaps in the model are closed, and optionally loops are ab initio constructed. In 
step 5, the side chains are added using rotamer libraries to find the best rotamer for that local backbone 
conformation. Step 6 consists of a molecular dynamics simulation on the complete model in order to remove 
(the majority of) the introduced errors. In step 7 the model is checked for remaining errors using validation 
software. Depending on the outcome of the validation step we either approve the model or iterate the 
modeling process (step 8), starting from step 1-6. 
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Finding the best possible template is not limited to searching the PDB with (PSI-)BLAST. There may 
be several candidate templates with similar sequence identities to the query. In that case, the 
optimal template must be selected based on other criteria. The X-ray resolution is, although 
frequently used as such, only a limited measure of structure quality because it says something about 
the experimental data, not about the quality of the structure model. I.e. with 1.8Å data one can 
typically make a better structure model than with 2.2Å data, but whether or not this better structure 
model is actually made, depends on the crystallographer and the software he/she uses.  
The crystallographic residual, the so-called R-factor, tells us something about the correlation 
of the structure model with the experimental data and therefore seems more indicative than the X-
ray resolution alone. Unfortunately, acceptable and even seemingly nice R-factors can be attained by 
adding more parameters to the structure models, effectively over-fitting/over-refining the model26. 
This problem was solved by the introduction of the free R-factor27, which is much more robust 
against over-fitting because the value is calculated only with the fraction of the X-ray data that was 
not used to build the structure model. Therefore, R-free can be seen as a description of how well the 
structure model predicts an ‘independent’ measurement.  
While very robust, the free R-factor is a global indicator: it describes the structure model as 
a whole, but not a particular part of the protein that may interest us. A local measure of fit with the 
experimental data is needed, for instance the real-space R-factor28. For PDB entries these values can 
be obtained from the Electron Density Server (EDS)29. 
So, with the X-ray resolution, the (free) R-factor, and the real-space R-factor one can select a 
proper template from the (PSI-)BLAST results. That is, one can select a template that corresponds 
well with the X-ray experiment. A more in depth analysis of the template structure is needed to see 
whether it also corresponds with our current knowledge of protein structures. Structure validation 
scores like Ramachandran Z-score30, the fraction of Ramachandran plot outliers31, side chain rotamer 
normality scores32, residue packing scores33, hydrogen bond network quality34, and many others are 
used to get insight in the geometric quality of the template structure. Most of these validation 
scores, both global and local scores, can be obtained via the PDB and the linked databanks. 
Another possible step in the template selection is the optimisation of the template before 
the actual modeling. We have recently shown that validation scores such as the Ramachandran Z-
score and the number of atomic clashes (bumps) can be improved by a fully automated re-
refinement of the PDB entry with its original experimental data35. In addition, the crystallographic R-
factor, or rather the free R-factor is also improved by this re-refinement. This optimisation is 
particularly useful for templates that will be used for drug docking studies because their success 
often depends critically on the quality of the atomic model. The benefit of re-refinement is tightly 
correlated with sequence identity between the template and the model sequence. That is, any 
improvement of the atomic coordinates of a residue is lost when this residue (or just its side chain) 
has to be rebuilt. Fortunately, even with low sequence identity, there may be regions of the 
template that are not changed in the modeling process and thus can be improved by re-refinement. 
Of course, when sufficient CPU time is available to the modeller, it may be beneficial to use a 
number of (re-refined) PDB entries as templates, instead of a single one. 
 
Step 2: Alignment correction 
Having identified one or more possible modeling templates using the initial screen described above, 
more sophisticated methods are needed to arrive at a better alignment.  Molecular class-specific 
information systems (MCSISs) can be a great asset in the homology modeling process. MCSISs 
contain a large number of heterogeneous data on one particular class of proteins. The GPCRDB at 
www.gpcr.org/7tm/36 is a good example of such a system. It contains sequences, structures, 
mutation data, ligand binding data, and much more. All of this information is used (directly or in an 
indirect way) for creating sequence profiles for GPCR (sub)families. Profile-based alignments37 are 
used to generate alignments that are of a significantly higher quality than alignments generated by 
automatic methods based solely on sequence data.  
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Currently, MCSISs are available for only a small number of protein families and therefore in most 
cases other sequence alignment tools are needed. 
Many programs are available to align a number of related sequences, for example 
CLUSTALW38. The resulting multiple sequence alignment implicitly contains a lot of additional 
information. For example, if at a certain position only exchanges between hydrophobic residues are 
observed, it is highly likely that this residue is buried. Multiple sequence alignments are also useful 
to place deletions or insertions in areas where the sequences are strongly divergent. To consider this 
knowledge during the alignment, one uses the multiple sequence alignment to derive position 
specific scoring matrices, also called "profiles"39; 40. In recent years, new programs like MUSCLE41 and 
T-Coffee42 have been developed that use these profiles to generate and refine the multiple sequence 
alignments.  
When building a homology model, we are in the fortunate situation of having an almost 
perfect profile:  the known structure of the template. We simply know that a certain alanine sits in 
the protein core and must therefore not be aligned with a glutamate. Alignment techniques like 
SSALN make use of this structural knowledge found in the template43. 
 
Step 3: Backbone generation 
Aligned residues occupy the same position in template and model. Coordinates can thus simply be 
copied to create the initial model backbone. In practice, there are many ways to improve this crude 
recipe. First, the template is likely to be present more than once in the PDB (e.g. a bundle of NMR 
structures, multiple copies in the crystal, or solved multiple times under different conditions). Here, 
one can use structure validation tools31,32, like the PDBREPORT (www.cmbi.ru.nl/gv/pdbreport/) 
databank to pick the best one, correcting errors where possible. Second, one can combine multiple 
templates, because residues missing in one template can sometimes be found in the other, or 
because the alignment covers more than one template, which is common for multi-domain targets. 
The well-known SwissModel server (http://swissmodel.expasy.org/44) selects fragments from 
different PDB files that locally are most similar to the corresponding model fragment. The Zhang 
(http://zhang.bioinformatics.ku.edu/I-TASSER/45) and Robetta (http://robetta.bakerlab.org/46) 
modeling servers have successfully extended on this concept and are today among the best 
homology modeling servers available on-line. Some methods do not even create a single backbone 
at all, instead they use the alignment to derive restraints (hydrogen bonds, backbone torsion angles, 
etc.), and only later build the model, while trying to satisfy the restraints47. 
 
Step 4: Loop modeling 
Any insertion or deletion in the alignment implies a structural change of the backbone, and can thus 
not be modeled in the previous step. Since these changes usually take place outside regular 
secondary structure elements, their prediction is referred to as 'loop modeling'. There are two major 
approaches to the problem: first knowledge-based methods48, which search the PDB for known 
loops with high sequence similarity to the target and endpoints that match the anchor residues 
between which the loop has to be inserted. And second energy-based methods, which sample 
random loop conformations while minimizing an energy function49. Since loops never fit the anchor 
points exactly, they have to be closed, using for example an algorithm borrowed from robotics50. In 
practice, a combination of both methods is common. 
 
Step 5: Side chain modeling 
The most successful approaches to side-chain prediction are knowledge-based. They use libraries of 
common side-chain rotamers extracted from high resolution X-ray structures51-53. An essential 
feature of these libraries is backbone-dependence, hence they store the distribution of the side-
chain dihedral angles (χ1, χ2, etc.) as a function of the backbone dihedrals φ and ψ. This does not only 
increase the accuracy, but also helps to shrink the search space (i.e. the possible combinations of  
interacting side-chain rotamers) to a size that can be handled, for example using dead-end 
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elimination54. The prediction accuracy is usually highest for residues in the hydrophobic core, where 
more than 90% of all predicted χ1-angles fall within ± 20° from the experimental values, but 
significantly lower for residues on the surface where the percentage drops to 70%, and further down 
to 50% for the combined χ1/χ2 accuracy
54. This is mainly caused by the electrostatic and hydrogen 
bonding interactions, which are partly solvent mediated and much more difficult to get right than 
the simple repulsive Van der Waals interactions in the core. A second reason is the fact that flexible 
side chains on the surface tend to adopt multiple conformations, which are additionally influenced 
by crystal contacts, so there simply may not be a single correct conformation at all. Nevertheless, the 
surface residues are among the most important ones to get right; they mediate all the interactions, 
and applications like drug design or protein docking thus critically depend on them. 
 
Step 6: Model optimization 
Once all these steps are completed, one obtains the initial homology model, which hopefully looks 
broadly similar to the (usually unknown) target structure. The little details however, like the precise 
backbone conformation, hydrogen bonding networks or certain side-chain rotamers, are often 
wrong. While this deficiency keeps scientists working on experimental structure determination busy,  
predictors strive to bridge the gap between model and target (the 'last mile of the protein folding 
problem') using various optimization and refinement techniques, the most prominent ones being 
molecular dynamic55 and Monte Carlo simulations56. For a given model, there are unfortunately 
many more paths leading away from the target than towards it, and combined with the limited 
accuracy of empirical force fields, this makes it trivial to reduce the model accuracy during the 
refinement. Consequently, the best optimization was often no optimization. We did well in the early 
CASP homology modeling competitions simply by not performing MD simulations on the models 
(except for 25 energy minimization steps with CNS57 to introduce the same local geometric features 
that CNS put in the real structure our prediction would be compared against). Nevertheless, steady 
progress over the past years has changed this rule of thumb (see Results section). 
 
Step 7: Model validation 
Protein structures were error free till the landmark article in 1993 on Procheck by the Thornton 
group31. This article can be seen as the beginning of the realisation that crystallographers and NMR 
spectroscopists actually use experimental techniques to determine their coordinates. With the 
release of the first WHAT_CHECK32 structure validation became a common household technique for 
most scientists and, although not at the speed we hoped, errors in protein structures are becoming 
less frequent. The two main bottlenecks are the introduction of improved technologies in all 
structure solution software used all over the world, and the fact that the detection of an error does 
not implicitly mean that the error can be removed. 
 
Step 8: Iteration 
If the model is not good enough, (part of) the modeling process has to be repeated. For instance, 
wrong side chain conformations can be improved by iterating the process from step 5 onwards. 
Sometimes, this iteration-step means that one has to start the modeling process all over again using 
another template or alignment. Alternatively, one can start several modeling processes using 
different templates. The resulting models can be combined in the end to produce a hybrid model 
that consists of the strongest points of each separate model. 
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Unsolved problems and future directions in homology modeling 
While many scientific disciplines face huge difficulties when trying to experimentally validate 
theoretical predictions, protein modeling is in a fortunate situation: since 1994, the biennial CASP 
('Critical Assessment of Structure Prediction') contests58 provides an ideal opportunity to evaluate 
the accuracy of today's many protein structure prediction methods. During each CASP season 
(lasting about four months once every two years), about 200 research groups try to predict the 
structures of ~100 proteins, the CASP targets. The target sequences are provided to CASP by 
structural biology labs just before the corresponding structures are solved. The predictions are thus 
true blind predictions, allowing to measure performance in realistic test cases, locating areas of 
progress as well as yet unsolved problems. 
CASP regularly shows that the eight homology modeling steps summarized here allow in many cases 
building reliable models, from which a lot of structural and functional insights can be derived. 
However, these eight steps are unfortunately not sufficient to actually solve the protein structure 
prediction problem via homology modeling as soon as enough templates become available. Figure 
3.3 shows CASP8 targets T0498 and T0499: both proteins are 56 amino acids long, 53 of which are 
conserved (95% sequence identity). Still, the two structures are entirely different; just three point 
mutations completely change the fold. While this is an extreme example of human protein 
engineering art59, also naturally occurring proteins with similar sequences often show surprising 
structural diversity60, letting classic homology modeling fail miserably. The prion protein61 and other 
amyloid-forming proteins provide an even more dramatic case; here 100% identical sequences can 
exist in two totally different structures. Obviously, the homology modeling problem is tightly 
intertwined with the more general protein folding problem itself. Even if a close template is 
available, there can always be structurally diverging regions, which are either expected from the 
poor local alignment, or unexpectedly caused by critical point mutations, or widely differing crystal 
packing contacts. 
 
 
 
Figure 3.3: Comparison of CASP8 targets T0498 and T0499. The sequences of both proteins are 95% (53 of 56) 
identical (only residues 20, 30 and 45 differ), yet the structures are totally different. Classic homology 
modeling predicted T0499 correctly (which looks like the related homology modeling templates in the PDB), 
but failed completely for T0498. Since the structures of T0498 and T0499 have not been released yet, this 
figure is based on a closely related pair with PDB IDs 2jws and 2jwu from the same authors, who showed by 
NMR spectroscopy that these two structures look essentially the same as T0498 and T049959.  
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The only way to handle these difficult cases is to apply more general ab initio folding algorithms, 
which do not depend on template structures, but try to simulate the complete folding process from 
the stretched-out conformation. As it turns out, this 'one-algorithm-for-everything' approach is the 
currently most successful one at CASP45; 46: if available, it uses known templates (or fragments 
thereof) only to guide the search, but does not depend on them. As a side-effect, this allows to build 
hybrid-models, combining the best parts from multiple templates. 
Despite these encouraging developments, the protein folding problem is far from solved. 
The best models are still built by those who got the alignment right in the first place, which 
unfortunately implies that structural diversity is often missed: one cannot yet ignore the difficult-to-
align regions and simply predict them with ab initio folding instead. The sequence alignment 
problem thus remains an active research field for years to come. 
 
Noteworthy progress has been made with model optimization to bridge the structural gap between 
initial model and target. While in the early days of CASP, predictors were well advised to keep the 
backbone of their model fixed (the 'frozen core approach'), simply because the danger of messing up 
the model was just too large, the situation is quite different today: force field accuracy55 and 
sampling efficiency56 have improved to a level that allows well performing methods like Modeller-
CSA62, Rosetta46, WHAT IF63, and YASARA64 to free all atoms during the refinement, often moving 
models considerably closer to the target.  
While homology modeling currently focuses on the protein in a model, other entities, i.e. 
carbohydrates, small molecules, and ions, also make up important parts of certain proteins and 
protein complexes. For instance, zinc atoms in so-called zinc fingers are important for the stability of 
the protein, and a common protein like haemoglobin would be useless without its haem groups and 
the iron atoms therein. Carbohydrates in glycoproteins perform numerous functions, ranging from 
providing stability to signalling and labeling for intracellular transport65. The many roles of non-
protein entities make it obvious that homology modeling should look beyond the protein. A 
complete model should thus be more than a 3D representation of an amino acid sequence. One 
major challenge for homology modeling is recognising binding sites for non-protein entities. 
Drug docking software66; 67 can be used to detect the binding sites of compounds such as 
heme groups or coenzymes. However, relevant biological information is needed to select 
compounds that may be bound to the protein. Copying the binding site from the template structure 
is the simplest method, but does not work for ab initio folding models. For such models, 
spectroscopic analysis of the protein can provide insight on which compounds are bound. This 
approach is not limited to homology modeling; X-ray crystallography can also benefit from 
spectroscopic analysis of a protein to identify a bound compound68. 
Incorporating ions can be an additional step of the modeling process. Nayal and Di Cera69 
have suggested a method to detect sodium binding sites in protein structures which can be 
extended to detect various other ion binding sites. Of course, any additional experimental data can 
guide this ion site detection process. Especially tightly bound functional ions that co-purify with the 
protein can be detected by means of spectroscopic analysis. A significant number of PDB files have 
bound ions or water molecules that were erroneously assigned. We have observed H20, and Na
+, K+, 
Mg2+, Ca2+, and NH4
+ ions that should actually be one of the others in this list. This is the result of X-
ray spectroscopy having difficulties distinguishing between H2O, NH4
+, Na+ and Mg2+ because these 
entities have equally many electrons, and so do K+ and Ca2+.  
The power of force-field based model optimisation methods can be reduced significantly 
when such problems include a difference in the ionic charge. It is therefore very important to 
(experimentally) validate the ions in template structures when these are important for the final 
homology model. 
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Carbohydrates can be modeled at the final stage of the homology modeling process, but this does 
not always reflect the protein folding process. Carbohydrates are not only added in post-
translational modification (that is, when the protein is ‘done’), but also during the protein expression 
by the ribosome. They are important in the protein folding process and the detection of misfolded 
proteins70. It may therefore prove interesting to add the necessary carbohydrates to the unfolded 
protein before ab initio folding. Apart from their role in protein folding, carbohydrates are 
sometimes important in oligomerisation of proteins. For instance, the neuraminidase protein from 
influenza shows different glycosylation states in its monomeric, dimeric, and tetrameric states. The 
carbohydrates in tetrameric state provide extra stability (see figure 3.4) and, in the case of the 
Spanish flu influenza virus, resistance to trypsin digestion leading to increased virulence71. This 
shows the vital (and sometimes lethal) importance of considering carbohydrates in homology 
models. 
 
Figure 3.4: Tetrameric form of whale influenza neuraminidase (PDBid 2b8h72), coloured by monomer. Protein 
chains are displayed in ribbon representation, carbohydrate atoms in ball representation. The carbohydrates 
of one monomer interact with the adjacent monomer thus stabilising the tetramer. 
 
Results and discussion: other roles for homology modeling 
In the 1990's most articles that included homology modeling described only how the model of one 
protein was constructed, and ended with the ominous sentence "...this model will help us perform 
our research on this intriguing protein", after which the group would start working on something 
else. Here, we will illustrate the importance of homology modeling for the study of inheritable 
diseases, but the value of models has been amply illustrated for fields ranging from drug design to 
laundry powder enzyme engineering, from validating experimental structures to the design of 
humanized antibodies, and from mutation analysis to intelligent experimental design in many 
spectroscopic research projects. 
 
In the following examples building the homology model was not the ultimate goal but one of the 
tools used to gain more information about a mutation, a disease, or a process in the human body. 
These examples prove that homology models can be of great use in the (bio)medical field. 
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Modeling of the LRTOMT-COMT domain 
In a study for non-syndromic deafness four pathogenic mutations were found in a so-far 
uncharacterized gene which codes for two different proteins, called LRTOMT1 and LRTOMT273. 
Three of these mutations were missense mutations located in the catechol-O-methyltransferase 
(COMT, EC 2.1.1.6) domain of LRTOMT2, one introduced a stop codon causing the loss of a large 
fraction of the protein. The COMT domain catalyzes the transfer of a methylgroup from S-adenosyl-
L-methionine (Ado-Met) to a hydroxyl group of catechol. No structure for LRTOMT2 was known, so 
we needed a homology model to study the missense mutations in more detail.  
Using the crystal structure of rat COMT (39% identity to LRTOMT2 over 212 amino acids, (PDBid 
1h1d74) we were able to model the COMT domain of human LRTOMT2. The three mutated residues 
are located in helix 1 (Arg81Gln), helix 2 (Trp105Arg) and the loop that follows helix 2 (Glu110Lys), 
and thus not in the hypothetical substrate-binding pockets. However, the loop is predicted to be 
important for the groove that binds the putative methyl acceptor. The Arg81 and Glu110 residues 
are predicted to form a hydrogen bonded salt bridge between helix 1 and the loop, and Trp105 is 
predicted to make hydrophobic interactions in the core between these helices (see fgure 3.5). These 
residues may therefore be important for local protein stability and can affect the substrate binding 
region.  
 
 
Figure 3.5: A) Molecular model of the catechol-O-methyltransferase domain of LRTOMT2, residues 79–290. 
The affected residues are depicted in blue. The predicted ligands are coloured yellow, and the tyrosine residue 
(Tyr111) that lines the hydrophobic groove of the ligand binding site is shown in cyan. The boxed region 
containing residues affected by missense mutations of LRTOMT2 is enlarged in panels B–D. The helices 1 (H1) 
and 2 (H2) are shown with wild-type residues Arg81, Trp105 and Glu110 depicted in blue and mutated 
residues in green. Hydrogen bonds are represented by yellow dotted lines. B) The Arg81 and Glu110 residues 
form a salt bridge between helix 1 and the loop following helix 2. The Gln81 residue cannot form this salt 
bridge as it is not positively charged. Also, the formation of hydrogen bonds is impaired because of the smaller 
size of glutamine as compared to arginine. C) The Trp105 residue is predicted to make hydrophobic 
interactions as a result of its big side chain. Most of these interactions would be lost by the Trp105Arg 
substitution. D) Substitution Glu110Lys is predicted to lead to the loss of hydrogen bonds and a salt bridge. 
There would likely be repulsion between the side chains Lys110 and Arg81 as both are positively charged. 
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Modeling of the ligand binding domain of ESRRB 
Sequence analysis revealed four missense mutations of the ESRRB gene leading to autosomal-
recessive non-syndromic hearing impairment75. Experimental results indicated that ESRRB is 
essential for inner-ear development and function. ESRRB encodes the estrogen-related receptor 
protein beta, a member of the nuclear hormone receptor (NHR) family. In general, members of this 
family share a zinc finger C4 DNA-binding domain at their N-terminus and a ligand-binding domain 
that is located near the C-terminus. The ligand-binding domain of nuclear hormone receptors is a 
well conserved and highly organized structure containing 12 alpha-helices. Three mutations 
(Leu320Pro, Val342Leu, and Leu347Pro) were located within this ligand-binding domain. The fourth 
mutation was located in the DNA binding domain and will not be discussed here.  
To study the three mutations in the ligand binding domain in more detail we built a 
homology model of this domain using the structure of the ESRRG receptor (PDBid 1kv676) as a 
template. It had 79% sequence identity over 229 amino acids. The molecular model showed that the 
three missense mutations in the ligand binding domain are likely to affect the structure and stability 
(see figure 3.6). Two of the mutations involved a leucine to proline mutation, Leu320Pro in helix 7 
and Leu347Pro in helix 8. In general, the introduction of proline residues within helices reduces the 
stability of the helix, and therefore, these mutations will disturb the structure of the helices and 
probably the complete ligand-binding domain. In addition, the loss of the leucine side chain 
abrogates a number of hydrophobic interactions. The other mutation in this domain (Val342Leu) 
substitutes a leucine for a valine residue resulting in the occurrence of a somewhat larger side chain 
that bumps into the molecular surface of helix one. This substitution is predicted to reduce the 
strength of the interaction between helix 1 and 8.  
 
 
Figure 3.6: A) Molecular modeling of the ligand-binding domain of the human ESRRB protein. The structure 
was deduced from the known ESRRB structure. The various helices are presented by cylinders. The three 
amino acids that are affected by the missense mutations are indicated in green. Detailed view of the three 
mutations are shown in panels B, C and D. The wildtype residue is depicted in green, whereas the side chain of 
mutant residue is presented in red. B) Leu320 makes hydrophobic contacts in the core between two helices, 
the mutation into Pro causes loss of many hydrophobic interactions. Additionally, the Pro will disturb the 
structure of the helix. C) Val342 is tightly packed in the core between two helices. This core will be disturbed 
by the Val342Leu mutation because Leu has a larger side chain. D) Leu347Pro will cause loss of hydrophobic 
interactions between the helices and the introduction of Pro will disturb the structure of the helix. 
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In summary, the molecular modeling data predicts that mutations of ESRRB will result in 
conformational changes near the substituted amino acids or decreased helix stability and are 
therefore likely to affect the stability and function of the complete ligand-binding domain. 
 
Functional states of alcohol oxidase 
Van der Klei and co-workers studied four different conformational states of the flavoenzyme alcohol 
oxidase (AO) from the methylotrophic yeasts Hansenula polymorpha and Pichia pastoris, including 
assembly intermediates77. These proteins had to be homology modeled from the enzyme glucose 
oxidase that shows only 25% sequence identity with the AOs. With so little similarity homology 
modeling is very difficult and large modeling errors are to be expected. An additional problem is that 
glucose oxidase is a dimer while AO is an octamer. The low quality of the model certainly precluded 
any form of protein-protein docking to construct an octamer from the dimer. The model fortunately 
revealed a series of hydrophobic surface patches, some of which have tryptophan residues at the 
surface. As there were also tryptophans observed in the model near the FAD group, the suggestion 
to apply spectroscopic techniques to extend the modeling study came shouting from figure 3.7. A 
series of spectroscopic techniques, including time resolved fluorescence, fluorescence anisotropy 
decay, steady-state fluorescence, and visible and near-UV circular dichroism, was used to 
characterize native AO several putative assembly intermediates. A good working hypothesis for the 
AO folding pathway could be derived. The study also triggered the search for chaperones that 
seemed needed to allow FAD to bind to AO in vivo.  
 
Figure 3.7: Model of one monomer of AO shown as ribbon; helix in blue, strand in red, loop and turn in shades 
of green. All tryptophan side chains are shown in yellow, the FAD group is shown in purple. 
 
Conclusion 
Homology modeling will always be needed because it is impossible to solve the three dimensional 
structure for each determined sequence. An increasing number of scientists are now using protein 
structures for mutational analysis and experimental design. It is a good thing that the process of 
homology modeling has improved dramatically over the years, but still there are many problems to 
solve. It is a reassuring fact for homology modellers that modeling problems often can be solved 
using spectroscopic techniques. Spectroscopists, on the other hand normally need homology models 
to fully harvest the results from their spectroscopic studies. And that brings us back to the title of 
this article, homology modeling and spectroscopy indeed are a never ending love story. 
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green fluorescence when exposed to blue light. Ever since it 
was first isolated from jellyfish it’s been used in life science 
experiments as a reporter of expression. (PDB file 1q4a) 
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Background 
The omics-revolution has led to a rapid increase in detected disease-related human mutations. A 
considerable fraction of these mutations is located in protein-coding regions of the genome and thus 
can affect the structure and function of that protein, thereby causing a phenotypic effect. 
Knowledge of these structural and functional effects can aid the design of further experiments and 
can eventually lead to the development of better disease diagnostics or even medicines to help cure 
patients. The analysis of mutations that cause the EEC syndrome, for example, revealed that some 
patients carry a mutation that disturbs dimerisation of the affected P63 protein1. This information 
has triggered a search for drugs2. In another case, the study of a mutation in the human 
hemochromatosis protein (HFE), which causes hereditary hemochromatosis, resulted in new insights 
that are now being used to develop novel diagnostic methods3. These and numerous other examples 
have highlighted the importance of using heterogeneous data, especially structure information, in 
the study of human disease-linked protein variants.  
The data that can aid our understanding of the underlying mechanism of disease related 
mutations can range from the protein's 3D structure to its role in biological pathways, or from 
information generated by mutagenesis experiments to predicted functional motifs. Collecting all 
available information related to the protein of interest can be challenging and time-consuming. It is 
a difficult task to extract exactly those pieces of information that can lead to a conclusion about the 
effects of a mutation. Several online Web servers exist that offer help to the (bio)medical researcher 
in predicting these effects. These servers use information from a wide range of sources to reach 
conclusions about the pathogenicity of a mutation. The PolyPhen server, for example, is widely used 
by researchers to predict the possible impact of an amino acid substitution on the structure and 
function of human proteins4. PolyPhen combines a subset of the UniProt sequence features, 
structural information (when available), and multiple sequence alignments in order to draw 
conclusions about the impact of a mutation4. SIFT, on the other hand, bases its mutation analysis 
purely on a multiple sequence alignment5. This server gives probability scores for each amino acid 
type at the position of interest to separate the harmless mutations from disease-causing ones. The 
ALAMUT software (http://www.interactive-biosoftware.com) is widely used in human genetics 
research groups. It focuses on making many forms of software and databases available to their 
users. The ALAMUT system also automatically calls the PolyPhen Web server as part of its decision 
process. ALAMUT is not available as a Web server. PolyPhen, SIFT and ALAMUT all have an excellent 
track-record make existing data accessible for (bio)medical scientist to aid them with the 
interpretation of mutational effects. We built on their strengths to produce the HOPE software that 
was written to optimally use the advantages of the novel tools of the e-Science era. 
The recent increase in data types and data volumes has gone hand-in-hand with large efforts 
in bioinformatics that have led to numerous new databases and computational methods, and in this 
era of e-Science, Web services provide on-demand access to these facilities6-8. The development of 
Web services facilitates the usage of external databases and methods in in-house developed 
software and eases software maintenance and development by out-sourcing logic to Web services. 
Web services have a series of advantages for the software developers: 
• They save time by reusing program code; 
• They tend to always be up-to-date; 
• They are executed remotely, which gives access to large amounts of (free) CPU time, thus 
not overloading the local machine; 
• No need to maintain in-house data and software collections. 
 
Web services also have disadvantages: 
• Source code of Web services often is not available; 
• Web services are not guaranteed to always be available. 
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HOPE (Have (y)Our Protein Explained) is a next-generation web application for automatic mutant 
analysis. We have designed HOPE to explain the molecular origin of a disease related phenotype 
caused by mutations in human proteins. In this aspect HOPE resembles the aforementioned systems 
(PolyPhen, SIFT, ALAMUT). With HOPE we have taken the logical next step in the e-Science era in 
that the data gathering is done using Web services and DAS servers. Additionally, in HOPE we have 
taken a protein 3D-structure centred approach. HOPE collects information from data sources such as 
the protein's 3D-structure and the UniProt database of well-annotated protein sequences. For each 
protein this data is stored in a PostgreSQL-based information system. A decision scheme is used to 
process these data and to predict the effects of the mutation on the 3D-structure and the function of 
the protein. A life-scientist friendly report is produced that explains and illustrates the effects of the 
mutation. This report is presented using an interface that is designed specifically for the intended 
user community of human genetics researchers. The report is enriched with figures that illustrate 
the effects of the mutation, while any residual bioinformatics jargon is linked to our in-house, online 
dictionary. The conclusions drawn in the report can be used to design follow-up experiments and 
eventually can lead to the development of better diagnostics or medicines. Figure 4.1 illustrates the 
major steps of HOPE. We have tested HOPE on a series of mutations that we have previously 
analyzed manually. In all straightforward cases HOPE performed equally well as a trained protein 
structure bioinformatician.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Overview of HOPE's process flow. The user submits a sequence and a mutation. HOPE will first 
collect information from a wide range of information sources. These sources include: WHAT IF for structural 
calculations on either the PDB file or a homology model that was build by YASARA, HSSP for conservation 
scores, DAS-servers for sequence-based predictions and Uniprot for sequence annotations. The data is stored 
in HOPE's information system. The data is combined with the known properties of the amino acids in a 
decision schedule. The result is a report shown on the HOPE website that will focus on the effect of the 
submitted mutation on the 3D-structure of the protein. The text and figures can be used in articles and 
publications.  Availability: The HOPE Web server is freely available on http://www.cmbi.ru.nl/hope/ 
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Results and discussion 
Input 
The intended users of HOPE are life scientists who neither routinely use protein structures nor 
bioinformatics in their research. Therefore, both HOPE's input and its results are designed to be 
intuitive and simple, and all software used will run with default settings so that the user neither 
needs to set parameters nor needs to read documentation. Actually, the user will not even know 
which software runs in the background. The interface of HOPE is a website that enables the user to 
submit a sequence and a mutation. The user can indicate the mutated residue and the new residue 
type by simple mouse-clicks. Figure 4.2 shows the input screen, filled with an example protein 
sequence and a mutation. 
 
Figure 4.2: HOPE's input screen. The user can submit a sequence of interest and indicate the mutated residue 
with two simple mouse-clicks. In this example HOPE will analyze a Leu->Pro mutation on position 25 of the 
protein Crambin. 
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Information retrieval 
HOPE uses the submitted sequence as query for BLAST9 searches against both the UniProt 
database10 and the Protein Data Bank (PDB)11. The search against the UniProt database identifies the 
protein's UniProt entry and the accession code of the protein, a unique identifier that is used later in 
the process to obtain DAS-predictions. Alternatively, it is possible to submit this accession code 
directly. The BLAST search against the PDB is required to find the protein's structure or a possible 
template for homology modeling. HOPE uses the actual PDB-file when it contains the residue that is 
to be mutated and when it is 100% identical with the submitted sequence.  
 
HOPE identifies among multiple 100% hits the best structure for analysis based on resolution, 
experimental method, and length of the protein covered in the PDB (a full protein is preferred over a 
fragment). Nowadays, 20% of the human sequences available from SwissProt have a (partly) known 
structure and for another 30% a homology model can be built. To be able to build a homology 
model, the BLAST results should contain the equivalent location of the mutation and the percentage 
sequence identity should fall above the Sander and Schneider curve shown in figure 4.3. Homology 
modeling is performed using the Twinset version of YASARA which contains an automatic homology 
modeling script that requires only a sequence as input12. The script fully automatically performs the 
modeling process including sequence alignment, loop building, side chain modeling, and energy 
minimization. This script was the top contestant in the CASP8 modeling competition in terms of 
model detail accuracy13. 
 
 
Figure 4.3: The two zones of sequence alignment identity that indicate the likelihood of adopting similar 
structures. Two aligned sequences are highly likely to have similar folds if their length and percentage 
sequence identity fall in the region above the threshold (black line). HOPE will build a homology model when 
the identity between the template and submitted sequence falls in this zone. In case the sequence identity is 
less than 5% above this threshold (grey line) HOPE will build a model but will also warn that the model is based 
on a template with low identity. The region below the threshold (indicated with a cross) indicates the zone 
where inference of structural similarity cannot be made, thus making it difficult to determine if model building 
will be possible. (Figure modified after Sander and Schneider14).  
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The structure of the protein of interest, either a PDB-file or a homology model, is analyzed using 
WHAT IF Web services7. These services can calculate a wide range of structural features (e.g. 
accessibility, hydrogen bonds, salt bridges, ligand or ion interactions, mutability, variability, etc). 
When neither a 3D-structure nor a possible modeling template is available, HOPE cannot use 
structural information and will instead base its conclusions only on the sequence related data, and 
published mutation and variation results. 
The UniProt database (http://www.uniprot.org/) is used for the retrieval of features that can be 
mapped on the sequence15. This information includes the location of active sites, transmembrane 
domains, secondary structure, domains, motifs, experimental information, and sequence variants. 
The UniProt accession code is used to retrieve data from a series of DAS-servers for sequence based 
predictions such as possible phosphorylation sites. The DAS-servers form a widely used system for 
biological sequence annotation16. The conservation score of the mutated residue is calculated from a 
HSSP multiple sequence alignment17. 
Data storage in HOPE 
Information obtained from the protein structure or model, the UniProt record, and the DAS-
predictions are stored in a protein-specific information system based on the PostgreSQL database 
system. One new information system is produced for each submitted protein. Differences in the 
protein sequence might exist between data sources, for example sequences from UniProt often 
contain the signal peptide while the sequences stored in the PDB tend to lack these residues. 
Therefore, sequences obtained from different sources are aligned using ClustalW. This enables us to 
transfer information to the residue of interest without the need to deal with the residue numbering 
problem that results from these sequence differences. Protein features are stored in the information 
system on a per-residue basis, and can have one of the following four data-types: 
•Contacts: Interaction of the residue with another entity; for example DNA, a metal-ion, a 
ligand, hydrogen bond, disulfide bond, salt bridge, etc; 
•Variable features: Type with a value: for example, accessibility or torsion angle; 
•Fixed features: Labels a residue (or stretch of residues) with a feature without a value. This 
indicates that the residue is located in a domain or motif (for example a residue can be part 
of the active site or in a transmembrane region); 
•Variants: Mutations or other variations in sequence known at this position; for example 
splice variants, mutagenesis sites, SNPs. 
After a user request has triggered the generation of an information system for the protein of 
interest, the system for this protein is kept on disk for one month just in case the same user (or 
another user for that matter) requests information about other mutations in the same molecule. 
After one month every system is thrown away to ensure that conclusions are never based on 
outdated information. So, there does not really exist a HOPE database as all HOPE's data is, in total 
agreement with e-Science paradigms, scattered over the internet, and is each time combined upon 
request. 
 
Decision scheme 
The decision scheme in HOPE uses all collected information combined with known properties of the 
wild-type and mutated amino acid, such as size, charge, and hydrophobicity, to predict the effect of 
the mutation on the protein's structure and function. The scheme consists of six parts that each 
correspond to a paragraph in the output. Each part analyzes the effect of the mutation on one of the 
following aspects of the residue: 
•Contacts: Any interaction with other molecules or atoms, like DNA, ligands, metals, etc, but 
also hydrogen bonds, disulfide bridges, ionic interactions, etc; 
•Structural domain: Any part of the protein with a specific name (and often function), such 
as domains, motifs, regions, transmembrane domains, repeats, zinc fingers, etc; 
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•Modifications: Features that do not directly influence the structure of the protein but 
might influence post-translational processes like phosphorylation. 
•Variants: Known polymorphisms, mutagenesis sites, splice variants, etc; 
•Conservation: The relative frequency of an amino acid type at each position taken from a 
multiple sequence alignment. 
•Amino acid properties: The differences in the known properties of the wild-type and 
mutant residue (size, charge, hydrophobicity). 
HOPE will produce its conclusions for each of these six aspects separately. For example, a residue 
can be located in a transmembrane domain and also be important for ligand interaction. HOPE will 
in this case produce a paragraph about the effect of the mutation on the contacts and a separate 
paragraph describing the effect of the mutation on the structural location, in this example the 
transmembrane domain. 
Some types of information can be obtained from multiple sources, which are not equally reliable. 
Experimentally determined features and calculations performed on the 3D coordinates are more 
likely to be correct than any prediction. For example, transmembrane domains can be predicted by a 
DAS-server which normally will produce less reliable results than the annotations in UniProt. 
Therefore, HOPE ranks the information and uses the most accurate source available for its 
conclusions. WHAT IF calculations are preferred, followed by UniProt annotations, and DAS 
predictions are used only when neither WHAT IF nor UniProt data are available. In case no 
information about the mutated residue is found, HOPE will show a conclusion based only on 
biophysical characteristics between the wild type and mutant amino acid type. The conservation 
score is obtained either from the HSSP database that holds multiple sequence alignments for all 
proteins in the PDB, or through the HSSP Web services if a PDB file is not available17. 
Output 
The report focuses on the effect of the mutation on the 3D-structure, and is aimed at a specific 
audience in the field of (bio)medical science. It shows the methods used and the sources of the 
combined information. This can either be an analysis of the real structure or homology model, or a 
prediction based on the sequence. The results of the mutation analyses are illustrated with figures of 
the amino acids and, if available, figures and animations of the mutation in the structure. The HOPE 
output is rather extensive and way too large to put in print. In figure 4.4 we just show a small part of 
one mutation report. A series of examples of HOPE output is available at the ‘about’ section of the 
HOPE pages.  
A HOPE result consists of one HTML page that contains all results. This makes it easy for 
users to print the results, or to make their own Web-page with HOPE results for long-term storage. 
 
Test cases 
HOPE was validated in a series of collaborations with scientists from different fields of life sciences. 
Experiences from these real-world examples where used to design and adjust the decision scheme. 
So far, most mutation studies involved non-sense and missense mutations. Descriptions of these 
projects can be found at the HOPE website. The resulting reports often contain a molecular 
explanation of the observed phenotype that can suggest further experiments. The majority of these 
projects included the building of a homology model as in most cases no 3D-structure of the protein 
of interest was available. 
We also validated HOPE's conclusions by comparing them with the output of PolyPhen and SIFT. 
Even though it is very difficult to compare the results from PolyPhen, SIFT, and HOPE, we can still 
draw a few general conclusions, that will be elaborated in the following paragraphs. 
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Figure 4.4: Example of HOPE's output. A simplified example of HOPE's output. A) Explanation of the used 
method (structure, modeling or predictions) and links to the relevant databases. B) Text and pictures that 
explain the differences between the wild-type and mutant residue. (Text is left out of this figure for clarity.) C) 
Paragraph of the report explaining the effect of the mutation on contacts made by the residue, a disulfid bond 
in this case. It contains a link to the wiki-entry ‘cysteine’ and ‘disulfid bond’. D) Images/animations that show 
the effect of the mutation on the structure. 
Structure adds value 
The use of a protein's 3D-structure or homology model increases the prediction quality in terms of 
reliability and detail. The possibility offered by the YASARA software to fully automatically build high 
quality homology models increases the number of sequences for which HOPE can use structure data. 
The protein structure, either a PDB-file or a homology model, can reveal information that currently 
cannot be predicted accurately from sequence alone, such as ionic interactions, ligand-contacts, etc.  
The value of the extra information that HOPE can extract from a protein's structure or model 
is illustrated, for example, by the Leu320Pro and Leu347Pro mutations in ESRBB (see the ‘about’ 
section of the HOPE website). All Web servers correctly predict the effect of these mutations as 
damaging for the protein. However, HOPE completes the story by an extensive explanation of the 
disturbing effect of prolines on alpha-helices. In cases for which no 3D-structure data is available, the 
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three Web servers seem to perform similarly albeit that PolyPhen's output often tends to be scarce 
and a bit cryptic and SIFT's output is limited to conservation scores. 
 
Biomedicist understandable results 
HOPE's interface was designed especially for users that work in the (bio)medical sciences. Instead of 
displaying data in the form of detailed tables and numerical values, HOPE writes human readable 
reports that explain the structural and functional effects of the mutation, and illustrates this with 
figures and animations. When other Web servers list the effects of a mutation as "Hydrophobicity 
change at buried site; normed accessibility: 0.00, hydrophobicity change: -2.7". HOPE will instead 
report that "the mutation introduces a less hydrophobic residue in the core of the protein which can 
destabilize the structure". Many more examples of HOPE's readable output can be found at the 
‘about’ section of the HOPE website. HOPE's comprehensibility is improved by the Help-function that 
links difficult bioinformatics keywords to our own in-house dictionary based on Wikipedia's 
software. In this dictionary the user can find text, illustrations, and sometimes a short video-clip that 
explains the keyword. 
 
Conclusions 
Upon running 24 test cases, listed on the website, we can conclude that the present version of HOPE 
is useful and reliable in analysing point mutations. The next generation of HOPE will, however, need 
to reach a higher level of data integration to address more complicated cases. Some answer might 
be found only by combining the calculations with literature data and general knowledge of the 
protein's structure function relations. For example, PolyPhen predicts the Asn255Asp mutation in 
Kv1.1 (discussed in18) as being benign, while SIFT shows that this residue is 100% conserved. 
Combination of the conservation information with the fact that this residue is located in the voltage 
sensor of the channel can result in the hypothesis that the mutation disturbs the channel's voltage 
sensing mechanism. Such conclusions are still beyond the capabilities of today's Web servers, but 
the software design of HOPE will one day allow us to introduce the features needed to deal which 
these more complicated cases. 
HOPE is an example of the new way of doing data- and software-intensive research in the 
era of e-Science. Nowadays, the ongoing developments in experimental techniques like high-
throughput sequencing will continue to produce large amounts of data and will therefore demand 
new, further automated approaches towards the analysis of these data. The e-Science approach 
used will allow us to easily extend HOPE with more Web services, data sources, and DAS predictions 
when these become available. In the years to come HOPE can be extended with the possibility to 
analyze double-mutants, to quantitatively score the structural effects of the mutation and thereby 
provide the possibility to automatically rank candidate mutations that are the result of a sequence 
project, or to further improve the already user-friendly HOPE user interface. 
 
Methods 
The HOPE system is schematically shown in figure 4.5. The individual elements of this scheme are 
described in the remainder of this section. The HOPE website is implemented using the Wicket web 
framework (http://wicket.apache.org/), which allows us to provide a fluent and responsive user 
experience. The web application is deployed on the GlassFish web (https://glassfish.dev.java.net/) 
application container. HOPE obtains information from different sources beyond our control. 
Therefore, the data gathering is set up as fail-safe as possible to handle service unavailability. Data is 
cached to speed up the process, to reduce dependencies and to put less strain on external 
resources. The data-retention time is 30 days, after which time the data is renewed at the moment 
someone runs an analysis on the same sequence. The database scheme (available at the ‘about’ 
section of the HOPE pages) is the result of an iterative design process using both Java and Hibernate 
to manage all data and to create the database tables. The database engine is PostgreSQL version 8.4. 
The MRS BLAST version 4 Web service (http://mrs.cmbi.ru.nl/mrsws/blast/wsdl) is used for most 
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database searches with an e-value cut-off of 1e-5 and the low-complexity filter switched off19. This 
Web service is backed by an in-house implementation of the standard BLAST algorithm. ClustalW 
version 2.0.10 is used for sequence alignments20. ClustalW is also offered as a Web service through 
MRS (http://mrs.cmbi.ru.nl/mrsws/clustal/wsdl). WHAT IF Web services are used to calculate 
secondary structure (http://wiws.cmbi.ru.nl/wsdl/) (using DSSP21), accessibility values, structural fits 
of mutations, contacts with ligands or ions, salt bridges, disulfide bridges, and hydrogen bonds22. 
These calculations are performed either on the deposited PDB structure, or a homology model. 
Homology modeling is performed fully automatically using a locally installed WHAT IF & YASARA 
Twinset12; 13. This installation runs on a separate server, and is controlled through a Perl CGI script. 
Sequence annotations are obtained from the UniProt database15 XML records 
(http://www.uniprot.org/). The obtained information includes sequence features such as active site, 
motifs, domains, variants and binding sites. Conservation scores are obtained from HSSP using a 
Web service (http://mrs.cmbi.ru.nl/hsspsoap/wsd). When a PDB deposited structure is available, the 
pre-calculated HSSP scores maintained at the CMBI are used. In case a homology model is available a 
DSSP file is generated for the homology model, which in turn is used to create a HSSP file. In case no 
structure or model is available, a HSSP file is generated using only the user sequence. Distributed 
Annotation (DAS) servers16; 23  are used to obtain predictions regarding transmembrane regions by 
Phobius23, accessibilities by PHDacc24, secondary structure by PHDsec24, and phosphorylation sites by 
NetPhos25. 
 
Figure 4.5: Detailed overview of HOPE's components. HOPE's input consists of the sequence and the mutation. 
The sequence is used for a BLAST search against the databases. Using the accession code (and PDB-file if 
available) HOPE can collect information from a series of information sources: WHAT IF calculations on the PDB-
file or homology model built by YASARA, annotations in the Uniprot database, HSSP conservation scores and 
sequence-based predictions by DAS-servers. The information is combined in a decision scheme and a report is 
generated. This report is illustrated with pictures and animations and difficult keywords are linked to our own 
online dictionary. 
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The decision scheme is implemented in Groovy, a dynamic language that runs on the Java Virtual 
Machine. The simple Groovy language enables other users to design their own decision schemes and 
run a specific version of HOPE for their own purposes. The decision scheme is divided into separate 
branches targeted towards certain aspects of the mutant analysis, each producing a paragraph or 
sub-report. The decision scheme logic is separated from the phrases used to compose the report, for 
a cleaner separation in code and to allow for internationalization. 
The HOPE report is presented on a self-contained webpage, allowing the user to save the page 
without breaking links and images. The user can bookmark the URL to perform the same mutant 
analysis at a later point in time, incorporating any newly available data. The output web pages are 
intended to be free from bioinformatics jargon. An online dictionary based on MediaWiki's software 
(http://www.mediawiki.org/) is used to explain bioinformatics-specific terms. JavaScript is used to 
link keywords on the webpage to articles present in the local MediaWiki instance. This functionality 
is available at any time via the omni-present blue help-button. Images and movies in the report are 
generated using the YASARA & WHAT IF Twinset. 
Availability and Requirements  
The full description of the design and implementation of the HOPE server is available from the 
"about" section of the HOPE pages. HOPE can be used freely and no licenses are required. The 
source code has been made open source and can be freely obtained from the HOPE website. HOPE 
uses Java, Groovy, and PostgreSQL; it has been implemented on a Linux system while care has been 
taken to avoid system dependencies. 
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Introduction 
In the previous chapters, we described a method and the recent improvements to build homology 
models. We also described Project HOPE, a web server that is able to build and use these models or, 
if available, experimentally determined protein structures for the analysis of the effects caused by 
point mutations. This chapter contains short summaries of those projects that contributed to HOPE’s 
development. 
 
During the last years we have collaborated in a series of projects with researchers from departments 
ranging from human genetics to organic chemistry, and from physiology to internal medicine. A few 
projects were carried out together with researchers from laboratories in other cities (Utrecht, 
Groningen), and even with colleagues from institutes located in other countries (USA, Korea). Some 
of our collaborators we have never even met in person yet, which illustrates that it is not only 
computers that meet in the internet. 
 In all these projects, our colleagues spent numerous hours working in the lab collecting data 
for their project. Wet-lab experiments are the only way to identify that one particular mutation in 
one particular gene causes the phenotype of interest. Therefore, experiments in the laboratory 
undoubtedly form the starting point of interesting discoveries and publications. The bioinformatics 
analysis was often an important issue in the last phase of the project. In all cases presented here, 
analysis of the protein structure provided a better understanding of the effect of the mutation on 
the protein´s 3D-structure and its function. In some cases, our analyses resulted in suggestions for 
new experiments but in all cases bioinformatics provided new and useful insights in the molecular 
origin of the disease. Therefore, our findings can often be regarded as the last piece of the molecular 
puzzle, and at the same time, as first part of the new puzzle.  
 The collaboration between bioinformatics and the (bio)medical field works both ways. 
Through bioinformatics the (bio)-medical researcher can access large amounts of data, knowledge, 
and tools, which can all be beneficial for his/her project. On the other side, bioinformaticians can use 
the questions, ideas, and information to work on their own projects. Project HOPE is an excellent 
example of this process. While collecting information, building models, and answering the questions 
from researchers we worked on the development of Project HOPE. Collaborating in many different 
projects has not only taught us what questions should be answered but also how we should present 
our answers in such a way that they are understandable and useful for everyone who is not a 
bioinformatician. Every article summarized in this chapter has contributed to the development of 
Project HOPE.  
 
The articles summarized on the following pages discuss the effect of at least one point mutation on 
the protein’s 3D-structure. We used all our knowledge and bioinformatics tools to visualize and 
explain these effects.  
We followed the same protocol for each project albeit that some of these aspects were not 
yet available in older projects. First, we tried to find the 3D-structure of the protein of interest in the 
PDB. Sometimes, experimentally determined structures were available in the PDB. As the structures 
deposited in the PDB usually still contain errors, we used a re-refined version downloaded from the 
PDB-redo database for our analyses.  
In a major part of the cases without known 3D-coordinates we were able to perform homology 
modeling (see chapter 2 for methods). Models for earlier projects were built using the WHAT IF 
modeling server, often in combination with loop modeling and energy minimization scripts in 
YASARA. Models for more recent projects were built using YASARA’s automatic modeling script. The 
latter method has 2 main advantages: 
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 It can perform the complete modeling process automatically; all it needs is the sequence of 
interest. This enables us to incorporate the program in a pipeline that requires homology 
models. 
 It builds very good models. The automatic YASARA modeling method was ranked first overall 
in the category 'high-resolution server accuracy’ during CASP8.  
 
Therefore, automatic modeling by YASARA is nowadays our method of choice for modeling in Project 
HOPE and in all other projects (http://www.cmbi.ru/nl/~hvensela/HOPEresults). Both the 
downloaded PDB-files and the models produced by YASARA were visualized and analyzed using the 
WHAT IF & YASARA Twinset1; 2. All figures shown in this chapter were made using this software 
package in combination with POV-Ray (http://www.povray.org/). In cases for which no structural 
information was available at all, we used servers that can provide predictions based on the 
sequence, such as PsiPred3 for secondary structure predictions, Phobius for transmembrane domain 
predictions4, and NetPhos for predictions of phosphorylation sites5. In a few cases the authors also 
used other methods, such as EsyPred3D, to build a homology model.  
 
The summaries on the following pages will all first describe the disease or syndrome that was found 
in the patient, followed by information about the affected protein(s). The text will contain only a 
minimal description of the experiments done in the lab because this goes beyond the scope of this 
thesis. The short introduction is followed by a paragraph that describes the method that was used to 
obtain structural information about the protein. In case of homology modeling, the method, the 
template, and the percentage sequence identity will be mentioned. In case no structure or template 
was found, the other methods used to collect more information about the protein of interest will be 
described. The modeling method itself will not be discussed in detail because this can be found in 
chapter 2.  The effect of each point mutation on the protein 3D-structure will be described. We will 
only study missense mutations, even though other mutations such as nonsense mutation, deletions 
and insertions were sometimes also studied in the original article. These other mutations can be 
found on the corresponding project website (www.cmbi.ru.nl/~hvensela). At this site more 
information, figures, animations, and explanations are shown. This site was used to communicate 
with collaborators in the projects and was often mentioned in the articles as supplementary data.  
 
The last paragraph of each project will show HOPE’s main conclusions about the effect of the 
mutations on the 3D-structure. The text about the method and amino acids is summarized to save 
space. We will only highlight the most striking results, such as a feature that still needs to be 
improved or an important difference between the manual and automatic analysis. Due to the ever 
ongoing work on HOPE some of the answers provided by the current version of the server might 
slightly differ from the ones shown here. We also used these, and many other, mutations in a large 
validation-study of Project HOPE, which will be described in the next chapter. 
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Project: HFE 
Title: A novel (Leu183Pro-)mutation in the HFE-gene co-inherited with the Cys282Tyr mutation in 
two unrelated Dutch hemochromatosis patients 
Authors: D. W. Swinkels – H. Venselaar – E. T. Wiegerinck – E. Bakker – I. Joosten – C. A. J. J. Jaspers – 
W. L. Vasmel – M. H. Breuning 
Published in:  Blood Cells, Molecules, and Diseases 2008 (40(3): 334–338) 
 
We studied the heterozygous mutation Leu183Pro in the HFE-gene found in two unrelated Dutch 
men who both presented a classical form of hereditary haemochromatosis (HH). Individuals 
suffering from HH have, among other symptoms, a disturbed iron metabolism resulting in iron 
overload in the joints. Many of the European HH patients are homozygous for the Cys282Tyr 
mutation while another 4–7% are Cys282Tyr/His63Asp compound heterozygotes6. In Caucasians, 
around 25% of the HH patients carry at least one chromosome without any of the known HFE-
mutations  (Cys282Tyr, His63Asp, or Ser65Cys)6. In addition to these common mutations, a series of 
rare HFE mutations that are usually found in only one family exists6.  
The HFE protein is an atypical major histocompatibility complex class I molecule that 
interacts with the transferrin receptor 1 (TfR1) that is a type II transmembrane glycoprotein and the 
primary effector of cellular iron uptake7; 8. It has been proposed that the most important role for HFE 
is iron-sensing in the liver by conveying the whole-body iron status. This status is expressed by 
transfer of Fe2-TF from the HFE–TfR1 complex to TfR2, resulting in potential signaling of downstream 
events9. HFE-mutations are supposed to exert their effect by disrupting either the interaction with 
β2-microglobulin (β2M) and/or TfR1 (figure 5.1A). The Cys282Tyr mutation in HFE-related 
haemochromatosis disrupts the disulfide bridge in the HFE α3-domain, thereby impairing its β2M 
binding and its HFE cell surface expression10; 11. The His63Asp mutation in a loop of the α1-domain is 
also a frequent, but much less severe HFE variant. It probably induces a minor rearrangement that 
slightly influences the structure of the TfR1 interacting domain, but this has been an area of 
controversy8; 11; 12.  
Here, we assess the functional consequences of the newly discovered Leu183Pro mutation 
by studying its effect on the interaction with TfR1 in the structure of the HFE–β2M-TfR1 complex.  
 
Manual study of mutation Leu183Pro in HFE 
The HFE–β2M-transferrin dimer complex has been solved by X-ray diffraction and the atomic 
coordinates can be found in PDB-file 1de48.  
HFE contains a MHC-like structure comprising a β-sheet topped by two α-helices. These 
helices form a cleft that upon signaling interacts with the helix α1 from TfR1 (see figure 5.1A). The 
Leu183Pro mutation is situated in the α2-helix of the HFE-protein but the mutated leucine residue 
does not directly interact with the receptor. The Leu183Pro mutation results in destabilization of the 
protein structure for two reasons. First, the proline side chain is attached to its own backbone twice, 
and thus does not have a backbone proton to form the hydrogen bond required for stabilization of 
the helix. Second, the smaller size of proline might result in instability in the hydrophobic core of the 
protein.  
This HFE-mutation clearly affects the stability of the α2-helix of the HFE-protein, thereby 
disrupting the interaction with the TfR1 protein that is essential to exert the iron sensing function of 
the HFE-protein (see figure 5.1B and C). The idea that a stable α1/2 domain is essential for the 
correct function of HFE is coroborated by the fact that other HFE missense mutations in this area 
have been shown to result in the classic hemochromatosis phenotype13,14 (reviewed in6). A closer 
study of these mutations (including the newly found Leu163Pro) showed that the effect of these 
mutations on the 3D-structure was directly correlated with the severity of the phenotype found in 
the patient. These findings may have implications for HFE-testing of iron overloaded heterozygous 
Cys282Tyr-patients of Northern European origin and their relatives. 
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Figure 5.1: A) Overview of the crystal structure of HFE (green)–β2M (blue)–TfR1 (yellow)-complex, indicating 
the location of the Cys282Tyr, His63Asp and Leu183Pro mutations found in different patients. B) Close-up of 
Leu183 in the HFE-protein. C) Changes in the α-helix caused by the substitution of a proline for a leucine at 
position 183 of the HFE-protein. The irregular area in the helix is light green.  
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Project HOPE’s conclusion about the HFE mutation 
Method Analysis on existing structure PDB 1a6z 
Mutation Leu183Pro 
 
Structure The mutation is located within a stretch of residues identified as a special region: "Alpha-
2". The differences in amino acid properties can disturb this region and disturb its function. In the 3D 
structure can be seen that the wild-type residue is located in an α-helix. Proline disrupts an α-helix 
when not located in the first 3 residues. In this case the helix will be disturbed and this can have 
severe effects on the structure of the protein.  
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is smaller than the wild-type residue. The mutation will cause an empty space in the core of 
the protein (complex).  
 
 
Conclusion HOPE correctly predicts the disturbing effect of the proline on the α2-helix, and the size 
difference between proline and leucine. HOPE does not draw the conclusion that disturbing this 
helix will also disturb interaction with the transferrin receptor. This information requires another 
PDB-file for analysis and/or knowledge from literature. Currently, HOPE identifies PDB-file 1a6z as 
the best structure to use for the analysis. However, this file contains a dimer of the HFE-β2M 
complex while the HFE-β2M-TfR1 (1de4) complex was used for the manual analysis. This explains the 
differences between the manual and automatic analyses. In the future HOPE will be able to use 
complex information and thus will be able to identify the lost interaction between HFE and 
transferrin. 
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/HFE/ 
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Project: ESRRB 
Title: Mutations of ESRRB Encoding Estrogen-Related Receptor Beta Cause Autosomal-Recessive 
Nonsyndromic Hearing Impairment DFNB35 
Authors: R.W. Collin – K. Kalay – M. Tariq – B. van der Zwaag – H. Venselaar - J. Oostrik – K. Lee – 
Z.M. Ahmed – R. Caylan – Y. Li – H. A. Spierenburg - E. Eyupoglu – A Heister – S. Riazuddin – E. Bahat 
– M. Ansar – S. Arslan – B. Wollnik – H. G. Brunner – C. W. Cremers – A. Karaguzel – W. Ahmad – F. P. 
Cremers – G. Vriend – T. B. Friedman – S. Riazuddin - S. M. Leal – H. Kremer 
Published in: American Journal of Human Genetics 2008 (824(1): 125-138) 
 
Autosomal-recessive non-syndromic hearing impairment (ARNSHI) is a genetically heterogeneous 
disorder. Sixty-seven loci for ARNSHI, referred to as DFNB loci, have been mapped, and 24 of the 
causative genes have been identified15. Genome-wide homozygosity mapping revealed a locus for 
nonsyndromic hearing impairment on location 14q24.3–q34.12 that partly overlaps with the DFNB35 
locus16. Among the candidate genes in this region was the gene for Estrogen Related Receptor Beta 
(ESRRB). Sequence analysis of this gene revealed a frameshift leading to a premature stop codon in 
the affected proband family members. Subsequent mutation analysis in the proband familiy and 
three other families of Pakistani origin revealed four missense mutations in ESRRB.  
The ESRRB protein is a member of the nuclear hormone receptor transcription factor family. 
All family members share the same fold but for only two of the domains the function is known: the 
DNA-binding domain and the ligand binding domain (see figure 5.2A). Structures of these 2 domains 
have been solved for many family members. The ligand binding domain generally consists of twelve 
α-helices, although the second α-helix is very irregular in some family members including ESRRB. 
Together with a two-stranded β-sheet the α-helices fold into a three-layered helical sandwich (see 
figure 5.2B). Activation of a receptor depends on the binding of an agonist and one or more co-
factors. The ligand binding pocket is formed by the β-sheet and α-helices 3, 5, 6, and 11. Upon ligand 
binding, helix 12 is repositioned into a groove between helices 3 and 11, thereby forming a new 
groove for co-activator binding. In contrast, antagonist binding prevents the repositioning of helix 12 
thereby allowing co-repressors to occupy the available space in the groove between helices 3 and 11 
and preventing activation of the receptor17.  
 
Manual study of the mutations in the ESRRB ligand-binding domain 
The missense mutations discussed here (Leu320Pro, Val342Leu, and Leu347Pro) affect amino acids 
in the ligand-binding domain of ESRRB. The sequence of the ESRRB ligand-binding domain shows 
high sequence similarity (79%) with the corresponding domain of Estrogen Related Receptor Gamma 
(ESRRG), found in PDB-file 1kv618. The crystal structure of ESRRG was used as a template to build a 
model of the human ESRRB ligand-binding domain.  
Although the missense variants found in the ligand-binding domain do not affect the α-
helices directly involved in ligand binding, the structural changes that occur near the substituted 
amino acids are likely to influence the structure and the stability of the domain. Leucine to proline 
mutations in an α-helix tend to disrupt the helical conformation. In the case of Leu320Pro and 
Leu347Pro the absence of the leucine side chain also results in the loss of hydrophobic interactions 
between helices (figure 5.2C-E). The Val342Leu substitution in helix 8 is predicted to disrupt the 
interaction between helix 8 and helix 1 because the introduction of the bigger leucine will result in 
steric clashes between the leucine side chain and residues in helix 1 and 8 (see figure 5.2E). Our 
hypothesis that this might impair the function of the ligand binding domain is supported by 
mutations found in either α-helix 8 of the estrogen receptor or α-helix 1 of the androgen 
receptor19,20,21. These mutations are located far away from the binding site but still affected the 
binding affinity of the ligand. In addition, hydrophobic interactions between α-helices 1 and 8 have 
been reported to be required for maintenance of the conformation of the receptor PPARγ, and it is 
has been suggested that these results can be extrapolated to other members of the nuclear receptor 
family, including the estrogen-related receptors19.  
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The present study describes the identification of ESRRB as the gene involved in autosomal 
recessive hearing impairment DFNB35. Characterization of the exact molecular mechanisms by 
which genetic defects in ESRRB cause nonsyndromic hearing loss will contribute to the 
understanding of the processes that are essential for normal hearing and might therefore be 
important for therapeutic intervention.  
 
Figure 5.2: A) Schematic representation of the domain structure of human ESRRB. The zinc finger C4 DNA-
binding domain (DBD) and the ligand binding domain (LBD) are depicted in red and blue, respectively. B) 
Structure of the ligand binding domain of the human ESRRB protein. Helices are shown as cylinders and 
numbered. The positions of the three amino acids that are affected by the missense mutations, are indicated 
in green. D-E) Close-ups of Leu320Pro, Val342Leu and Leu347Pro. Side chains of the wild type and mutant 
residues are shown in green and red respectively. In panel D a semitransparent surface is shown (gray). 
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Project HOPE’s conclusion about the ESRRB mutations 
Method Model based on template PDB 2e2r 
Mutation Leu320Pro 
 
Contacts In the 3D-structure van be seen that the wild-type residue makes interaction with a ligand 
annotated as 2OH. The differences in properties between wild-type and mutation can easily cause 
loss of interactions with the ligand. Because ligand binding is often important for the protein's 
function, this function might be disturbed by this mutation. 
Structure In the 3D-structure can be seen that the wild-type residue is located in an α-helix. Proline 
disrupts an α- helix when not located at one of the first 3 positions. In case of the mutation at hand, 
the helix will be disturbed and this can have severe effects on the structure of the protein. 
Amino acid properties The wild-type and mutant amino acids differ in size. The mutant residue is 
smaller than the wild-type residue. The mutation will cause an empty space in the core of the 
protein (or protein-complex). 
 
 
Conclusion HOPE correctly predicts the disturbing effect of a proline in an α-helix, that the mutation 
will cause an empty space in the core, and that this residue can be important for ligand binding.  
 
Mutation Val342Leu 
 
Amino acid properties The wild-type and mutant amino acids differ in size. The mutant residue is 
bigger than the wild-type residue. The wild-type residue was buried in the core of the protein. The 
mutant residue is bigger and probably will not fit.  
 
Conclusion 
HOPE correctly predicts that the size difference can be responsible for the effect. Although the 
report might seem very short, this conclusion agrees completely with the manual analysis. 
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Mutation Leu347Pro 
 
Structure In the 3D-structure can be seen that the wild-type residue is located in an α-helix. Proline 
disrupts an α-helix when not located in the first two residues. In this case the helix will be disturbed 
and this can have severe effects on the structure of the protein. 
Amino acid properties The wild-type and mutant amino acids differ in size. The mutant residue is 
smaller than the wild-type residue. The mutation will cause an empty space in the core of the 
protein (or protein-complex).  
 
  
 
Conclusion HOPE correctly predicts the disturbing effect of a proline in an α-helix, similar to 
mutation Leu320Pro. 
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/estrogen/ 
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Project: PCDH15 
Title: Gene structure and mutant alleles of PCDH15: nonsyndromic deafness DFNB23 and type 1 
Usher syndrome 
Authors: Z. M. Ahmed – S. Riazuddin – S. Aye – R. A. Ali – H. Venselaar – S. Anwar – P. P.  Belyantseva 
–M. Qasim – S. Riazuddin – T. B. Friedman 
Published in: Human Genetics 2008 (124(3): 215-223) 
 
We analyzed mutations in PCDH15 causing either combined hearing and vision impairment (type 1 
Usher syndrome; USH1F) or nonsyndromic deafness (DFNB23). In 13 families selected on the basis of 
prelingual hearing loss we observed co-segregation of deafness with homozygosity for 
USH1F/DFNB23-linked STR marker genotypes. Sequence analyses identified homozygous mutant 
alleles of PCDH15 in affected individuals from 8 of these 13 families. These variants co-segregated 
with deafness and were not found in 100 ethnically matched hearing control individuals. 
Human PCDH15 encodes protocadherin 15. The protein exists in a variety of isoforms with 
3–11 ectodomains (ECs), a transmembrane domain, and a carboxy-terminal cytoplasmic domain 
(CD). Human PCDH15 encodes three alternative, evolutionarily conserved unique cytoplasmic 
domains (CD1, CD2, or CD3)22. The ectodomains are connected by a short stretch of residues that 
can bind 3 Ca2+-ions. These Ca2+-ions are thought to stabilize a conformation in which the 
ectodomains are available for protein-protein interactions23.  
Molecular modeling provided mechanistic insight into the phenotypic variation in phenotype 
severity of three PCDH15 missense mutations. 
 
Manual study of the mutations in PCDH15 ectodomain 1-3 
Molecular modeling was performed using the C-cadherin crystal structure, PDB-file 1q55, as a 
template24. Sequence identity between C-cadherin and protocadherin EC repeats 2-3 was 26% over 
252 amino acids. Modeling was done using the WHAT IF server for model building and YASARA for 
subsequent energy minimization using standard parameter settings2.  
Mutation Arg134Gly is located in the first ectodomain (EC1). Unfortunately, we were not 
able to model the complete EC1 (see figure 5.3). However, we can assume that EC1 adopts a fold 
similar to EC2 and 3. A ClustalW sequence alignment of the eleven EC domains reveals that Arg134 is 
conserved and that this mutation does not disrupt a calcium-binding motif. Arg134 is located in the 
middle of EC1 with its side chain pointing outwards. This domain is known to be important for 
interaction with a partnering cadherin or protocadherin monomer25. Mutation of the hydrophilic and 
positively charged arginine into a glycine might disturb these interactions. Indeed, Arg134Gly has 
been shown in vitro to result in the loss of interaction between protocadherin 15 and cadherin 2326.  
The homozygous mutation Asp178Gly is located in the calcium-binding motif in the loops 
between EC2 and EC3. The multiple sequence alignment shows that this mutation disrupts a 
conserved DXD calcium-binding motif. Glycine does not have a side chain and therefore cannot 
interact with the calcium atoms. As a result, the Asp178Gly mutation is predicted to cause decreased 
calcium affinity.   
The previously reported27 Gly262Asp mutation is located close to the calcium-binding 
residues in the loops between EC2 and EC3, but is not in contact with the calcium itself. Glycine does 
not have a side chain and is therefore very flexible and able to form unusual backbone angles that 
are likely to maintain the correct shape of the calcium binding domain. The introduction of a less 
flexible and larger aspartic acid will disturb the local structure needed to bind calcium.  
The three missense mutations Arg134Gly, Asp178Gly, Gly262Asp of PCDH15 are located in 
the extracellular N-terminus of protocadherin 15. Arg134Gly and Gly262Asp are associated with 
nonsyndromic deafness DFNB23 while mutation Asp178Gly is associated with USH1F. By 
comparison, all truncating mutant alleles of PCDH15 are associated with type 1 USH28,29,30. A better 
understanding as to how the retina is spared in deaf individuals homozygous for presumably 
hypomorphic mutations of PCDH15, CDH23, MYO7A or USH1C should be helpful in developing 
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interventions that delay the age of onset and/or slow the progression of the retinitis pigmentosa 
component of Usher syndrome. 
Figure 5.3: Structure of the homology model of EC domains 2 and 3 and a small part of EC domain 1 in 
PCDH15. Side chains of the mutated residues are shown as sticks and coloured red. Yellow balls represent 
calcium atoms.  
 
 
Project HOPE’s conclusion about the PCDH15 mutations 
Method Model based on template PDB 1ncj 
Mutation Arg134Gly 
 
Contacts The size difference between wild-type and mutant residue makes that the new residue is 
not in the correct position to make the same hydrogenbond as the original wild-type residue did. 
The difference in hydrophobicity will affect hydrogenbond formation. The difference in charge will 
disturb the ionic interaction made by the original wild-type residue. 
Structure The mutation is located within a domain, annotated as: "Cadherin 1". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function. The mutation introduces a glycine at this position. Glycines are very flexible and can 
disturb the required rigidity of the protein on this position. 
Amino acid properties There is a difference in charge between the wild-type and mutant amino acid. 
The charge of wild-type residue is lost by this mutation. This can cause loss of interactions with other 
molecules. The wild-type and mutant amino acids differ in size. The mutant residue is smaller than 
the wild-type residue. This will cause a possible loss of external interactions.  
 
Conclusion HOPE correctly mentions all the facts it can find (including lost hydrogenbond, lost ionic 
interaction, and possible loss of external interactions). The residue is located in a loose end, which 
makes it difficult to confirm the result. The fact that other mutations in this area disturb interactions 
with cadherin can be found in literature only and is not (yet) available to HOPE. 
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Mutation Asp178Gly 
 
Contacts In the 3D-structure can be seen that the wild-type was involved in a metal-ion contact. The 
mutant residue is smaller than the wild-type residue. The size differences between the wild-type and 
mutant residue disturb the interaction with the metal-ion: "CA". The wild-type residue was 
negatively charged, the mutant residue is neutral. Because the negative charge is lost the interaction 
with the metal "CA" will be less stable, this can disturb the domain. The difference in charge will 
disturb the ionic interaction made by the original, wild-type residue. 
Structure The mutation is located within a domain, annotated as: "Cadherin 2". The mutation 
introduces an amino acid with different properties, which can disturb this domain and abolish its 
function. The mutation introduces a glycine at this position. Glycines are very flexible and can disturb 
the required rigidity of the protein at this position. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The charge of the buried wild-type residue is lost by this mutation. The wild-type and mutant 
amino acids differ in size. The mutant residue is smaller than the wild-type residue. The mutation 
will cause an empty space in the core of the protein (or protein-complex). The hydrophobicity of the 
wild-type and mutant residue differs. The mutation can cause loss of hydrogenbonds in the core of 
the protein and as a result disturb correct folding.  
Conclusion (left picture) HOPE correctly predicts that the metal-contact is lost here and that a 
smaller and flexible residue is introduced which will disturb the structure that facilitated Calcium 
binding. 
  
 
Mutation  Gly262Asp 
 
Structure The mutation is located within a domain, annotated as: "Cadherin 2". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function. The wild-type residue was a glycine, the most flexible residue of all. This flexibility might 
be necessary for the protein's function. Mutation of this glycine can abolish this function. 
Amino acid properties There is a difference in charge between the wild-type and mutant amino acid. 
The mutant residue introduces a charge in a buried residue which can lead to protein folding 
problems. The wild-type and mutant amino acids differ in size. The mutant residue is bigger than the 
wild-type residue. The wild-type residue was buried in the core of the protein (or protein-complex). 
The mutant residue is bigger and probably will not fit. The hydrophobicity of the wild-type and 
mutant residue differs. The mutation will cause loss of hydrophobic interactions in the core of the 
protein (or protein-complex). The torsion angles for this residue are unusual. Only glycine is flexible 
enough to make these torsion angles, mutation into another residue will force the local backbone 
into an incorrect conformation and will disturb the local structure.  
Conclusion (right picture) 
HOPE correctly mentions all differences between Gly and Asp, including the difference in flexibility. It 
correctly predicts that the bigger side chain will not fit here.  
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/PCDH15 
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Project: LRTOMT 
Title: Mutations of LRTOMT, a fusion gene with alternative reading frames, cause nonsyndromic 
deafness in humans 
Authors: Z. M. Ahmed – S. Masmoudi – E. Kalay – I. A. Belyantseva – M. A. Mosrati – R. W .J. Collin – 
S. Riazuddin – M. Hmani-Aifa – H.  Venselaar – M. N. Kawar – A. Tlili – B. van der Zwaag – S. Y Khan- 
L. Ayadi - S. A. Riazuddin – R. J. Morell – A. J. Griffith – I. Charfedine – R. C. Aylan – J. Oostrik – A. 
Karaguzel – A. Ghorbel – S. Riazuddin – T. B. Friedman – H. Ayadi – H. Kremer 
Published in: Nature Genetics 2008 (40(11): 1335-1340) 
 
Sequence analysis of Pakistani, Turkish, and Tunisian families revealed four pathogenic mutations in 
a previously uncharacterized gene, LRRC51 renamed LRTOMT. All four mutations co-segregate with 
deafness; carriers have normal hearing; and none of the four mutations was detected in ancestry-
matched, normal-hearing subjects.  
The LRTOMT gene consists of ten exons that can produce five alternatively spliced 
transcripts that are widely expressed in the human body. Translation beginning in exon 5 produces 
isoform LRTOMT2, which is predicted to have a catechol-O-methyltransferase (COMT) domain. 
Catechol-O-methyltransferase catalyzes the transfer of a methyl group from S-adenosyl-L-
methionine (Ado-Met) to a catechol hydroxyl group of catechols31. The homozygous mutation 
358+4A>C in hearing-impaired individuals alters the splice donor site of exon 8 of LRTOMT. This 
results in the absence of exon 8, a reading frameshift, and a premature downstream translation stop 
codon A29SfsX54 in the mRNA encoding LRTOMT2. The other three mutations are all predicted to 
affect the structure of the catechol-O-methyltransferase domain of LRTOMT2 and will be discussed 
here.  
 
Manual study of mutations in the COMT-domain 
The crystal structure of rat COMT can be found in PDB-file 1h1d31 and shares 39% sequence identity 
with the human protein. This structure was used to model the COMT domain of human LRTOMT2. 
The WHAT IF server was used for modeling. Energy minimization and analysis were done with 
YASARA2. 
The three mutated residues are located in helix 1 (Arg81Gln), helix 2 (Trp105Arg), and the 
loop that follows helix 2 (Glu110Lys) respectively, and thus not in the substrate-binding pockets 
(figure 5.4A). However, the loop is predicted to be important for the groove that binds the methyl 
acceptor31. Arg81 and Glu110 form a salt bridge between helix 1 and the loop following helix 2 
(figure 5.4B-D). A glutamine at position 81 cannot form this salt bridge as it is not positively charged. 
The formation of hydrogen bonds is also impaired because of the smaller size of glutamine 
compared to arginine. The Trp105 residue makes hydrophobic interactions with its big side chain 
(figure 5.4C) Most of these interactions would be lost by the Trp105Arg substitution. Mutation 
Glu110Lys is predicted to lead to the loss of hydrogen bonds and a salt bridge. There will be 
repulsion between the side chains of Lys110 and Arg81 as both are positively charged. 
The mutations may cause protein instability and could indirectly affect the substrate binding 
region31. Deafness may be due to the predicted destabilizing effects of these mutations on the 
catechol-O-methyltransferase domain of LRTOMT2.  
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Figure 5.4:  Molecular model and predicted effects of missense mutations. A) Molecular model of the COMT-
domain (residues 79–290) of LRTOMT2. The affected residues are depicted in blue. The predicted ligands are 
coloured yellow, and tyrosine 111 that lines the hydrophobic groove of the ligand binding site is shown in cyan. 
The boxed region is enlarged in panels B-D.  B/C/D) Residues affected by missense mutations of LRTOMT2. The 
region of helices 1 and 2 and part of the flanking loops are enlarged. Wild-type residues Arg81, Trp105, and 
Glu110 are depicted in blue, mutated residues in pink. Hydrogen bonds are represented by yellow dotted lines. 
H1 = helix 1; H2 = helix 2; L = loop. 
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Project HOPE’s conclusion about the LRTOMT mutations 
 
Method Model based on template PDB 1h1d 
Mutation Arg81Gln 
 
Contacts The size difference between wild-type and mutant residue makes that the new residue is 
not in the correct position to make the same hydrogenbond as the original wild-type residue did. 
The difference in charge will disturb the ionic interaction made by the original wild-type residue. 
Amino acid properties There is a difference in charge between the wild-type and mutant amino acid. 
The charge of wild-type residue is lost by this mutation. This can cause loss of interactions with other 
molecules. The wild-type and mutant amino acids differ in size. The mutant residue is smaller than 
the wild-type residue. This will cause a possible loss of external interactions. 
  
 
Conclusion HOPE correctly predicts that the hydrogenbond and saltbridge will be lost. HOPE also 
predicts an effect on the external interactions, which can be an indirect effect.  
 
Mutation Trp105Arg 
 
Amino acid properties There is a difference in charge between the wild-type and mutant amino acid. 
The mutant residue introduces a charge in a buried residue, this can lead to protein folding 
problems. The wild-type and mutant amino acids differ in size. The mutant residue is smaller than 
the wild-type residue. The mutation will cause an empty space in the core of the protein. The 
hydrophobicity of the wild-type and mutant residue differs. The mutation will cause loss of 
hydrophobic interactions in the core (or protein-complex). 
 
 
Conclusion HOPE predicts correctly the loss of hydrophobic interactions in the core of the protein.  
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Mutation Glu110Lys 
 
Contacts In the 3D-structure can be seen that the wild-type residue makes interaction with a ligand 
annotated as NHE. The differences in properties between wild-type and mutation can easily cause 
loss of interactions with the ligand. Because ligand binding is often important for the protein's 
function, this function might be disturbed by this mutation. The size difference between wild-type 
and new mutant residue makes that the new residue is not in the correct position to make the same 
hydrogen bond as the original wild-type residue did. The difference in charge will disturb the ionic 
interaction made by the original wild-type residue. 
Amino acid properties There is a difference in charge between the wild-type and mutant amino acid. 
The mutation introduces the opposite charge at this position. This possibly disrupts contacts with 
other molecules. The wild-type and mutant amino acids differ in size. The mutant residue is bigger 
than the wild-type residue. The residue is located on the surface of the protein, mutation of this 
residue can disturb interactions with other molecules or other parts of the protein. 
 
 
Conclusion HOPE correctly predicts the loss of a hydrogenbond and saltbridge. It also sees a contact 
with a putative ligand that might be biologically irrelevant.  
 
General conclusion about LRTOMT mutations 
The effects of all three mutations are predicted correctly by HOPE. However, the longer distance 
relation between the domain and the putative ligand binding site can only be found by doing a 
manual study of the structure and literature.  
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/catechol/ 
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Project: EHMT1 
Title: Further clinical and molecular delineation of the 9q Subtelomeric Deletion Syndrome supports 
a major contribution of EHMT1 haploinsufficiency to the core phenotype 
Authors: T. Kleefstra – W. A. van Zelst-Stams – W. M. Nillesen – V. Cormier-Daire – G. Houge – N. 
Foulds – M. van Dooren – M. H. Willemsen – R. Pfundt – A. Turner – M. Wilson – J. McGaughran – A. 
Rauch – M. Zenker – M. P. Adam – M. Innes – C. Davies – A. G. López -  R. Casalone – A. – L. A. 
Brueton – A. D. Navarro – M.P. Bralo – H. Venselaar – S.P.A. Stegmann – H.G. Yntema – H. van 
Bokhoven – H.G. Brunner 
Published in: American Journal of Medical Genetics 2009 (46(1): 598-606) 
We studied the clinical and molecular characteristics of a cohort of newly identified cases with 9q 
subtelomeric deletion syndrome (9qSTDS), one of the first clinically recognizable telomeric 
syndromes. It was demonstrated earlier that the syndrome is caused by haplo-insufficiency of Eu-
chromatin Histon Methyl Transferase 1 (EHMT1), a gene involved in histone methylation32-37.. In 6 of 
24 patients (25%) selected for exhibiting the 9qSTDS core phenotype, a pathogenic EHMT1 mutation 
was found. Five out of six mutations affect the open reading frame of the EHMT1 gene and are 
predicted to create premature termination codons which may lead to nonsense mediated decay. 
One de novo missense change (Cys1042Tyr) was found. This mutation affects a highly conserved 
cysteine residue located in the pre-SET domain. 
 
Manual study of mutation Cys1042Tyr in EHMT1  
We used the structure of the pre-SET and SET-domains, PDB-file 2rfi38, of EHMT1 to study the effect 
of the missense mutations on the 3D-structure of the protein. The WHAT IF & YASARA Twinset was 
used to analyze the effect of the amino acid substitution on the protein structure. 
Cysteine 1042 is located in a cysteine cluster surrounding three zinc-ions (see figure 5.5). 
This cysteine/zinc-cluster is important for the local structure of this particular region of the pre-SET 
domain. The cysteines make strong interactions with the zinc-ions thereby placing the intervening 
loops in the correct position for dimer interactions. Mutation of cysteine 1042 into a tyrosine will 
abolish the strong cysteine/zinc interaction, causing a less stable domain. Moreover, introduction of 
the much bigger tyrosine will completely disturb the structure of the zinc/cysteine-cluster and 
displace the residues in the loops that interact with the other monomer. The mutation will destroy 
the conformation of this local area that is needed for dimer-contacts.  
Previously reported missense changes all turned out to be polymorphisms33. However, the 
de novo occurrence and the severe effect on the protein conformation indicate that the Cys1042Tyr 
missense change studied here is most likely to be causal for the phenotype.  
 
 
  
Figure 5.5: Location of the Cys1042Tyr mutant. 
All cysteines in the cluster are coloured yellow, 
including cysteine 1042. This residue is 
mutated into a tyrosine (red). The side chain of 
tyrosine is shown to indicate the difference in 
size compared to the cysteine side chain. The 
cysteines surround three zinc-ions (green). 
These interactions are indicated as grey 
cilinders. The cluster is important for the 
correct position of the loops that interact with 
the other monomer represented by the light 
blue surface. 
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Project HOPE’s conclusion about the EHMT1 mutations 
 
Method Model based on template PDB 3hna 
Mutation Cys1042Tyr 
 
Contacts The cysteine residue that was originally located on this position was involved in a metal 
contact with ZN. The mutant residue is bigger than the wild-type residue. The size differences 
between the wild-type and mutant residue disturb the interaction with the metal-ion: "ZN". 
Structure The mutation is located within a domain, annotated as: "Pre-SET". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function. 
Amino acid properties The wild-type and new mutant amino acids differ in size. The mutant residue 
is bigger than the wild-type residue. The wild-type residue was buried in the core of the protein. The 
mutant residue is bigger and probably will not fit. The hydrophobicity of the wild-type and mutant 
residue differs. The mutation will cause loss of hydrophobic interactions in the core of the protein 
(or protein-complex).  
 
Conclusion HOPE correctly predicts the lost contact between the cysteine and the zinc-ion. It also 
predicts that the large tryptophan side chain will not fit in the core of the protein. However, HOPE 
does not (yet) mention that the mutation can also disturb dimerisation as this requires complex 
information. 
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/EHMT1/ 
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Project: C3ORF60 
Title: Mutations in NDUFAF3 (C3ORF60), encoding an NDUFAF4 (C6ORF66)-interacting complex I 
assembly protein, cause fatal neonatal mitochondrial disease 
Authors: A. Saada – R. O. Vogel – S. J. Hoefs – M. A. van den Brand –H. J. Wessels – P. H. Willems – H. 
Venselaar – A. Shaag – F. Barghut – O. Reish – M. Shohat – M. A. Huynen – J. A.M. Smeitink – L. P. 
van den Heuvel – L. G. Nijtmans 
Published in: American Journal of Human Genetics 2009 (84(6): 718-727) 
 
In this study we analyze 3 mutations in NDUFAF3 causing complex 1 deficiency, a disorder of the 
oxidative phosphorylation (OXPHOS) system. OXPHOS-disorders frequently result in severe 
multisystem disease with a consequence of early childhood death39-41. The most prevalent and least 
understood OXPHOS disorder is isolated complex I deficiency (MIM 252010). This disease is 
frequently caused by mutations that disturb complex I assembly, an intricate 45-component 
puzzle42. At present, we know that complex I assembly involves the formation of multiple assembly 
intermediates, presumably starting with several highly conserved subunits (NDUFS2, NDUFS3, and 
NDUFS7)42-47. In addition, aided by recent developments in bioinformatics and genetics, the number 
of putative complex I assembly proteins has grown considerably. One of the candidate genes with a 
putative role in complex 1 assembly picked up in this study is C3ORF60, hereafter referred to as 
NDUFAF3.  
Homozygosity mapping and gene sequencing identified NDUFAF3 mutations in five complex 
I-deficient patients from three different families. One of these mutations (M1T) affected the first 
methionine located in the mitochondrial target signal, the other 2 mutations were located in a 
domain that could be modeled and will be discussed here. 
 
Manual study of mutations in NDUFAF3  
Homology modeling was performed using the NMR structure of Rpa2829 protein from 
Rhodopseudomonas palustris as a template (PDB-file 2fvt) (30% sequence identity). The 
mitochondrial target signal at the N-terminus and the 11 C-terminal residues could not be modeled. 
A model was built using the WHAT IF web server for modeling and the WHAT IF & YASARA Twinset 
for model optimization and analysis48. The resulting model is shown in figure 5.6.  
 
 
Figure 5.6: Model of NDUFAF3 and the two mutations found in the patients. Middle panel: NDUFAF3 is shown 
in ribbon visualization and coloured by secondary structure element (red β-strand, blue α-helix, green turn, 
cyan coil). The positions of the two mutations found in patients are indicated by the arrows and coloured 
yellow. Side panels: the R122P and G77R mutations shown in more detail. The protein is gray. The side chains 
of both the wild-type residue (green) and the mutant residue (red) are shown. Both mutations result in 
modifications at the same side of the protein. 
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The Arg122Pro mutation is located at the C-terminal side of the central β-sheet and is predicted to 
change the local structure of the loop, which might influence either the interactions or the stability 
of the protein. Gly77 is conserved between the 2fvt template and the NDUFAF3 model and has 
backbone-torsion angles that are very unfavorable for other residue types. The Gly77Arg mutation is 
therefore energetically unfavorable and likely to disrupt the structure. The model of the NDUFAF3 
structure exposes a large hydrophobic domain of about 600 squared Ăngstrøm, which is commonly 
observed for protein-protein interactions49; 50.   
 
In conclusion, we found that NDUFAF3 is a genuine mitochondrial complex I assembly protein that 
interacts with complex I subunits. We show that mutations in NDUFAF3 cause complex I deficiency.   
 
 
Project HOPE’s conclusion about the C3ORF60 mutations 
 
Method Model based on template PDB 2fvt 
Mutation Gly77Arg 
 
Structure The wild-type residue is a glycine, the most flexible of all residues. This flexibility might be 
necessary for the protein's function. Mutation of this glycine can abolish this function. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The new mutant residue introduces a charge in a buried residue, this can lead to protein folding 
problems. The wild-type and new mutant amino acids differ in size. The new mutant residue is 
bigger than the wild-type residue. The wild-type residue was buried in the core of the protein. The 
new mutant residue is bigger and probably will not fit. The hydrophobicity of the wild-type and new 
mutant residue differs. The mutation will cause loss of hydrophobic interactions in the core of the 
protein (or protein-complex). The torsion angles for this residue are unusual. Only glycine is flexible 
enough to make these torsion angles, mutation into another residue will force the local backbone 
into an incorrect conformation and will disturb the local structure. 
 
 
 
Conclusion HOPE correctly predicts the structural impact of the glycine to arginine mutation and 
that glycine is needed for its flexibility. 
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Mutation Arg122Pre 
 
Contacts The size difference between wild-type and mutant residue makes that the new residue is 
not in the correct position to make the same hydrogenbond as the original wild-type residue did. 
The difference in hydrophobicity will affect hydrogenbond formation. The difference in charge will 
disturb the ionic interaction made by the original wild-type residue. 
Structure The proline that is introduced by this mutation is a very rigid residue. The mutation might 
abolish the required flexibility of the protein at this position. 
Amino acid properties  There is a difference in charge between the wild-type and mutant amino 
acid. The charge of wild-type residue is lost by this mutation. This can cause loss of interactions with 
other molecules. The wild-type and mutant amino acids differ in size. The mutant residue is smaller 
than the wild-type residue. This will cause a possible loss of external interactions.  
 
 
Conclusion HOPE correctly predicts that a hydrogenbond and saltbridge are lost by this mutation, 
and also mentions the structural impact when a rigid proline is introduced at this position. However, 
the fact that this mutation might influence the active site can only be found in the literature as this is 
not yet annotated in SwissProt. 
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/C3ORF60 
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Project: POU3F4 
Title: Clinical and molecular characterizations of novel POU3F4 mutations reveal that DFN3 is due to 
null function of POU3F4 protein  
Authors: H. K. Lee – M. H. Song – M. Kang – J. T. Lee – K. Kong –S.J. Choi – K. Y. Lee – H. Venselaar – 
G. Vriend – W. S. Lee – H. J. Park – T. K. Kwon – J. Bok- U. K.Kim 
Published in: Physiological Genomics 2009 (39(3): 195-201) 
 
X-linked deafness type 3 (DFN3) is the most prevalent X-linked form of hereditary deafness and 
accounts for ~50% of all families carrying X-linked nonsyndromic hearing loss51. Clinical 
characteristics of DFN3 in affected males include temporal bone abnormalities, stapes fixation, and, 
in most cases, a mixed type of hearing loss, which is often progressive52-54. Female carriers of a 
mutation in the DFN3 locus typically show little or no hearing loss51. 
DFN3 is associated with mutations in the POU3F4 locus that encodes Pou3f4, a member of 
the POU family of transcription factors53.  Members of this family are characterized by a conserved 
bipartite DNA binding domain55,56. This C-terminal domain consists of a POU-specific domain and a 
POU homeodomain, both of which are helix-turn-helix structural motifs that are responsible for DNA 
binding and specificity (see figure 5.7). The Pou3f4 protein binds to DNA on the POU-specific binding 
motif and regulates downstream target genes57.  
Numerous genetic analyses of DFN3 families have identified mutations in the POU3F4 gene 
including intragenic mutations, partial or complete deletions of the gene, as well as deletions, 
inversions, and duplications of the POU3F4 genomic region not encompassing the coding 
sequence54. Nevertheless, little is known about how such mutations that lead to the characteristic 
inner ear defects and deafness affect the normal function of the Pou3f4 protein.  
Using linkage and sequence analyses we found three novel mutations in the POU3F4 gene in 
three Korean families carrying X-linked hereditary hearing loss. The three mutations included 
frameshift Ala116fs, deletion delSer310, and missense mutation Arg329Pro. The latter will be 
discussed here. 
 
Manual study of mutations in POU3F4  
The crystal structure of Pou2f1 Oct-1 domain, PDB-file 1oct,58 was used as a template to build a 
model of wild-type and mutant Pou3f4 proteins. Modeling was performed with the WHAT IF 
software1 with standard parameter settings and protocols59,60. Optimalisation of the model was 
performed using YASARA2. Sequence identity between the template and model was 65%.  
The Arg329Pro mutation converts an arginine to a proline at the amino acid position 329, 
which is one of the most conserved residues in the POU homeo-domain of the protein. Arginine 329 
is located in the third α-helix of the domain, which is crucial for protein-DNA interactions (see figure 
5.7). Its side chain is located in the core between the helices and thus not in contact with the DNA.  
The substitution of proline for the wild-type arginine at this position is expected to be detrimental to 
the α-helix structure due to destabilization of two important salt-bridges with glutamates as well as 
loss of a series of hydrophobic contacts. In addition, the side chain structure of proline typically 
destabilizes the α-helical structures which will reduce the proper protein-DNA interactions.   
The results demonstrate that the mutations identified in the DFN3 patients abolish the 
transcriptional activity of the protein.  
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Figure 5.7: A) Overview of the Pou3f4 homology model, POU-specific domain (right) and POU-homeo domain 
(left). The model is shown as a grey ribbon. The DNA is indicated in yellow, the phosphate backbone of the 
bases is not shown for clarity. The side chain of the mutated Arg329 is shown green. The box indicates the 
domain shown in the close-ups. B) Close-up of residue Arg329. The hydrogen bonds between arginine and the 
glutamic acids (blue) are visible as yellow dots. C) Close-up of the mutant residue Pro329. The side chain is 
coloured red, the hydrogen bonds are lost. 
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Project HOPE’s conclusion about the POU3F4 mutations 
 
Method Model based on template PDB-file for modeling: 1oct 
Mutation  Arg329Pro 
 
Contacts The residue makes DNA interactions or is located in a DNA binding region. The differences 
in properties between wild-type and new mutant residue can easily cause loss of these interactions 
or disturb the domain which will affect the function of the protein. The wild-type residue was 
annotated in the Uniprot database to be involved in DNA interaction type: "Homeobox". The size 
difference between wild-type and new mutant residue makes that the new residue is not in the 
correct position to make the same hydrogenbond as the original wild-type residue did. The 
difference in hydrophobicity will affect hydrogenbond formation. The difference in charge will 
disturb the ionic interaction made by the original wild-type residue. 
Structure In the 3D structure can be seen that the wild-type residue is located in an α-helix. Proline 
disrupts an α-helix when not located in the first two residues. In this case the helix will be disturbed 
and this can have severe effects on the structure of the protein. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The charge of wild-type residue is lost by this mutation. This can cause loss of interactions with 
other molecules. The wild-type and new mutant amino acids differ in size. The new mutant residue 
is smaller than the wild-type residue. This will cause a possible loss of external interactions.  
 
 
 
Conclusion HOPE finds that proline will disturb the helix and that introduction of the proline will 
cause loss of a hdyrogenbond, ionic interactions and hydrophobic interactions. Currently, the 
information about the lost interaction with DNA is obtained from SwissProt, in the future HOPE will 
be able to use complex information. 
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/pou3f4/ 
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Project: Kv1.1 
Title: Functional analysis of the Kv1.1 N255D mutation associated with autosomal dominant 
hypomagnesemia 
Authors: J. van der Wijst – B. Glaudemans – H. Venselaar – A. Nair – A. Forst – J. G.J. Hoenderop – R. 
J. M. Bindels 
Published in: Journal of Biological Chemistry 2009 (285(1):  171-178) 
 
Voltage-gated K+ channels (Kv) are a diverse family of membrane proteins61-63. The members of the 
major Shaker-related sub-family (Kv1) play an important role in excitable cells by setting the resting 
membrane potential, shaping the action potentials, thus controlling the neuronal excitability64. 
Mutations in Kv1.1 in humans are the cause of periodic episodic ataxia type 1 (EA1, severe 
discoördination) and/or myokymia (continuous muscle movement)65-70. 
Kv-channels comprise four subunits that surround a central ion-conduction pore. Kv1.1 
subunits consist of six transmembrane segments (S1-S6, see figure 5.8A). Both the N- and the C-
terminal tails of the protein are located at the intracellular side71,72. The S1-S4 segments form the 
voltage sensing domain, whereas S5 and S6 along with the intervening reentrant P-loop form the 
pore domain73; 74. Kv-channels are known to switch between a closed and an open conformation 
upon cell (de)polarization74; 75. S4 contains a long array of positive charges that have been shown to 
sense differences in voltage and start the transition from the closed to open conformation by 
forming stabilizing hydrogen bonds with the external and internal negative clusters in the voltage-
sensing domain74,76,77 .  
Recently, a missense mutation in Kv1.1 was found in patients with isolated autosomal 
dominant hypomagnesemia, converting the highly conserved aspargine at position 255 into an 
aspartic acid78. To examine the importance of Asn255 in Kv1.1 channel function, we substituted the 
asparagine by six different amino acids with distinct chemical and physical properties (Asn255Glu, 
Asn255Gln, Asn255Ala, Asn255Thr, Asn255Val, and Asn255His). The mutant Kv1.1 channels were 
analyzed electrophysiological, biochemical, and in silico. 
 
Manual study of Asn255Asp and other mutations in Kv1.1 
The structural model of Kv1.1 was built based on the 3D-structure of a chimeric Kv1.2-Kv2.1 channel 
(75% identity, PDB-file 2r9r79). In order to obtain optimal modeling results, we used a re-refined 
version of this template from the PDB-REDO database80. The WHAT IF server was used for model 
building, YASARA was used for loop building2, energy minimization and manual mutation analysis. 
The tetrameric model was obtained by superposing four models on the biological subunit of PDB file 
2r9r, followed by an energy minimization with YASARA.  
The Asn255Asp mutation is located in the third transmembrane segment (S3) close to the 
intracellular compartment and the S4 voltage-sensor element (figure 5.8). The mutated channel was 
non-functional with a dominant negative effect on wild-type channel activity.  
Mutation of asparagines 255 into different amino acids did affect neither channel trafficking 
nor expression of the channels at the plasma membrane. However, the amino acid substitutions had 
a clear effect on channel activity, as Asn255Glu and Asn255Gln were non-functional. This indicates 
that next to the addition of a negative charge at position 255 also an additional CH2-group in the 
side-chain influences channel function, likely via affecting conformational rearrangements.  
All mutations stabilized the open state of Kv1.1, measured as negative shifts in the voltage 
dependence of channel activation. There was no obvious correlation between charge and the 
magnitude of this shift as the effect was not significantly changed for Asn255His. The hydrophilic 
asparagine could be important for structural rearrangements within the channel in response to 
voltage changes, which can be affected by conversion into hydrophobic amino acids like alanine and 
valine. Interestingly, the change in activation kinetics was most evident with these two residues as 
Asn255Ala and Asn255Val activated 2 to 3-fold faster than wild-type channels. The magnitude of 
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shift in V1/2 was highest for Asn255Thr, which suggests that channel gating is independent of 
hydrogen bonding with the residue at position 255.  
The voltage-dependence of inactivation was significantly affected in all mutant Kv1.1 
channels compared to wild-type Kv1.1 except for Asn255His. We suggest that the additional 
negative charge of Asp at position 255 near S3 could keep the channel in the inactivated state, which 
may explain the non-functionality of the mutation found in patients with hypomagnesemia 
(Asn255Asp). 
We have previously described hypomagnesemia as a new phenotypic variability associated 
with mutation of the highly conserved Asn255 in Kv1.178. This study provided more information 
about the structural arrangement of Asn255 and its involvement in channel activity. Asn255 is 
essential for normal channel function, since substitution by other amino acids significantly altered 
channel activity, voltage-dependence and kinetics of Kv1.1 channels. 
Figure 5.8: A) Overview of a tetramer of the Kv1.1-model. The 
four monomers are shown as ribbon and coloured grey, blue, 
cyan and green, respectively. The mutated residue is coloured 
red in the grey monomer. B) Close-up of the wildtype and 
mutant residues. The mutated residue and surrounding side 
chains are shown and coloured by element; oxygen = red, 
nitrogen = blue, and carbon = grey.  
 
Project HOPE’s conclusion about the Kv1.1 mutation 
 
Method Model based on template PDB-file 2a79 
Mutation Asp255Asn  
 
Structure The residue is located in a region annotated in the Uniprot database as a transmembrane 
domain. The wild-type residue was neutral, the mutant residue is negatively charged. This can 
disturb the (ionic) interactions with the other transmembrane helices.  
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The new mutant residue introduces a charge in a buried residue, this can lead to protein folding 
problems. 
Conclusion HOPE correctly mentions that the only 
difference between the two residues is the charge and 
that this charge can affect interactions with other 
transmembrane helices. There is no information source 
that identifies the residues in his domain as important for 
voltage-sensing. This information can only be found in 
literature. 
 
Manual analysis can be found online: 
http://www.cmbi.ru.nl/~hvensela/Kv1.1
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Project: PRKCSH & SEC63 
Title: Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver 
disease genes PRKCSH and SEC63 
Authors: E. Waanders – H. Venselaar – R. H.M. te Morsche – D. B. de Koning – P. S. Kamath – V. 
E.Torres – S. Somlo – J. P.H. Drenth  
Published in: Clinical Genetics 2010 (78(1):47-56) 
 
Polycystic liver disease is a rare but potentially disabling disease characterized by overgrowth of 
fluid-filled cysts in the liver. The cysts originate from the intralobular bile ducts and are lined with a 
single layer of biliary epithelial cells81; 82. The cysts may cause severe hepatomegaly (enlarged liver) 
with concomitant symptoms such as severe dyspnea (shortness of breath) and wasting83; 84. PCLD is a 
congenital disease and is inherited in an autosomal dominant fashion85; 86.   
Mutations in two genes, PRKCSH and SEC63, have been found as the molecular culprit 
causing PCLD87; 88. PRKCSH encodes hepatocystin, the non-catalytic β-subunit of glucosidase II which 
is apparently unrelated to known pathways of cystogenesis. Glucosidase II is located in the 
endoplasmic reticulum (ER) and is involved in carbohydrate processing and quality control of 
glycoproteins82; 89. SEC63 encodes Sec63p, which, like the protein product of PRKCSH, is an ER 
resident protein82. Sec63p functions in the protein translocation into and out of the ER90; 91.  
We identified a total of 26 novel mutations in PRKCSH (n = 14) and SEC63 (n = 12), including 
four splice site mutations, eight insertions/ deletions, six nonsense mutations, and eight missense 
mutations. Where possible we estimated the effect of the missense mutations using homology 
models, for the remaining mutations we used other bioinformatics tools.  
 
Manual study of mutations in PRKCSH and SEC63 
We analyzed the effects of the mutations using a combination of splice site recognition, evolutionary 
conservation, secondary and tertiary structure predictions, and pathogenicity prediction. We 
examined the conservation of the proteins using multiple sequence alignments constructed with the 
ENSEMBL genome browser, Clustal-W, and Jalview92. Mutations in the helical domains of PRKCSH 
were analyzed using a helical wheel predictor. (http://cti.itc.virginia.edu/∼cmg/Demo/wheel/ 
wheelApp.html) 
We were able to identify homology modeling templates for two domains of Sec63p: the 
luminal DnaJ domain and SEC63-2 domain (amino acids 626–719). The model of the human J-domain 
was based on the J-domain from mouse DnaJ subfamily C (PDB-file 2ctw, 45% identity). The model 
for the SEC63-2 domain was based on PDB-file 2q0z (38% identity). Homology modeling and 
subsequent analysis were performed using YASARA’s automatic homology modeling script2. To 
assess the effect of the mutations in the unmodeled part of the proteins, we used a secondary 
structure prediction generated by the PsiPred-server3; 93.  
The luminal DnaJ domain of Sec63 mainly consists of α-helices and contains two mutations 
(see figure 5.9A). The side chain of Ile120 makes important stabilizing hydrophobic interactions 
between these helices. Mutation of this isoleucine into the smaller and less hydrophobic threonine 
might result in loss of these interactions in the core thus cause loss of stability. A second mutation in 
this domain, Asp168His, was found in an earlier study94. The side chain of histidine does not fit in the 
space between the helices and is likely to disturb the local conformation (see figure 5.9A). 
The model of a second Sec63p domain showed that the large side chain of Trp651 is located 
in the core between two β-sheets (figure 5.9B). A mutation into a glycine (with no side chain) results 
in an empty space in the middle of the domain. This will cause stability loss and may alter the 
structure profoundly thereby affecting the protein function.  
The other mutations in Sec63 and PRKCSH are all located outside the modeled domains. 
Mutation Arg217Cys is predicted to be located in an α-helix in the cytoplasmic domain of Sec63p just 
downstream of the DnaJ domain. Arginine is positively charged and can make hydrogen bonds. It is 
likely that a mutation to a hydrophobic, neutral and smaller cysteine will cause loss of interactions 
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with other residues. Gln375Pro is predicted to be located in an α-helix. This mutation will have 
severe impact on the structure of this helix as proline causes loss of one hydrogenbond, which will 
severely destabilize the helix. Arg267Ser is located in a region with no clear secondary structure 
preference. We were not able to explain the effects of the mutation other than the fact that arginine 
is a big and positively charged residue whereas serine is small and neutral. The difference between 
arginine and serine will abolish any structural function or interaction made by the arginine. 
 
   
Figure 5.9: Homology models of two Sec63p domains. The models are shown in gray with the side chain of the 
residues exposed. The side chains of the wild-type residues are shown in green and mutation side chain in red. 
A) Model of the DnaJ domain with the Asp168His and Ile120T mutations. B) Model of the C-terminal 626–719 
amino acids of Sec63p. The side chain of wildtype tryptophan 651 is visible in green while no glycine side chain 
is visible as this is only one H-atom. 
 
Unfortunately, neither a structure nor a modeling template was found for PRKCSH which 
complicated tertiary structure analysis. Structural analyses on PRKCSH mutations were therefore 
based on secondary structure predictions.  
The Glu381Lys mutation was located in a predicted α-helix. Using a helical wheel predictor, 
we showed that this helix is amphipathic, containing hydrophobic and hydrophilic sides (see figure 
5.10). The hydrophobic side can interact with other domains of the protein, leaving the hydrophilic 
side free for complex formation with other proteins or maybe another part of the protein. A 
mutation from the negatively charged glutamic acid into a positively charged lysine might disturb 
these interactions. The PRKCSH Thr261Ser mutation is located in the loop between two helices in the 
EF-hand domain. The small difference between threonine and serine can affect the conformation of 
residues between two α-helices. This conformation is reminiscent of a calcium-binding domain. The 
Met175Val mutation is predicted to be located in a helix. Helices often interact with each other by 
hydrophobic side chains and therefore this residue might be important for the packing between two 
helices. Both methionine and valine are hydrophobic but a mutation from a large side chain to a 
smaller β-branched side chain might lead to fewer hydrophobic interactions and thus destabilization 
of the domain. 
In conclusion, we identified 26 novel mutations associated with PCLD and we provide in 
silico analyses to delineate the role of these mutations. Most mutations were located in highly 
conserved regions and homology modeling for two domains of Sec63p illustrated the severity of the 
substitutions. As it is unclear how mutations in hepatocystin and Sec63p lead to cystogenesis in 
PCLD, the identification of important protein domains by mutational analysis might reveal the 
mechanism of molecular functions, protein–protein interactions, or protein–glycan interactions. 
Furthermore, mutation analysis of both the PRKCSH and the SEC63 genes may become increasingly 
important for establishing a diagnosis of PCLD in affected patients.  
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Figure 5.10: Helical wheel prediction of the residues surrounding the Glu381Lys mutation in PRKCSH (Glu10 in 
the wheel). The helical plot was constructed using amino acids 372–395 of the PRKCSH protein sequence. 
 
Project HOPE’s conclusion about PRKCSH mutations 
 
Method No structure or modeling template, report based on predictions 
Mutation Met175Val  
 
Structure The wild-type residue is predicted to be located in an α-helix. The mutation converts the 
wild-type residue in a residue that does not prefer α-helices as secondary structure. 
Amino acid properties The wild-type and new mutant amino acids differ in size. The mutant residue 
is smaller than the wild-type residue. The mutation will cause an empty space in the core of the 
protein (or protein-complex).  
Conclusion HOPE gives a possible reason why this mutation is damaging for the protein. 
 
Mutation Thr261Ser  
 
Structure The mutation is located within a domain, annotated as: "EF-hand 2". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function. 
Amino acid properties The wild-type and new mutant amino acids differ in size. The mutant residue 
is smaller than the wild-type residue. The mutation will cause an empty space in the core of the 
protein (or protein-complex). 
Conclusion HOPE’s answer is based on the differences in amino acid properties. Information about 
the function of EF-hands can be found in literature but is not annotated in a database. 
 
Mutation Glu381Lys  
 
Amino acid properties There is a difference in charge between the wild-type and mutant amino acid. 
The charge of the buried wild-type residue is reversed by this mutation, this can cause repulsion 
between residues in the protein core. The wild-type and new mutant amino acids differ in size. The 
mutant residue is bigger than the wild-type residue. The wild-type residue was buried in the core of 
the protein. The mutant residue is bigger and probably will not fit. 
Conclusion HOPE can only use the differences in amino acid properties. 
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/PRKCSH/ 
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Project HOPE’s conclusion about SEC63 mutations 
 
Method Model based on template PDB 2ctw (Ile120Thr/Asp168His),  
2q0z (Arg257Ser/ Gln375Pro/ Trp651Gly/ Asp675Glu), no structure or modeling template for 
Arg217Cys 
Mutation  Ile120Thr 
 
Structure The mutation is located within a domain, annotated as: "J". The mutation introduces an 
amino acid with different properties here which can disturb this domain and abolish its function. The 
mutation is located within a topological domain (domain with certain spatial position) annotated in 
the Uniprot database as "Lumenal". The mutation might disrupt this topological domain. 
Amino acid properties The wild-type and new mutant amino acids differ in size. The mutant residue 
is smaller than the wild-type residue. The mutation will cause an empty space in the core of the 
protein (or protein-complex). The hydrophobicity of the wild-type and mutant residue differs. The 
mutation will cause loss of hydrophobic interactions in the core. 
 
Conclusion HOPE correctly predicts the lost 
hydrophobic contacts in the core which will destabilize 
the J-domain. 
 
 
 
 
 
 
 
 
Mutation Asp168His 
 
Contacts The size difference between wild-type and mutant residue makes that the new residue is 
not in the correct position to make the same hydrogenbond as the original wild-type residue did. 
Structure The mutation is located within a topological domain (domain with certain spatial position) 
annotated in the Uniprot database as "Lumenal". The mutation might disrupt this topological 
domain. 
Amino acid properties There is a difference in charge between the wild-type and mutant amino acid. 
The charge of wild-type residue is lost by this mutation. This can cause loss of interactions with other 
molecules. The wild-type and mutant amino acids differ in size. The mutant residue is bigger than 
the wild-type residue. The residue is located on the surface of the protein, mutation of this residue 
can disturb interactions with other molecules or other parts of the protein. 
 
Conclusion The model used by HOPE slightly differs 
from the one used in our manual analysis and therefore 
the accessibility differs. As the mutation is located in a 
terminal end, it is impossible to say which one of the 
predictions is correct. However, HOPE correctly predicts 
that a possible hydrogen bond might be lost. 
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Mutation Arg217Cys 
 
Structure The mutation is located within a domain, annotated as: "SEC63 1". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The charge of the buried wild-type residue is lost by this mutation. The wild-type and mutant 
amino acids differ in size. The mutant residue is smaller than the wild-type residue. The mutation 
will cause an empty space in the core of the protein (or protein-complex). The hydrophobicity of the 
wild-type and mutant residue differs. The mutation can cause loss of hydrogenbonds in the core of 
the protein and as a result disturb correct folding.  
Conclusion HOPE can be correct about the loss of interactions in the core of the protein. 
 
Mutation Arg267Ser 
 
Contacts The size difference between wild-type and mutant residue makes that the new residue is 
not in the correct position to make the same hydrogenbond as the original wild-type residue did. 
The difference in hydrophobicity will affect hydrogenbond formation. The difference in charge will 
disturb the ionic interaction made by the original wild-type residue. 
Structure The mutation is located within a domain, annotated as: "SEC63 1". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function. 
Amino acid properties There is a difference in charge between the wild-type and mutant amino acid. 
The charge of wild-type residue is lost by this mutation. This can cause loss of interactions with other 
molecules. The wild-type and mutant amino acids differ 
in size. The mutant residue is smaller than the wild-type 
residue. This will cause a possible loss of external 
interactions.  
 
Conclusion HOPE is probably correct about the lost 
hydrogenbonds and ionic interactions. This analysis is 
even more complete than our manual analysis. 
 
 
 
 
Mutation Glu375Pro 
 
Structure The mutation is located within a domain, annotated as: "SEC63 1". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function. According to the 3D-structure, the wild-type residue is located in an α-helix. Proline 
disrupts an α-helix when not located at one of the first 3 positions. In case of the mutation at hand, 
the helix will be disturbed and this can have severe 
effects on the structure of the protein.  
Amino acid properties The wild-type and mutant amino 
acids differ in size. The mutant residue is smaller than 
the wild-type residue. This will cause a possible loss of 
external interactions.  
 
Conclusion HOPE predicts the damaging effect of a 
proline in a helix.  
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Mutation 6 Trp651Gly  
 
Contacts The size difference between wild-type and mutant residue makes that the new residue is 
not in the correct position to make the same hydrogenbond as the original wild-type residue did. 
The difference in hydrophobicity will affect hydrogenbond formation. 
Structure The mutation is located within a domain, annotated as: "SEC63 2". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function. The mutation introduces a glycine at this position. Glycines are very flexible and can 
disturb the required rigidity of the protein on this position. 
Amino acid properties The wild-type and new mutant amino acids differ in size. The mutant residue 
is smaller than the wild-type residue. The mutation will cause an empty space in the core of the 
protein (or protein-complex). The hydrophobicity of the wild-type and mutant residue differs. The 
mutation will cause loss of hydrophobic interactions in the core of the protein (or protein-complex). 
 
Conclusion HOPE correctly finds that this mutation will cause an empty space in the core of the 
protein. HOPE also finds a rare hydrogen bond formed by the nitrogen in the Trp-side chain that will 
be lost.  
 
Mutation Asp675Glu 
 
Structure The mutation is located within a domain, annotated as: "SEC63 2". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function. 
Amino acid properties The wild-type and new mutant amino acids differ in size. The mutant residue 
is bigger than the wild-type residue. The residue is located on the surface of the protein, mutation of 
this residue can disturb interactions with other molecules or other parts of the protein.  
 
Conclusion Our manual analysis did not find an answer, but HOPE’s analysis underlines our 
hypothesis that this mutation affects interaction with other proteins. 
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/PRKCSH/ 
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Project: FZD4, LRP5 and NDP 
Title: Identification of 21 novel variants in FZD4, LRP5, NDP and an overview of the mutation 
spectrum in familial exudative vitreoretinopathy and Norrie disease. 
Authors: K. Nikopoulos – H. Venselaar – R. W. J. Collin – R. Riveiro-Alvarez -F. N. Boonstra – J. M. M. 
Hooymans – A. Mukhopadhyay – D. Shears – M. van Bers – I. J. de Wijs – R. H. Sijmons – M. A.D. 
Tilanus - C. E. van Nouhuys -  C. Ayuso – L. H. Hoefsloot – F. P.M. Cremers 
Published in: Human mutation 2010 (31(6):  656-666) 
 
We report 21 novel variants for FZD4, LRP5 and NDP that cause familial exudative vitreoretinopathy 
(FEVR) and Norrie disease. FEVR and Norrie disease share similar phenotypic characteristics including 
abnormal vascularisation of the peripheral retina with the formation of retinal folds, retinal 
detachment, and in many cases the formation of fibrovascular masses in the eye that can lead to 
blindness95-97. The LRP5, FZD4, and NDP genes encode proteins involved in the evolutionary highly 
conserved Wnt-signalling network which (among other roles) regulates eye organogenesis and 
angiogenesis. LRP5 and FZD4 act as co-receptors for Wnt ligands, such as NDP. Mutations in FZD4 
and LRP5 are associated with autosomal dominant FEVR whereas X-linked recessive FEVR is caused 
by mutations in the Norrie disease gene (NDP)98-102. 
FZD4 is a member of the Frizzled gene family and encodes a protein of 537 amino acids. 
Similar to the other members of the Frizzled family it is composed of a seven transmembrane helix 
domain and an extracellular Frizzled (FZ) domain with unknown function. Mutations that have been 
reported for FZD4 include premature stop codons, missense changes, and one in-frame deletion but 
no splice mutations have been observed. Mutations are not clustering in a specific ‘hotspot’. All 
patients with FZD4 mutations are heterozygous carriers.  
 LRP5 is a 1615 AA cell surface receptor that belongs to the low-density lipoprotein receptor 
(LDLR) superfamily. Its function is associated with receptor-mediated endocytosis of a wide 
spectrum of ligands. Upon ligand binding, LRP5 can act synergistically with FZD4 or other members 
of the Frizzled family by activating the canonical Wnt and/or Norrin/β-catenin pathway and induce 
the transcription of target genes103-105. LRP5 consists of four extracellular domains, each of which is 
composed of six segments. Those segments form a β-propeller structure that is followed by an EGF-
like domain. Five of those segments are YWTD LDL-class B repeats, whereas the sixth does not 
contain the required YWTD motif to be recognized as a LDL-class B repeat. The first two propeller 
domains have been suggested to be important for interaction with the Wnt/Frizzled complex106. The 
four propeller domains are followed by three LDL-class A repeats (also known as LDL-receptor like 
ligand binding domains), one TM domain, and a cytoplasmic region with one or multiple short signals 
for receptor internalization through coated pits. 
The NDP gene encodes Norrin, a small (133 AA) and cysteine rich protein with low sequence 
similarity to the transforming growth factor (TGF)-β family of ligands100; 102; 107; 108. Norrin consists of 
two major parts: a signal peptide at the amino-terminus of the protein that directs its localization 
and a region containing a typical motif of six cysteines forming a cysteine-knot that provides the 
structural conformation required for receptor binding and subsequent signal transduction108.  
 
Manual study of mutations in LRP5, FZD4 and NDP 
The 21 novel mutations reported here are scattered throughout the LRP5, FZD4, and NDP genes. We 
used YASARA2 with standard parameter settings to build a model of the β-propeller domain of  LRP5. 
As a template we used the re-refined80 version of PDB-file 1npe which shares 41% sequence identity 
with the Nodigen protein (PDB-file 1npe109). A second model was made of the EGF-like domain of 
LRP5 based on PDB-file 1aut110. The sequence identity between this domain and the template was 
very low, but the presence of the six cysteines indicated that the EGF-like domain and EGF itself 
adopt similar structures. We were not able to build a model of FZD4 that contained the locations of 
the mutations. No modeling template with sufficient identity was found for NDP. However, this 
protein is known to contain a cysteine-knot in its structure and we used the structure of cysteine-
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knot containing Sclerosterin as a template (PDB-file 2kd3111). Our model of NDP agrees with 
structures previously described112 and contains two antiparallel β-sheets and one α-helical structure. 
Analysis of mutations that were not covered by the models was done using sequence based 
predictions. 
Three novel missense mutations were found in FZD4: Glu40Gln, Cys204Tyr, and Gly525Arg. 
Glutamic acid 40 is located at the N-terminus, directly following the putative signal peptide at the FZ 
domain. It is predicted to be located in a coiled domain on the surface of the protein where 
interactions might occur. The function of the FZ domain is not fully elucidated, although it has been 
suggested that it may be important for interaction with other proteins such as Wnts or NDP113. 
Glutamic acid is a negatively charged amino acid and is often involved in ionic interactions; mutation 
into a glutamine will cause loss of the negative charge and as a result also cause loss of ionic 
interactions of the FZ domain with other protein domains. The Cys204Tyr variant is located in a 
stretch of residues that connects the FZ domain with the first TM domain of FZD4. Predictions 
indicate that the residue is placed in a large coiled region, buried in the core of the protein preceding 
the first TM helix. Mutation of a cysteine residue, possibly employed to form a disulfide bond, into a 
tyrosine, a hydrophilic amino acid with a large bulky side chain, is expected to lead to destabilization 
or even unfolding of the domain. The Gly252Arg mutation affects a buried amino acid located in the 
intracellular C-terminal tail of FZD4. Glycines are known for their flexibility and no other residue can 
make the same backbone angles. It is possible that this residue is required for a specific backbone 
formation. This is underlined by the fact that the glycine residue at position 525 is preceded by an 
asparagine (a residue often present in structural turns) and by another flexible glycine. The 
Gly525Arg variant changes the flexible glycine into a less flexible arginine, thereby disturbing the 
putative backbone structure. This could potentially affect the normal function of the conserved 
KTXXXW motif and PDZ binding in the Wnt/β-catenin pathway, thereby impeding the action of FZD4 
receptor complex.  
Two new missense mutations were found in LRP5: Glu441Lys and Cys1253Phe. The 
Glu441Lys variant is located in the second ‘β-propeller’ domain of the protein (see figure 5.11B), at a 
highly conserved position. The negatively charged and hydrophilic glutamic acid creates ionic 
interactions with two positively charged arginine residues in its close proximity, thereby stabilizing 
the local structure of the domain. Introduction of an additional positive residue such as lysine is 
likely to disturb the ionic interactions, thereby destabilizing the domain structure and thus impeding 
its normal function. This would certainly have an effect on its potential interaction with NDP. The 
second variant Cys1253Phe, is located in the EGF-like domain following the third ‘β-propeller’ 
module of LRP5, and also affects a well-conserved residue. The third ‘β-propeller’ structure and the 
three LDL-class A repeats play a role in binding of ligands such as Dkk-1. The EGF-like domains are 
generally stabilized by three disulfide bridges. The introduction of a phenylalanine at the position of 
cysteine residue is predicted to disturb one of the existing disulfide bridges. Moreover, 
phenylalanine has a much bulkier side chain than compared with cysteine and might exert steric 
hindrance effects (see figure 5.11C). 
 Six missense mutations were found in NDP. The missense change Cys55Arg influences a 
cysteine residue located on the ‘top’ of one of the anti-parallel β-sheets which forms a disulphide 
bridge with a cysteine on the top of the other β-sheet (see figure 5.12B). The exact function of this 
bond is unclear, but it could be speculated that it might be necessary to stabilize the conformation of 
the two β-sheet domains that contain hydrophobic residues that can interact with another NDP 
monomer. Without the disulfide bridge the two sheets will have more freedom to move, thereby 
making it difficult to form the correct structure for dimerization. Moreover, this disulfide was shown 
to be evolutionary conserved108. The glycine residue at position 67 is highly conserved among many 
NDP orthologues and the Gly67Glu and Gly67Arg variants change a small and flexible glycine into 
either a negatively charged residue (glutamic acid) or into a positively charged residue (arginine). 
Glycine is required at this position in order for the backbone to adopt the correct formation for the 
cysteine knot (figure 5.12C). No other residue can make the correct backbone angles, and therefore, 
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mutation of the glycine will disturb cysteine knot formation and thereby the structure of the protein. 
The missense mutation Phe89Leu is located in a highly conserved domain that adopts an α-helical 
structure. This amino acid is predicted to participate in the dimerization of NDP108. The hydrophobic 
phenylalanine interacts with other hydrophobic residues on the other monomer. Leucine is also 
hydrophobic, but has a smaller sidechain (figure 5.12D). It seems possible that this leucine could 
make the same type of interactions, but because of altered side chain conformation the dimer will 
be less strong and stable. The missense change Ser92Pro was identified in a simplex Norrie disease 
patient. This mutation affects a serine that precedes a cysteine in the cysteine knot motif, and.  It is 
critical that the cysteines are placed correctly in NDP, as they are crucial for its structure. The 
missense change introduces proline (figure 5.12E), which is known to be a very rigid residue that 
often forces the backbone to bend and thereby might disturb the formation of the disulfide bridge 
and thus the conformation of NDP. Pro98Leu is located close to the last cysteine in the knot motif 
and to the unbound cysteine that is needed to form dimers (figure 5.12F). The local backbone 
structure that is created by proline, might be necessary for the correct positioning of cysteines. A 
leucine will cause more flexibility in the backbone that might result in difficulties during dimerization 
and/or formation of the cysteine knot. Another possibility is that the hydrophobic side chain of 
proline might be needed for interactions with another monomer. 
 
Figure 5.11: Schematic representation of LRP5 and 3D modeling of LRP5 missense changes. A) Schematic 
overview of LRP5 and its domains. B) Overview of the second β-propeller domain of LRP5 and a close-up of the 
Glu441Lys change in the second β-propeller domain. The side chain of the wild-type residue (glutamic acid) in 
position 441 is shown in green, whereas the mutant lysine is shown in red. Two neighboring arginines are 
coloured blue. C) Overview of one of the EGF-like domains and the Cys1253Phe change. Cysteines forming 
disulfide bridges are shown in yellow. One of these cysteines is mutated into a phenylalanine, depicted in red. 
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We have provided a comprehensive summary of novel mutations in FZD4, LRP5, and NDP 
that have been reported to affect these genes, with a focus on FEVR and Norrie disease. Our 
emerging understanding of Wnt-signaling offers hope that pharmaceutical agents that selectively 
target this pathway will be developed to treat some phenotypic characteristics of these diseases. 
  
 
Project HOPE’s conclusion about LRP5 mutations 
 
Method Model based on template PDB-file 1npe for E441K and 2fcw for C1253 
Mutation Glu441Lys 
 
Contacts The size difference between wild-type and new mutant residue makes that the new 
residue is not in the correct position to make the same hydrogenbond as the original wild-type 
residue did. The difference in charge will disturb the ionic interaction made by the original wild-type 
residue. 
Structure The mutation is located within a stretch of residues identified as a special region: "Beta-
propeller 2". The differences in amino acid properties can disturb this region and disturb its function. 
The mutation is located within a stretch of residues that is repeated in the protein, this repeat is 
named "LDL-receptor class B 7". The mutation into another residue might disturb this repeat and 
consequently any function this repeat might have. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The charge of the buried wild-type residue is reversed by this mutation, this can cause 
repulsion between residues in the protein core. The wild-type and new mutant amino acids differ in 
size. The new mutant residue is bigger than the wild-type residue. The wild-type residue was buried 
in the core of the protein (or protein-complex). The new mutant residue is bigger and probably will 
not fit. 
Figure 5.12: A) Ribbon model of 
NDP. The protein is coloured in 
gray, the cysteine side chains that 
participate in forming disulfide 
bonds and creating the critical 
knot motif are shown in yellow. 
B-F) Close-ups of the NDP 
missense mutations. The wild-
type and mutant residues are 
depicted in green and red, 
respectively.  
 
A 
D 
B 
C 
E F 
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Conclusion HOPE mentions correctly that the hydrogen 
bond and ionic interaction will be disturbed and that this 
will affect the LDL-repeat in the beta-propeller domain.  
 
 
 
 
 
 
Mutation Cys1253Phe 
 
Contacts In the 3D-structure can be seen that this residue is involved in a cysteine bridge, which is 
important for stability of the protein. Only cysteine can make these type of interactions, the 
mutation causes loss of this interaction and will have a severe effect on the 3D-structure of the 
protein. Together with loss of the cysteine bond, the differences between the old and new residue 
can cause destabilization of the structure. 
Structure The mutation is located within a domain, annotated as: "EGF-like 4". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function.  
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is bigger than the wild-type residue. The wild-type residue was buried in the core of the 
protein. The new mutant residue is bigger and probably will not fit. 
 
 
 
 
 
 
 
 
 
 
Conclusion Even though residues with Phenylalanine-like properties have been found on this 
position, it is very likely that HOPE is correct in predicting the lost cysteine-bond and introduction of 
a big side chain that will disturb the structure. 
 
Project HOPE’s conclusion about FZD4 mutations 
 
Method No structure or modeling template, reports based on predictions 
Mutation Glu40Gln 
 
Structure The mutation is located within a domain, annotated as: "FZ". The mutation introduces an 
amino acid with different properties here which can disturb this domain and abolish its function. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The charge of wild-type residue is lost by this mutation. This can cause loss of interactions with 
other molecules. 
Conclusion HOPE’s conclusion is based on the amino acid properties and predictions only. Still, it 
gives a plausible reason for the phenotypic effect of this mutation. 
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Mutation Cys204Tyr 
 
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is bigger than the wild-type residue. The wild-type residue was buried in the core of the 
protein. The new mutant residue is bigger and will probably not fit. The hydrophobicity of the wild-
type and new mutant residue differs. The mutation will cause loss of hydrophobic interactions in the 
core (or protein-complex).  
Conclusion HOPE’s conclusion is based on the amino acid properties and predictions only. Still, it 
gives a plausible reason for the phenotypic effect of this mutation.  
 
Mutation  Gly525Arg 
 
Structure The wild-type residue was a glycine, the most flexible residue of all. This flexibility might 
be necessary for the protein's function. Mutation of this glycine can abolish this function.  
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The new mutant residue introduces a charge in a buried residue, this can lead to protein folding 
problems. The wild-type and new mutant amino acids differ in size. The new mutant residue is 
bigger than the wild-type residue. The wild-type residue was buried in the core of the protein. The 
new mutant residue is bigger and probably will not fit. The hydrophobicity of the wild-type and new 
mutant residue differs. The mutation will cause loss of hydrophobic interactions in the core of the 
protein (or protein-complex). The glycine residue is the most flexible residue. It is possible that the 
residue is needed at this position to make a special backbone conformation or to facilitate 
movement of the protein. The mutation introduces a less flexible residue thereby disturbing this 
conformation or movement.  
Conclusion HOPE’s conclusion is based on the amino acid properties and predictions only. Using the 
fact that glycine is required for flexibility, it gives a plausible reason for the phenotypic effect of this 
mutation.  
 
Project HOPE’s conclusion about NDP mutations 
 
Method No structure or modeling template, reports based on predictions 
Mutation Cys55Arg 
 
Contacts The wild-type residue is annotated to be involved in a cysteine bridge, which is important 
for stability of the protein. Only cysteines can make these type of bonds, the mutation causes loss of 
this interaction and will have a severe effect on the 3D-structure of the protein. Together with loss 
of the disulfid bridge, the differences between the old and new residue can cause destabilization of 
the structure 
Structure The mutation is located within a domain, annotated as: "CTCK". The mutation introduces 
an amino acid with different properties here which can disturb this domain and abolish its function. 
Conservation Only this residue type was found at this position. Mutation of a 100% conserved 
residue is usually damaging for the protein. The mutant and wild-type residue are not very similar. 
Based on this conservation information this mutation is probably damaging to the protein.  
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The new mutant residue introduces a charge in a buried residue, this can lead to protein folding 
problems. The wild-type and new mutant amino acids differ in size. The new mutant residue is 
bigger than the wild-type residue. The wild-type residue was buried in the core of the protein. The 
new mutant residue is bigger and probably will not fit. The hydrophobicity of the wild-type and new 
mutant residue differs. The mutation will cause loss of hydrophobic interactions in the core. 
Conclusion Correct prediction of a lost disulfide-bridge. The accessibility prediction might be 
incorrect.  
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Mutation Gly67Gln 
 
Structure The mutation is located within a domain, annotated as: "CTCK". The mutation introduces 
an amino acid with different properties here which can disturb this domain and abolish its function. 
The wild-type residue was a glycine, the most flexible residue of all. This flexibility might be 
necessary for the protein's function. Mutation of this glycine can abolish this function.  
Conservation Only this residue type was found at this position. Mutation of a 100% conserved 
residue is usually damaging for the protein. The mutant and wild-type residue are not very similar. 
Based on this conservation information this mutation is probably damaging to the protein. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The mutation introduces a charge at this position, this can cause repulsion between the new 
mutant residue and neighboring residues. The wild-type and new mutant amino acids differ in size. 
The new mutant residue is bigger than the wild-type residue. The residue is located on the surface of 
the protein, mutation of this residue can disturb interactions with other molecules or other parts of 
the protein. The hydrophobicity of the wild-type and new mutant residue differs. The mutation 
might cause loss of hydrophobic interactions with other molecules on the surface of the protein. The 
glycine residue is the most flexible residue. It is possible that the residue is needed at this position to 
make a special backbone conformation or to facilitate movement of the protein. The mutation 
introduces a less flexible residue thereby disturbing this conformation or movement. 
Conclusion HOPE correctly uses all the differences in properties between Glycine and Glutamic acid. 
The idea that this residue enables a special conformation for neighboring cysteines cannot be 
predicted by HOPE yet as there is no structure to identify Cysteine bonds close to the mutated 
residue. 
 
Mutation Gly67Arg 
 
Structure The mutation is located within a domain, annotated as: "CTCK". The mutation introduces 
an amino acid with different properties here which can disturb this domain and abolish its function. 
The wild-type residue was a glycine, the most flexible residue of all. This flexibility might be 
necessary for the protein's function. Mutation of this glycine can abolish this function.  
Conservation Only this residue type was found at this position. Mutation of a 100% conserved 
residue is usually damaging for the protein. The mutant and wild-type residue are not very similar. 
Based on this conservation information this mutation is probably damaging to the protein. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The mutation introduces a charge at this position, this can cause repulsion between the new 
mutant residue and neighboring residues. The wild-type and new mutant amino acids differ in size. 
The new mutant residue is bigger than the wild-type residue.  
The residue is located on the surface of the protein, mutation of this residue can disturb interactions 
with other molecules or other parts of the protein. The hydrophobicity of the wild-type and new 
mutant residue differs. The mutation might cause loss of hydrophobic interactions with other 
molecules on the surface of the protein. The glycine residue is the most flexible residue. It is possible 
that the residue is needed at this position to make a special backbone conformation or to facilitate 
movement of the protein. The mutation introduces a less flexible residue thereby disturbing this 
conformation or movement. 
Conclusion HOPE correctly uses all the differences in properties between Glycine and Arginine. The 
fact that this residue enables a special conformation for neighbouring Cysteines cannot be predicted 
by HOPE yet as there is no structure to identify Cysteine bonds close to the mutated residue. 
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Mutation Phe89Leu 
 
Structure The mutation is located within a domain, annotated as: "CTCK". The mutation introduces 
an amino acid with different properties here which can disturb this domain and abolish its function. 
Conservation Only this residue type was found at this position. Mutation of a 100% conserved 
residue is usually damaging for the protein. The mutant and wild-type residue are not very similar. 
Based on this conservation information this mutation is probably damaging to the protein.  
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is smaller than the wild-type residue. The mutation will cause an empty space in the core of 
the protein (or protein-complex). 
Conclusion HOPE can only use the differences in amino acid properties. The fact that this residue 
might be involved in dimer-interactions can be found in literature only. The accessibility prediction is 
probably incorrect.  
 
Mutation Ser92Pro 
 
Structure The mutation is located within a domain, annotated as: "CTCK". The mutation introduces 
an amino acid with different properties here which can disturb this domain and abolish its function. 
The proline that is introduced by this mutation is a very rigid residue. The mutation might abolish the 
required flexibility of the protein at this position. 
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is bigger than the wild-type residue. The wild-type residue was buried in the core of the 
protein. The new mutant residue is bigger and probably will not fit. The hydrophobicity of the wild-
type and new mutant residue differs. The mutation can cause loss of hydrogenbonds in the core of 
the protein and as a result disturb correct folding. 
Conclusion HOPE correctly predicts the differences between Serine and Proline. However, it does 
not use the fact that the preceding residue is one of the important Cysteines. 
 
Mutation Pro89Leu 
 
Structure The mutation is located within a domain, annotated as: "CTCK". The mutation introduces 
an amino acid with different properties here which can disturb this domain and abolish its function. 
The wild-type residue was a proline. Prolines are known to be very rigid and therefore induce a 
special backbone conformation which might be required at this position. The mutation can disturb 
this special conformation.  
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is bigger than the wild-type residue. The wild-type residue was buried in the core of the 
protein. The new mutant residue is bigger and probably will not fit. Prolines are known to have a 
very rigid structure, sometimes forcing the the backbone in a specific conformation. Possibly, your 
mutation changes a proline with such a function into another residue, thereby disturbing the local 
structure. 
Conclusion HOPE correctly uses the differences in amino acid properties but could benefit from an 
analysis of neighboring residues. 
 
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/PRKCSH/ 
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Project: ACAD9 
Title: Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation 
complex. 
Authors: J. Nouws – L. Nijtmans – S. M. Houten – M. van den Brand –M. Huynen –H. Venselaar – S. 
Hoefs – J. Gloerich – J. Kronick – T. Hutchin – P. Willems – R. Rodenburg – R. Wanders – L. van den 
Heuvel – J. Smeitink – R. O. Vogel 
Published in: Cell Metabolism 2010 (12(3):  283-294) 
 
We analysed 2 point mutations in Acyl-CoA dehydrogenase 9 (ACAD9) that were found in patients 
diagnosed with isolated complex 1 deficiency. This disease causes exercise intolerance, hypertrophic 
cardiomyopathy, lactic acidosis, and failure to thrive.  
The affected ACAD9 protein is a recently identified member of the acyl-CoA dehydrogenase 
family which closely resembles very long chain acyl-CoA dehydrogenases (VLCAD). Therefore, ACAD9 
has been proposed to be involved in mitochondrial β-oxidation of long-chain fatty acids114. However, 
none of the patients showed symptoms that would point to a defect in β-oxidation of fatty acids.  
Results show that ACAD9 is required for mitochondrial complex 1 assembly which seemingly 
conflicts with its previously described role. Our finding is underlined by the fact that ACAD9 
associates with the well-known mitochondrial assembly factors NDUFAF1 and Ecsit.  
Complex I (NADH: ubiquinone oxidoreductase) of the OXPHOS system plays a central role in 
mitochondrial metabolism as it is the entry point for NADH in the oxidative phosphorylation system. 
The biogenesis of complex I involves the combination of 45 subunits encoded by the mitochondrial 
and nuclear genomes, a process that requires the aid of specific chaperones such as AIF, Ecsit and 
Ind142, 115,116. The mechanisms by which these proteins aid and regulate the assembly of complex I 
remain to be elucidated.  
We found that ACAD9 mutations result in complex I deficiency and not in disturbed long-
chain fatty acid oxidation. This strongly contrasts with its evolutionary ancestor VLCAD which we 
show is not required for complex I assembly and clearly plays a role in fatty acid oxidation.  
 
Manual study of mutations in ACAD9  
Sequencing the ACAD9 gene of patients with isolated complex I deficiency uncovered two missense 
mutations in two unrelated patients. One patient was homozygous for Arg518His; the other patient 
was compound heterozygous for a stop codon after 62 amino acids, and Glu413Lys. To analyze these 
mutations, a homology model of ACAD9 was built using the structure of human very long-chain Acyl-
CoA dehydrogenase (VLCAD) as a template (PDB-file 3B96, 47% identity117). The model was built 
using YASARA’s homology modeling script with standard parameters48. A multiple sequence 
alignment of a series of ACAD9 and VLCAD proteins was made using ClustalX92. This alignment 
showed that both missense mutations affect highly conserved amino acids. 
The Arg518His mutation is located at the end of an α-helix with its side chain forming 
charged hydrogen bonds with glutamic acid 592. Substituting arginine by histidine will disturb the 
dimer formation due to the loss of stabilizing hydrogen bonds within this area (see figure 5.13A).  
Glu413 forms a hydrogenbond and ionic interaction with Arg417 at the dimerization surface. This 
interaction will be lost when the glutamic acid is replaced by charged lysine. Lysine has a positively 
charged side chain which will even repulse arginine (figure 5.13B). Among other results, our data 
also have clinical implications, as isolated complex I deficient patients should now also be screened 
for mutations in ACAD9. 
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Figure 5.13: Close-up of the two mutations found in the patients. The ACAD9 monomers are shown in green 
and blue (surface view) the wild type side chains are shown and coloured by element; carbon is cyan, nitrogen 
is blue, oxygen is red, and yellow dots indicate hydrogen bonds. The mutant residues are shown in grey. The 
locations of the mutations are indicated with arrows. 
 
 
Project HOPE’s conclusion about ACAD9-mutations 
 
Method Model based on template PDB 2uxw 
Mutation Glu413Lys 
 
Contacts The size difference between wild-type and new mutant residue makes that the new 
residue is not in the correct position to make the same hydrogenbond as the original wild-type 
residue did. The difference in charge will disturb the ionic interaction made by the original wild-type 
residue. The residue is involved in lots of multimer contacts. The mutation introduces a bigger 
residue at this position, this can disturb the multimeric interactions.  
 
 
 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The charge of the buried wild-type residue is reversed by this mutation, this can cause 
repulsion between residues in the protein core. The wild-type and new mutant amino acids differ in 
size. The new mutant residue is bigger than the wild-type residue. The wild-type residue was buried 
in the core of the protein (or protein complex). The new mutant residue is bigger and probably will 
not fit. 
 
Conclusion HOPE exactly mentions all the facts that were also seen in the manual analysis: 
hydrogenbond, ionic interaction, dimer surface, loss of charge and possible repulsion and size 
difference.  
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Mutation Arg518His  
 
Contacts The size difference between wild-type and new mutant residue makes that the new 
residue is not in the correct position to make the same hydrogenbond as the original wild-type 
residue did. The difference in charge will disturb the ionic interaction made by the original wild-type 
residue. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The charge of wild-type residue is lost by this mutation. This can cause loss of interactions with 
other molecules. The wild-type and new mutant amino acids differ in size. The new mutant residue 
is smaller than the wild-type residue. This will cause a possible loss of external interactions. 
 
 
 
Conclusion HOPE correctly predicts the loss of both the hydrogenbond and the ionic interaction and 
that this affects interaction with other molecules (or in this case, other parts of the same molecule). 
However, in our manual analysis we can see that disturbing the interaction with the other helix will 
also disturb dimerization. These long range effects are not yet included in HOPE. 
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/ACAD9/ 
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Project: EFG1 
Title: Mutation in subdomain G’ of mitochondrial elongation factor G1 is associated with combined 
OXPHOS deficiency in fibroblasts but not in muscle  
Authors: P. Smits – H. Antonicka – P. M. van Hasselt – W. Weraarpachai – W. Haller – M. Schreurs – 
H. Venselaar – R.J. Rodenburg – J.A. Smeitink – L.P. van den Heuvel 
Published in: European Journal of Human Genetics 2010 (19(3):275-279) 
 
We studied a mutation in mitochondrial elongation factor G1 (EFG1) that was found in a patient 
suffering from oxidative phosphorylation (OXPHOS) deficiency in fibroblast cells.  
EFG1 is a GTPase that catalyzes the translocation step of mitochondrial protein synthesis. 
During  this step, the deacylated tRNA moves from the ribosomal peptidyl (P) to the exit (E) site, the 
peptidyl-tRNA moves from the acceptor (A) to the P site and the mRNA is advanced by one codon, 
preparing for a new elongation cycle118. EFG1 consists of five domains of which the GTP-binding 
domain I (or G-domain) contains a large insert, subdomain G’, that is indirectly required for 
translocation.  
The OXPHOS system consists of 5 large protein complexes located in the inner mitochondrial 
membrane that together form the major energy-generating process in our cells. Mitochondrial 
translation of a large number of the OXPHOS subunits is controlled by various nuclear encoded 
proteins. We studied patients with combined OXPHOS deficiencies, in whom complex II (the only 
complex that is entirely encoded by nuclear DNA) showed normal activities, and mutations in the 
mitochondrial genome as well as polymerase gamma were excluded. A screen of all mitochondrial 
translation factors revealed a mutation in the gene for EFG1 causing severe and rapidly progressing 
mitochondrial encephalopathy.  
 
Manual study of the mutation in EFG1 
The modeled structures of the wild-type and mutant EFG1 proteins were based on the crystal 
structure of Thermus thermophilus EFG (PDB-file 2bm0, 45% identity)119. Modeling, energy 
minimization and analyses were performed using the  WHAT IF & YASARA Twinset2.  The first 43 
EFG1 residues could not be modeled.  
The mutation found in the patient converts an arginine at position 250 into a tryptophan. 
Sequence alignment of EFG1 orthologs in 8 different species shows that the arginine is highly 
conserved from humans to bacteria. Figure 5.14 depicts how the residue is located at the periphery 
of the protein and forms a saltbridge and hydrogenbond with glutamic acid 153; these interactions 
are lost when the tryptophan is introduced. Furthermore, a positive charge which might be 
important for interactions between helix A and other proteins, is lost because of the mutation. In 
addition, the large and aromatic tryptophan side chain will cause steric clashes with surrounding 
residues.  
Arginine 250 is located in helix A of the G’-domain. Several experiments have demonstrated 
that the bacterial G’ domain interacts with a ribosomal protein that promotes recruitment to the 
ribosome, greatly stimulates its GTP hydrolysis activity, controls the release of inorganic phosphate, 
and exerts indirect effects on translocation120-122. Mutation experiments in E. Coli resulted in severe 
defects in GTP hydrolysis in the presence of the ribosome and small defects in ribosomal 
translocation. Hence, the Arg250Trp mutation in EFG1 reported in the current study is presumed to 
hamper ribosome-dependent GTP hydrolysis, disturbing mitochondrial translation and oxidative 
phosphorylation and consequently causes fatal mitochondrial encephalopathy.  
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Figure 5.14: Homology modeling based on the crystal structure of the T. thermophilus EFG protein. The 
complete EFG structure (except for the first 43 amino acids) is shown at the left side. A close-up of the outlined 
region containing the mutation is show at the right side. The side chains of wild-type Arg250 and mutant Trp 
are depicted in green and red respectively. GDP is depicted in yellow. The close-up shows that the Trp residue 
fits in the structure; however, the hydrogen bond (yellow dots) between Arg and Glu 153 is lost.  
 
Project HOPE’s conclusion about the EFG1 mutation 
 
Method Model based on template PDB 2rdo 
Mutation Arg250Trp 
 
Contacts The size difference between wild-type and new mutant residue makes that the new 
residue is not in the correct position to make the same hydrogenbond as the original wild-type 
residue did. The difference in hydrophobicity will affect hydrogenbond formation. The difference in 
charge will disturb the ionic interaction made by the original wild-type residue. 
Conservation The wild-type residue is very conserved, but a few other residue types have been 
observed at this position too. Your mutant residue or any other residue type with similar properties 
was not observed at this position in other homologous sequences. Based on conservation scores this 
mutation is probably damaging to the protein. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The charge of wild-type residue is lost by this mutation. This can cause loss of interactions with 
other molecules. The wild-type and new mutant amino acids differ in size. The new mutant residue 
is bigger than the wild-type residue. The residue is 
located on the surface of the protein, mutation of this 
residue can disturb interactions with other molecules or 
other parts of the protein.  
Conclusion HOPE correctly predicts the loss of the 
hydrogen bond and the problems caused by size and 
charge differences. HOPE suggests that this might affect 
interaction with other proteins. The model and 
information in literature underline that this can indeed be 
the case.  
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Project: SMAD3 
Title: Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-
onset osteoarthritis. 
Authors: I. M. van de Laar – R. A. Oldenburg – G. Pals – J. W. Roos-Hesselink – B. M. de Graaf - J. M. 
Verhagen – Y. M. Hoedemaekers – R. Willemsen – L. A. Severijnen – H. Venselaar – G. Vriend – P. M. 
Pattynama – M. Collée – D. Majoor-Krakauer – D. Poldermans – I. M. Frohn-Mulder – D. Micha – J. 
Timmermans – Y. Hilhorst-Hofstee – S. M. Bierma-Zeinstra- P. J. Willems – J. M. Kros – E. H. Oei – B. 
A. Oostra – M. W. Wessels  A. M. Bertoli-Avella 
Published in: Nature Genetics 2011 (43(2): 121-126) 
 
We studied a new syndrome caused by mutations in the SMAD3 gene. This syndrome is 
characterized with aneurysms, dissections, and tortuosity throughout the arterial tree in association 
with mild craniofacial features and skeletal and cutaneous anomalies. In contrast with other 
aneurysm syndromes, most of the affected individuals presented with early-onset osteoarthritis.  
SMAD3 encodes a member of the TGF-β pathway that is essential for TGF-β signal 
transmission. The protein forms a hetero-trimeric complex consisting of two SMAD3, and one 
SMAD4 molecule. Trimer-formation is required for translocation to the nucleus where the complex 
acts as a regulatory unit. The SMAD3 mutations are located in the MH2 domain of the protein; a 
region that is extremely well conserved among other species and other SMAD proteins123-126.  
The mutations in SMAD3 were identified by a genome-wide linkage analysis using 250K SNP 
arrays. Two candidate genes (SMAD3 and SMAD6) in the locus related to the disease were selected 
for further sequence analyses based on their roles in TGFβ-signaling. Two point-mutations in SMAD3 
were found to segregate with the disease phenotype. Both Arg287Trp and Thr261Ile affect 
evolutionary highly conserved amino acids within the MH2 domain of SMAD3 and other SMAD-like 
proteins. 
 
Manual study of mutations in SMAD3  
The experimentally solved structure of the human SMAD3/4 complex (PDB-file 1u7f126) was used to 
predict the effect of the mutations on the structure and function of the protein. The re-refined 
structure of this complex was downloaded from the PDB-redo website80 and contains a 
SMAD3/SMAD3/SMAD4 trimer complex, of which each monomer contains the linker and the MH2 
domain. 
The missense mutations substitute amino acids essential for trimer formation which in turn 
is crucial for the translocation of the SMAD complex to the nucleus and subsequent gene regulation. 
Both altered amino acids are located at or very close to the SMAD/SMAD interfaces.  They make 
interactions required for the correct conformation of the loops that interact with the other 
monomers (see figure 5.15). Mutation of the threonine at position 261 into the bigger isoleucine will 
lead to steric clashes, conformational changes and disturbed dimer interactions. In a similar way, the 
replacement of a positively charged arginine at position 287 by the neutral and bigger tryptophan 
will cause loss of important hydrogenbond and ionic interactions, and will cause rearrangement of 
the residues and loops that interact with other SMAD3 and SMAD4 monomers (see figure 5.15). It 
has been shown that SMAD3 molecules in which the polar Arg287 is replaced by a non-polar residue 
were unable to form dimers with SMAD3 or SMAD4127. TGF-β signals cannot be propagated via 
SMAD3, if SMAD3 heterotrimer formation is affected.  
These findings implicate the TGF-β signaling pathway as the primary pharmacological target 
for the development of new treatment strategies for arterial wall anomalies and osteoarthritis. 
However, our limited understanding of the physiological functioning of this pathway and the 
paradoxical increased TGF-β signal propagation caused by mutations in key molecules within the 
pathway (SMAD3 and the TGF-β receptors) warrant further studies before clinical trials with TGF-β 
antagonists can commence. 
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Figure 5.15: Overview of the SMAD 3/4 trimeric complex of the MH2 domains and close-ups of the mutations. 
The trimeric complex is shown in the middle. Both SMAD3 molecules are coloured green and blue, the SMAD4 
is coloured yellow. The mutated Ile261 and Arg287 are shown as magenta balls. Ile261 is located on the 
SMAD3/SMAD3 interface (blue/green) and Arg287 is located on the SMAD3/SMAD4 interface(green/yellow).  
Both close-ups show the difference between wild-type side chain (green sticks) and mutant side chain (red 
sticks). 
 
 
Project HOPE’s conclusion about SMAD3 mutations 
 
Method Analysis on existing structure PDB1mjs 
Mutation Thr261Ile 
 
Contacts The size difference between wild-type and new mutant residue makes that the new 
residue is not in the correct position to make the same hydrogenbond as the original wild-type 
residue did. The difference in hydrophobicity will affect hydrogenbond formation. 
Structure The mutation is located within a domain, annotated as: "MH2". The mutation introduces 
an amino acid with different properties here which can disturb this domain and abolish its function. 
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is bigger than the wild-type residue. The residue is located on the surface of the protein, 
mutation of this residue can disturb interactions with other molecules or other parts of the protein.  
 
 
Conclusion HOPE uses the monomeric structure of SMAD3 for its prediction. All facts are correct, but 
HOPE misses the interactions between this residue and the other monomer in the complex. In the 
future this will be solved by using complex information. 
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Mutation Arg287Trp  
 
Contacts The size difference between wild-type and new mutant residue makes that the new 
residue is not in the correct position to make the same hydrogenbond as the original wild-type 
residue did. The difference in hydrophobicity will affect hydrogenbond formation. The difference in 
charge will disturb the ionic interaction made by the original wild-type residue. 
Structure The mutation is located within a domain, annotated as: "MH2". The mutation introduces 
an amino acid with different properties here which can disturb this domain and abolish its function. 
The mutation is located within a stretch of residues identified as a special region: "Sufficient for 
interaction with XPO4". The differences in amino acid properties can disturb this region and disturb 
its function. 
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The charge of wild-type residue is lost by this mutation. This can cause loss of interactions with 
other molecules. The wild-type and new mutant amino acids differ in size. The new mutant residue 
is bigger than the wild-type residue. The residue is located on the surface of the protein, mutation of 
this residue can disturb interactions with other molecules or other parts of the protein. 
  
 
Conclusion HOPE calculates that the arginine residue is accessible and therefore does not mention 
the detrimental effects in the core of the protein. However, it does mention the eventual effect on 
interactions with other proteins.  
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/smad3/ 
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Project: IMPAD1 
Title: Chondrodysplasia and Abnormal Joint Development Associated with Mutations in IMPAD1, 
Encoding the Golgi-Resident Nucleotide Phosphatase, gPAPP 
Authors: L.E.L.M. Vissers –  E. Lausch  – S. Unger – A. B. Campos-Xavier – C. Gilissen – A. Rossi – M. 
Del Rosario – H. Venselaar – U. Knoll – S. Nampoothiri – M. Nair – J. Spranger – H. G. Brunner – L. 
Bonafé – J. A. Veltman – B. Zabel – A. Superti-Furga 
Published in: The American Journal of Human Genetics 2011 (13;88(5):608-615) 
 
We studied three patients from two unrelated consanguineous families suffering from congenital 
joint dislocations, chondrodysplasia with short stature, micrognathia, and cleft palate, and a 
distinctive face. Whole exome sequencing was used to identify the cause of this disease under the 
assumption of an autosomal recessive mutation in one gene. After prioritizing and filtering the 
results a single gene was found to contain mutations in all three patients. Patient 1 was found to be 
homozygous for the Asp177Asn mutation in IMPAD1, whereas patients 2 and 3 showed 
homozygosity for Thr183Pro. Mutation analysis of IMPAD1 in a fourth patient identified a premature 
termination codon at position Arg178.  
IMPAD1 encodes a Golgi-resident PAP phosphatase (gPAPP) that is responsible for the 
hydrolysis of phosphoadenosine phosphate (PAP), a byproduct of sulfotransferase reactions, to 
AMP128. This process prevents product inhibition of the sulfotransferase reactions and possibly 
allows for reverse transport of AMP from the Golgi to the cytoplasm128. Independent groups 
associated inactivation of IMPAD1 with skeletal dysplasia and abnormal joint formation in mice, 
possibly related to undersulfation of proteoglycans128-130. We report on the human phenotype 
associated with IMPAD1 mutations and confirm the predictions made by Frederick et al.128 on the 
basis of the mouse knockouts and biochemical studies. 
 
Manual study of mutations in IMPAD1 
To study the structural effects of the mutations we built a homology model with the EsyPred3D 
website, using PDB-file 2wef as a template (26% sequence identity). Subsequent analysis was 
performed using the SPDBV software version 4.0.1131. We also used HOPE to build a model (using the 
same 2wef as a template) for subsequent analysis. The manual interpretation of the model made by 
EsyPred3D and the automatic HOPE analysis are in agreement. Mutation Asp177Asn causes the loss 
of a negative charge needed to bind an essential magnesium ion in the active site, thereby directly 
affecting the phosphatase activity of the protein (see figure 5.16). Both approaches were able to 
identify the detrimental effect on an α-helix caused by mutation Thr183Pro. Prolines lack the 
hydrogen on their backbone nitrogen and can therefore not form the hydrogenbonds required for 
the correct formation of an α-helix132. Thr183 is located at the C-terminal side of a short α-helix that 
also contains substrate binding residues at its N-terminal side. Mutation of this residue into a proline 
will disturb the helix and can indirectly affect substrate binding and consequently affect the function 
of the protein (see figure 5.16).  
 
We conclude that mutations found in this study will impair the enzymatic function of IMPAD1. 
Analysis of this gene should be included in the diagnostic procedure for infants presenting with 
congenital dislocations, chondrodysplasia, and short stature. 
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Figure 5.16: Overview of the protein in ribbon presentation. Middle: the protein is coloured gray, and the side 
chains of the mutated residue are coloured magenta and shown as small balls. Left and right: Close-up of the 
Thr183Pro and Asp177Asn mutations. Side chains of both the wild-type and the mutant residue are shown and 
are coloured green and red, respectively. 
 
 
Project HOPE’s conclusion about IMPAD1 mutations 
 
Method Model based on template PDB-file 2wef 
Mutation D177N 
 
Contacts In the 3D-structure can be seen that the wild-type was involved in a metal-ion contact. The 
wild-type residue was negatively charged, the mutant residue is neutral. Because the negative 
charge is lost the interaction with the metal "MG" will be less stable, this can disturb the domain. In 
the 3D-structure can be seen that the wild-type residue makes interaction with a ligand annotated 
as AMP . The differences in properties between wild-type and mutation can easily cause loss of 
interactions with the ligand. Because ligand binding is often important for the protein's function, this 
function might be disturbed by this mutation.  
Structure The mutation is located within a stretch of residues annotated in Uniprot as a special 
region: "Substrate binding". The differences in amino acid properties can disturb this region and 
disturb its function.  
Amino acid properties There is a difference in charge between the wild-type and mutant amino acid. 
The charge of the buried wild-type residue (either in the protein or in the protein-complex) is lost by 
this mutation.  
 
 
Conclusion HOPE finds correctly that D177 makes interactions with both the ligand and a 
magnesium-ion and that this mutation can therefore disturb the function of the protein.  
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Mutation T183P 
 
Contacts The difference in hydrophobicity will affect hydrogenbond formation.  
Structure In the 3D-structure can be seen that the wild-type residue is located in an α-helix. Proline 
disrupts an α-helix when not located at one of the first two positions. In case of the mutation at 
hand, the helix will be disturbed and this can have severe effects on the structure of the protein.  
Amino acid properties The hydrophobicity of the wild-type and new mutant residue differs. The 
mutation can cause loss of hydrogenbonds in the core of the protein (or protein-complex) and as a 
result disturb correct folding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion HOPE correctly finds that a hydrogenbond will be lost and that this mutation will disturb 
an α-helix. HOPE cannot yet see that the other side of this helix is involved in ligand binding.  
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Project: TMPRSS3 
Title: Genotype-Phenotype Correlation in DFNB8/10 Families with TMPRSS3 Mutations 
Authors:  Nicole J.D. Weegerink – M. Schraders – Jaap Oostrik – Patrick L.M. Huygen – Tim M. Strom 
– Susanne Granneman – Ronald J.E. Pennings – Hanka Venselaar – Lies H. Hoefsloot – Mariet Elting  
Published in: Journal of the Association for Otolaryngology 2011 (12(6):753-766) 
 
Autosomal recessive nonsyndromic hearing impairment (arNSHI) is the most common type of 
inherited hearing impairment, accounting for approximately 80% of inherited prelingual hearing 
disorders. The phenotype associated with arNSHI is usually prelingual, non-progressive, and severe 
to profound133. So far, 40 causative genes have been identified to be involved in arNSHI, indicating 
enormous genetic heterogeneity134. We studied and characterized the genotype–phenotype 
correlations in eight Dutch DFNB8/10 families with compound heterozygous mutations in the 
transmembrane protease serine 3 (TMPRSS3). Mutations in TMPRSS3 are responsible for arNSHI 
with both prelingual onset (DFNB10135) and postlingual onset (DFNB8136). Four different missense 
mutations and two frameshift mutations were detected, including one novel variant (Val199Met), 
four previously described pathogenic variants (Ala306Thr, Thr70fs, Ala138Glu, Cys107fs), and 
Ala426Thr, which had previously been reported as a possible polymorphism137. We compared 
phenotypes of the families that had at least one mutation in TMPRSS3 in common. This enabled us 
to address the effect of the second mutation on the phenotype in these families. 
 
Manual study of mutations in TMPRSS3 
The effects of the amino acid substitutions on the TMPRSS3 structure were analyzed both manually 
and by using Project HOPE138. The exact 3D structure of TMPRSS3 is unknown; therefore, we built a 
model based on the homologous structure in PDB-file 1z8g139. The model was built using an 
automatic script in the WHAT IF & YASARA Twinset1; 2.  
The clinical data suggest that mutations Val199Met and Ala306Thr have a more severe 
effect than Ala138Glu and Ala426Thr. Ala306Thr and Ala426Thr occur in the serine protease domain 
and result in the mutation of a small, hydrophobic, conserved residue into a bigger and more 
hydrophilic residue. This is predicted to destabilize the domain. The difference in severity of the 
effect of the two mutations might well be explained by the location of the substituted residue. The 
Ala306Thr is located close to one of the active residues, Asp304, and therefore this substitution can 
be predicted to directly disturb the function of the serine protease domain. In contrast to Ala306, 
which is completely buried in the protein, Ala426 is only semi-buried. As the side chain of threonine 
is only slightly bigger than the alanine side chain, there could be enough space for the side chain of 
the threonine at this position (see figure 5.17). This makes Ala426Thr a less detrimental mutation 
than Ala306Thr.  
Ala138Glu and Val199Met occur within the scavenger receptor cysteine-rich (SRCR) domain, 
which is thought to be involved in interactions with extracellular molecules. These two mutations 
affect conserved residues and substitute the wild-type residue for a larger one. This is predicted to 
cause steric clashes with other residues and hence to destabilize the protein (see figure 5.17). 
Analyses of the 3D-model could not directly explain the difference in the effect of Ala138Glu and 
Val199Met mutations since information about the exact function and location of binding partners of 
the SRCR domain cannot be obtained from the model. 
 The genotype–phenotype analysis suggests that not only the protein truncating mutation 
Thr70fs has a severe effect but also the amino acid substitutions Ala306Thr and Val199Met. A 
combination of two of these three mutations causes prelingual profound hearing impairment 
(DFNB10) whereas the combination with Ala426Thr or Ala138Glu leads to a milder phenotype with 
postlingual onset of the hearing impairment (DFNB8). Further studies are needed to distinguish 
possible phenotypic differences between different TMPRSS3 mutations.  
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Figure 5.17: Molecular modeling for TMPRSS3 missense mutations. Graphic representation of the effect of the 
Ala306Thr and Ala426Thr mutations in the serine protease domain (A) and of the Ala138Glu and Val199Met in 
the SRCR domain (B). The wild-type residues are depicted in green, while the mutant residues are shown in 
red. The yellow structure represents a substrate for the serine protease. 
 
 
Project HOPE’s conclusion about TMPRSS3 mutations 
 
Method Model based on template PDB-file 1z8g 
Mutation Ala138Glu 
 
Structure The mutation is located within a domain, annotated as: "SRCR". The mutation introduces 
an amino acid with different properties here which can disturb this domain and abolish its function.  
Amino acid properties There is a difference in charge between the wild-type and new mutant amino 
acid. The new mutant residue introduces a charge in a buried residue, this can lead to protein folding 
problems. The wild-type and new mutant amino acids differ in size. The new mutant residue is 
bigger than the wild-type residue. The wild-type residue was buried in the core of the protein. The 
new mutant residue is bigger and probably will not fit. The hydrophobicity of the wild-type and new 
mutant residue differs. The mutation will cause loss of hydrophobic interactions in the core.  
 
 
 
Conclusion HOPE is correct. The mutation introduces a bigger residue in the core of the protein 
which will cause steric clashes with the surrounding residues. The introduced residue is also more 
hydrophobic than the wild type residue, this can disturb the folding process because the new 
residue tends to make unwanted hydrogen bonds. The SRCR domain will be slightly destabilized. The 
report could be improved if we knew the exact function of this domain.  
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Mutation Val199Met 
 
Structure The mutation is located within a domain, annotated as: "SRCR". The mutation introduces 
an amino acid with different properties here which can disturb this domain and abolish its function.  
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is bigger than the wild-type residue. The wild-type residue was buried in the core of the 
protein. The new mutant residue is bigger and probably will not fit.  
 
 
 
Conclusion This is a straightforward example of a small residue that is mutated into something 
bigger. This does not fit and will cause steric clashed with other residues, and destabilize the 
domain. Again, it would be interesting to know the function of this SRCR domain. 
 
Mutation Ala306Thr 
 
Structure The mutation is located within a domain, annotated as: "Peptidase S1". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function.  
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is bigger than the wild-type residue. The wild-type residue was buried in the core of the 
protein. The new mutant residue is bigger and probably will not fit. The hydrophobicity of the wild-
type and new mutant residue differs. The mutation will cause loss of hydrophobic interactions in the 
core.  
 
 
 
Conclusion HOPE is right about the size difference between wildtype alanine and the new residue 
threonine. The threonine will not fit here because it is too big. What HOPE cannot (yet) see is that 
this occurs close to the active site residues. The mutation will surely affect this domain and affect 
ligand binding.  
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Mutation Ala426Thr  
 
Contacts The mutated residue is located very close to a residue that makes a cysteine bond. This 
cysteine bond itself is not mutated but could be affected by the mutation located in its vicinity. The 
mutated residue is not in direct contact with a ligand, however, the mutation could affect the local 
stability which in turn could affect the ligand-contacts made by one of the neighboring residues.  
Structure The mutation is located within a domain, annotated as: "Peptidase S1". The mutation 
introduces an amino acid with different properties here which can disturb this domain and abolish 
its function.  
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is bigger than the wild-type residue. The wild-type residue was buried in the core of the 
protein. The new mutant residue is bigger and probably will not fit. The hydrophobicity of the wild-
type and new mutant residue differs. The mutation will cause loss of hydrophobic interactions in the 
core.  
 
 
Conclusion The small residue is changed in a bigger one that does not fit. The introduction of a 
hydrophilic side chain will cause problems during folding. Ala 426 is located close to a cysteine bond 
(purple) that is important for the conformation surrounding the substraat. Mutation could affect 
substrate binding and the peptidase function of this domain. However, there seems to be more 
space here for the Threonine side chain than at position 306. 
 
Manual analysis can be found online: http://www.cmbi.ru.nl/~hvensela/tmprss3/ 
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Project: IER3IP1 
Title: Microcephaly with simplified gyration, epilepsy, and infantile diabetes linked to inappropriate 
apoptosis of neural progenitors. 
Authors: C.J. Poulton – R. Schot – S.K. Kia – M. Jones – F.W. Verheijen – H. Venselaar – M.C. de Wit – 
E. de Graaff – A.M. Bertoli-Avela – G. M. Mancini 
Published in: The American Journal of Human Genetics 2011 (89(2): 265-276) 
 
We describe a syndrome characterized with primary microcephaly (small brain size) with simplified 
gyral pattern in combination with severe infantile epileptic encephalopathy and early-onset 
permanent diabetes. Primary microcephaly is considered to be caused by a brain developmental 
defect140. So far, mutations in at least seven genes have been found that are causative for congenital 
primary microcephaly with normal or simplified gyration (MSG)141, whereas mutations in at least 
four genes have been identified in patients that suffer from MSG with additional features such as 
epilepsy141-143. Animal studies have shown that abnormal control of apoptosis is a possible cause for 
human MSG142. A disturbed apoptosis mechanism is also found in infantile-onset diabetes.  
In this study we ascertained 3 patients from two consanguineous families suffering from a 
combination of MSG, infantile encephalopathy, and infantile diabetes. Linkage analysis revealed an 
area with two homozygous missense mutations (Val21Gly and Leu78Pro) in immediate early 
response 3 interacting protein 1 (IER3IP1) in patients from both families.  
IER3IP1 is highly expressed in the fetal brain cortex and fetal pancreas and is thought to be 
involved in endoplasmic reticulum stress response. IER3IP1 encodes a small polypeptide of 82 amino 
acids. The protein is predicted to contain two hydrophobic transmembrane domains of which the 
first one possibly contains a signal peptide144, and a hydrophilic, glycine-rich domain (G-patch) that 
putatively interacts with RNA.  
 
Manual study of mutations in IER3IP1 
No protein structure or possible modeling template was known for IER3IP1. Therefore, an extensive 
in silico analysis was performed using a series of different prediction servers including Project 
HOPE138. 
The Val21Gly change introduces a glycine just before the G-patch. Signal P 3.0 suggests that 
this mutation is very close to a putative peptide cleavage site, possibly interfering with the cleavage 
of the signal sequence144. Project HOPE predicts that this mutation will affect a residue in a 
transmembrane domain, and will introduce a more flexible residue at this position.  
The Leu78Pro change is located in the second transmembrane domain. Project HOPE 
predicts that the mutation disturbs an α-helix which will have severe effects on the structure of the 
protein138. In silico analysis of both mutations using several other prediction programs, such as 
SIFT145, PMUT146 and PolyPhen147, predicted a pathogenic/non-neutral effect.  
 
The linkage and IER3IP1 sequence data, together with the expression pattern during brain 
development and its involvement in regulation of apoptosis in vitro indicate that the mutations 
observed are causally related to their disease. This directly implicates IER3IP1 in the regulation of 
cell survival. Identification of IER3IP1 mutations sheds light on the mechanisms of brain 
development and on the pathogenesis of infantile epilepsy and early-onset permanent diabetes. 
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Project HOPE’s conclusion about IER3IP1 mutations 
 
Method No structure or modeling template, report based on predictions 
Mutation Val21Gly   
 
Structure The residue is located in a region annotated in the Uniprot database as a transmembrane 
domain. The new mutant residue is smaller than the wild-type residue. This can disturb either the 
contacts with the other transmembrane domains or with the lipid-membrane. The wild-type residue 
was more hydrophobic than the new mutant residue. This can affect the hydrophobic interactions 
within the core of the protein or with the membrane lipids. The mutation introduces a glycine at this 
position. Glycines are very flexible and can disturb the required rigidity of the protein on this 
position.  
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is smaller than the wild-type residue. The mutation will cause an empty space in the core of 
the protein (or protein-complex). The hydrophobicity of the wild-type and new mutant residue 
differs. The mutation will cause loss of hydrophobic interactions in the core of the protein (or 
protein-complex).  
Conclusion There is hardly any information known for this protein but HOPE does a good job using 
prediction servers.  
 
Mutation Leu78Pro  
 
Structure The residue is located in a region annotated in the Uniprot database as a transmembrane 
domain. The new mutant residue is smaller than the wild-type residue. This can disturb either the 
contacts with the other transmembrane domains or with the lipid-membrane. The wild-type residue 
is predicted (by the PHDacc DAS-server) to be located in an α-helix. Proline disrupts an α-helix when 
not located at one of the first two positions. In case of the mutation at hand, the helix will be 
disturbed and this can have severe effects on the structure of the protein.  
Amino acid properties The wild-type and new mutant amino acids differ in size. The new mutant 
residue is smaller than the wild-type residue. The mutation will cause an empty space in the core of 
the protein (or protein-complex).  
Conclusion Even though there is hardly any information at all, HOPE gives a very plausible conclusion 
about the effect of this mutation. 
 
Manual analyses can be found online: http://www.cmbi.ru.nl/~hvensela/IER3IP1/ 
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Introduction 
The increasing application of large scale sequencing to patients with genetic diseases has made the 
accurate interpretation of genetic variants a challenge that is of paramount importance to both 
genetic diagnostic services and to disease gene discovery. This problem is not new, but it is clearly 
scaling up due to these new technologies. This requires that we rethink the criteria by which we 
declare pathogenicity, as well as the tools that we use for generating such calls. 
 One way in which we may possibly improve the accuracy of predictions about pathogenicity 
of individual mutations is to include information on protein structure for their annotation. We 
previously developed HOPE1 (Have yOur Protein Explained), a program that combines a number of 
features from existing software packages with extensive use of protein structure information. HOPE 
can automatically build homology models which enables the use of structural information for about 
40% of all human proteins. HOPE provides for each mutation a detailed description in order to aid 
scientists with interpretation of the data.  
 We have systematically compared the output from HOPE, with that of three widely-used 
methods for automatic variant annotation. As expected, we find that when structure information is 
available, the two methods that can use it (PolyPhen and HOPE) outperform both methods that do 
not incorporate information from protein structural modeling (Grantham scores and SIFT). 
Additionally, the HOPE report provides an extensive explanation of the mutational effect which leads 
to more insight in the protein and the mutation.  
 
Recent developments in Next Generation Sequencing (NGS) techniques have greatly increased the 
rate at which variation in the human genome is identified. It has been estimated that SNPs occur 
about every 200-300 base-pairs leading to ~15 million SNPs2 in an individual genome. Initiatives such 
as dbSNP3, HGMD4, and the 1000 genome project5 collect and analyse these variants in order to 
create an reliable overview of variation in the complete human genome. Currently, dbSNP contains 
more than 52 million SNPs (build 135, October 2011). 
 One interesting observation is that in any human exome sequenced today, the number of 
previously unidentified variants that affect the coding sequence and would lead to a predicted 
change in the amino acid composition of the protein, is 150-2006. This is true, even of individuals 
from populations for which a large number of exomes have already been sequenced. 
 NGS leads to easier detection of variants, but assessing a causal relation to disease remains 
difficult, and incomplete. This can be illustrated by the fact that for BRCA1 and BRCA2, two of the 
most studied human disease genes, 15% of the mutations remain 'unclassified'7. 
 A number of bioinformatics methods have been developed to tackle the challenge of 
annotating point-mutations in proteins. The Grantham-score8 was the first method that was based 
on differences in amino acid properties. Grantham himself already mentioned in his seminal 1974 
paper8 that his method has its limitations because it does not take structural features into account. A 
Ser->Thr mutation, for example, tends to be harmless unless the serine is an active site residue. SIFT9 
(Sorting Intolerant From Tolerant) is based on multiple sequence alignments which make its 
predictions generally more accurate than Grantham scores. The PolyPhen10 web server was the first 
of a new generation of servers that collect and combine information from a wide range of sources to 
infer conclusions about the effect of a mutation. Rapid proliferation of such computer programs has 
occurred in recent years. Table 6.1 provides a list of freely available web servers that can analyse 
point mutations in proteins and predict their effect.  
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Table 6.1: Internet based web servers that can aid with the prediction of the effects of point mutations on a 
protein’s structure and/or function. Left: name of facility, reference, and URL. Right: very short description of 
the main features. MSA=Multiple Sequence Alignment; SVM=Support Vector Machine; PSIC=Position Specific 
Independent Counts; GO=Gene Ontology.  
Servers that work with AA sequence (sometimes Uniprot ID) and mutation and that can predict 
the functional effect of the mutation 
PolyPhen10 
genetics.bwh.harvard.edu/pph2/  
Classifies a mutation as probably damaging,  
possibly damaging, or benign, uses annotations, 
info in PDB-file, MSA, UniProt and PSIC 11scores. 
SNAP12 
rostlab.org/services/snap/ 
Gives neutral or non-neutral. Uses sequence 
annotations, predictions on sequence, and 
MSA. 
PMut13 
mmb2.pcb.ub.es:8080/PMut/ 
Uses sequence based information and 
predictions but no structures. A set of pre-
calculated mutations on a reference PDB set is 
also available 
SNPS&GO14 
snps-and-go.biocomp.unibo.it/snps-and-go/ 
Mainly uses GO-terms to indicate disease 
versus neutral. 
nsSNPAnalyzer15 
http://snpanalyzer.uthsc.edu/ 
Uses environment scores and SIFT scores to 
classify a mutation as pathogenic or not (works 
for sequences with PDB only!) 
MutationAssesor16 
http://mutationassessor.org/ 
Lists information from Uniprot, variation 
scores, known regions/domains and SNPs for 
the whole gene. Gives a functional impact score 
(high, medium, low or neutral) 
SNPeffect17 
http://snpeffect.vib.be/ 
Predicts effects of mutations using aggregation, 
stability, etc scores 
Servers that only use conservation scores 
Panther18 
www.pantherdb.org/tools/csnpScoreForm.jsp 
Gives a score for deleterious or neutral, based 
on MSA only. 
PhD-SNP19 
gpcr.biocomp.unibo.it/cgi/predictors/PhD-
SNP/PhD-SNP.cgi 
Classifies a mutation as neutral or disease 
causing based on MSA only using SVM. 
SIFT9 
sift.jcvi.org/ 
Classifies a mutation as being tolerated or not 
tolerated, based on  MSA only 
Servers that calculate stability/energy changes (using PDB structure) 
MuPro20 
http://mupro.proteomics.ics.uci.edu/ 
Predict protein stability changes for single 
amino acid mutations  
AutoMute21 
http://proteins.gmu.edu/automute/ 
Indicates whether the stability and function of 
structure is affected 
Eris22 
http://troll.med.unc.edu/eris 
Calculates stability change causes by a 
mutation 
PopMuSiC23 
http://babylone.ulb.ac.be/popmusic 
Stability calculation only using, among others, 
atom/torsion angle potentials 
CUPSAT24 
http://cupsat.tu-bs.de/ 
 
Prediction of the protein stability change upon 
a mutation using aa-atom potentials and 
torsion angle distribution (calculations for all 
aa) 
I-mutant 2.025 
http://folding.uib.es/i-mutant/i-mutant2.0.html 
 
Can predict the protein’s stability change based 
on either the structure or the sequence 
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SDM26 
http://mordred.bioc.cam.ac.uk/sdm/sdm.php 
Structure based prediction of stability and 
disease association of the mutation (only one 
that gives disease association too) 
Servers that collect info about known SNPS (no option for de novo SNPs) 
FastSNP27 
 http://fastsnp.ibms.sinica.edu.tw 
Analyzes all SNPs but uses PolyPhen for the 
non-synonymous ones 
stSNP28 
http://ilyinlab.org/StSNP/ 
Lists the aa-differences per SNP and the KEGG 
pathway 
Omidios29 
http://sgu.bioinfo.cipf.es/services/Omidios/ 
Classifies SNPS in disease/polymorphism 
F-SNP30 
http://compbio.cs.queensu.ca/F-SNP/ 
Meta-server, collects classifications from others 
and uses multi-vote 
LS_SNP31 
http://modbase.compbio.ucsf.edu/LS-SNP/ 
Gives 3D-effect/stabilization of existing SNPS 
SNAP32 
http://snap.humgen.au.dk 
Loads of information about a variant 
SNPs3D33 
www.snps3d.org/ 
 
Lists molecular functional effects of non-
synonymous SNPs based on structure and 
sequence analysis. (only existing SNPS, no 
option for your own input) 
MutDB 34 
http://www.mutdb.org 
Collects human variants from Swiss-Prot and 
dbSNP organized by gene. Shows SIFT scores 
for the nsSNPS. 
 
HOPE 
We have designed HOPE1 (Have yOur Protein Explained) a program that combines the various 
features of existing software packages with the novel feature of extensive protein structure (or 
homology model) information. HOPE combines the results of dozens of computer programs and 
produces output in the form of a report that is intended to be understandable for trained molecular 
biologists, and life science experts. The use of structure information is a potentially important 
addition, because it allows the investigation of effects on features such as solvent accessibility, 
secondary structure, hydrogen bonding, ionic interactions, and location of the active site. However, 
the percentage of human proteins for which the 3D-structure was solved is only ~20%. HOPE can 
automatically build homology models when experimental structure information is available for a 
homolog of the protein of interest, thereby increasing the percentage of human proteins that can be 
analysed in detail to more than 40%. A decision scheme is applied to identify the effects of a 
mutation on the protein’s 3D-structure and function. This decision scheme ensures that the most 
reliable source of information is always used for the report; conclusions drawn from 3D-structures 
prevail over Swiss-Prot annotations that in turn prevail over sequence based predictions. In case no 
structure data is available and no model can be built, HOPE functions much like other methods and 
uses annotations obtained from a series of databases, and sequence based predictions obtained 
from Swiss-Prot35 and DAS-servers36. Conservation scores obtained from HSSP37 are always added to 
the report.  
 The report is illustrated with pictures and animations that are ready for use in presentations 
and articles. HOPE’s technical details have been described in chapter 4. HOPE’s workflow is 
illustrated in figure 6.1.  
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Figure 6.1: HOPE’s workflow. 1) The user submits the protein sequence and mutation of interest. 2) HOPE 
collects all information about the protein from different information sources (calculations on the 3D-structure 
or the homology model, annotations from SwissProt sequence features, sequence-based predictions by DAS-
servers, and conservation scores from HSSP) The data is stored for use in a database 3) The data is combined in 
a decision tree. HOPE will use information from the most reliable source first (the structure itself or a 
homology model), followed by annotations, and predictions. Conservation scores originate from HSSP. 4) The 
information is combined into a life-science-friendly written report which will be shown on the website. 
  
Since its first day online HOPE has analysed the predicted effect of hundreds of mutations for users 
from all over the world. Subjectively, HOPE provides very accurate detailed descriptions of the 
impact of a mutation on the protein. We compared HOPE’s performance with that of three 
commonly used methods for a set of manually analysed disease causing mutations. A test dataset of 
37 mutations was extracted from all 15 articles published in 2010 in the American Journal of Human 
Genetics that describe the effect of a disease causing mutation on the 3D-structure and/or function 
of the affected protein.  
As a negative control we used the 21 SNPs in the same set of proteins which have been 
annotated as non-damaging ‘polymorphisms’ at the UniProtKB/Swiss-Prot variant pages and which 
could be analysed using either the experimentally solved structure or a homology model. We 
analysed all 58 variants using HOPE and the three afore-mentioned methods (for PolyPhen the 
upgraded PolyPhen-2 server was used). The results are summarized in Table 6.2 and show that 
current methods agree on the interpretation of a newly found mutation in only a small majority of 
cases. A more extensive analysis of another 144 mutations described in previous projects and 
randomly selected articles showed results similar to those described here. Results of this extensive 
analysis can be found in Table 6.3 (page 151) and will be discussed in Chapter 6a. 
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Table 6.2: Analysis of 37 disease-causing mutations and 21 polymorphisms. The threshold for Grantham scores 
(benign < 62 < damaging) was obtained from Bell et al38. SIFT predicts either tolerated (does not cause a 
disease) or not-tolerated (causes a disease). PolyPhen-2 classifies mutation as ‘probably damaging’, ‘possibly 
damaging’, or 'benign'; the best correlation with experiment is obtained by considering the first two categories 
both as damaging. HOPE's decision tree produces rather elaborate results that have for this study been 
compressed into damaging and benign. Note that for only 59% of the disease-causing variants Grantham, SIFT, 
and PolyPhen-2 agree that the mutation is pathogenic, and that in 5% of the cases these 3 methods 
unanimously agree that the mutation is benign. 
 Pathogenic mutations Polymorphisms 
Number of variants 37 21 
Grantham (<62 is benign) 59% > 62 52% < 62 
SIFT 81% not tolerated 62% tolerated 
PolyPhen-2 89% damaging 
76% probably damaging 
52% benign 
Grantham/SIFT/PolyPhen-2 
are in agreement 
59% in agreement of which 
5% incorrect (all predict a 
benign mutation) 
48% in agreement of which 
19% incorrect (all predict a 
damaging mutation) 
HOPE 92% damaging of which 
76% obviously damaging 
67% mutant is not severe 
  
Table 6.2 shows that Grantham-scores correctly predict pathogenic mutations in only 59% of the 
disease-causing mutations and neutral for 52% of the neutral SNPs. SIFT performs better than 
Grantham as 81% of the pathogenic mutations are indeed predicted as not-tolerated and 62% of the 
polymorphisms are predicted to be tolerated. If we count both 'probably damaging' and 'possibly 
damaging' as ‘damaging’, PolyPhen-2 correctly identifies 89% of the pathogenic mutations and 52% 
of the SNPs.  
The analysis further shows that the SIFT, HOPE, and Polyphen-2 methods that use multiple 
sequence alignments clearly outperform Grantham scores. The use of structure information further 
increases the number of correctly predicted pathogenic mutations. Grantham, SIFT, and PolyPhen-2 
are often used in combination. From our results, we question this approach as it does not seem to 
increase accuracy. Our analyses show that these three algorithms agree for only 59% and 48% of the 
pathogenic mutations and neutral SNPs, respectively. We also found a few cases for which the 
combined analysis is unanimously incorrect; 5% of the pathogenic mutations are called benign and 
19% of the neutral SNPs were predicted to be disease-causing by all three methods.  
In terms of classification and accuracy, HOPE and Polyphen-2 appear to yield similar results. 
However, we note that there are a number of differences in their respective output formats which 
may be relevant to prospective users. Notably, HOPE was not primarily designed to serve as a 
mutation classifier. Its strength lies in the detailed yet easy to understand description of the effects 
of a mutation on various aspects of the protein structure and function. To make sure every user is 
able to read and understand the reports we have implemented a help-function that links all the 
difficult keywords from the fields of bioinformatics, biophysics, and protein structures to a dedicated 
online dictionary. Thus, HOPE produces reports that do not contain just a single pathogenicity score. 
Instead, HOPE reports describe the effect that the mutation might have on relevant features, such as 
contacts made by the residue, the structural domain in which the residue is located, post-
translational modifications. Additionally, the report provides information about variations found at 
the same position and conservation scores. A recent editorial in Nature Genetics39 stresses the 
importance of “mechanistic investigation and further value”. The HOPE reports can provide a good 
start towards providing such information. 
 To compare HOPE reports with the outcome of the other three methods the collected 
information was consistently interpreted. For instance, a report that mentions the loss of a salt-
bridge at a conserved position clearly describes a damaging mutation which we therefore scored 
‘pathogenic’ in this study. A HOPE report that mentioned a non-conserved residue at the surface was 
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scored as ’benign’. HOPE scores comparable to PolyPhen-2 with 92% of the pathogenic mutants 
correctly predicted to affect the protein’s structure and/or function and 67% of the polymorphisms 
predicted to have no severe structural effect. Our test set consists of mutations in proteins for which 
3D-structure information is available. HOPE will perform better than PolyPhen-2 in those cases for 
which no 3D-structure is available but for which a homology model can be build. 
The added value of HOPE over the other methods lies in the detailed description of the 
effects of the mutation on the protein structure and/or function. Whereas the other methods 
classify a mutation as damaging, HOPE provides the rationale why that mutation is damaging. This 
may lead to a better understanding of the effects of the mutation on the protein and further suggest 
new experiments. In 13 of the 15 cases in which the use of Grantham, PolypPhen-2, and SIFT did not 
unanimously result in a pathogenic prediction HOPE was able to provide the information required 
for a correct classification. For example, the pathogenic mutation Val2303Met in Aggrecan40 receives 
a very low Grantham score (21, corresponding to 'benign') based on the hydrophobic similarity of 
valine and methionine. SIFT predicts that this mutation is not tolerated, whereas PolyPhen-2 cannot 
classify the mutation due to lack of information. The HOPE report notes that the mutation will 
disturb the structural integrity of the core of the ‘C-type lectin’ domain and thus gives a clear reason 
for the pathogenic effect. This answer agrees with the conclusion drawn by the authors of the 
corresponding article40. The pathogenic mutation Glu325Lys in KLF1 has a benign Grantham score of 
56 because glutamic acid and lysine both are hydrophilic and charged. SIFT and PolyPhen-2 predict 
'not-tolerated’ and ’probably damaging’ respectively. The HOPE report describes that this mutation 
disturbs DNA binding which will affect the protein’s function. In this case, SIFT, PolyPhen-2, and 
HOPE are correct, while HOPE additionally agrees with the detailed description by the authors41.  
The neutral SNP Phe90Leu in DHB4 has a benign Grantham score of 22 but was predicted to 
be pathogenic by both SIFT and PolyPhen. The HOPE report additionally shows that the residue is 
located at the surface and that the mutant residue was also found at this location in other, 
homologous proteins so that the mutation might indeed be benign. Similarly, in 6 out of 10 neutral 
SNPs for which the three other methods disagreed about the classification, HOPE reported the 
variant to be benign.  
 
   
 
 
Figure 6.2: Mutation Trp177Arg in Opsin. The picture that is shown in the HOPE report for mutation Trp177Arg 
in opsin shows that Trp177 is located at the surface of a helix. This helix is a transmembrane helix and 
therefore the Trp177 residue is in contact with the membrane-lipids. The HOPE report correctly states that this 
mutation will affect the contacts with the membrane-lipid because the arginine residue differs from the wild-
type tryptophan in its size, charge and hydrophobicity.  
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 In five cases HOPE provided more, or more correct information than the description of the 
mutation in the article, and in all five cases manual inspection shows HOPE to be correct. For 
example, the authors state that residue Val359 is located at the surface of SPTC242 whereas HOPE 
analyses the homology model and finds that this residue is buried. In another example, the authors 
stated that mutation Trp177Arg in opsin43 will cause a major conformational change whereas HOPE 
finds that this mutation is more likely to disturb interactions with the membrane, a conclusion 
supported by dozens of studies listed in the GPCRDB44. Figure 6.2 shows the picture that was 
included in the HOPE report for this mutant. These examples further illustrate how HOPE can be 
used to gain more insight in the structural effects of mutations. 
 The 8% cases in which HOPE failed to identify a damaging effect of a causative variant was 
due to the misclassification of 3 mutations in the PRPS1 protein. In all three cases the mutated 
residue was not conserved and the mutant residue was also found at that particular position in the 
multiple sequence alignment. Glu43Asp and Asp65Asn both occur at the surface of the protein 
where a mutation might be less detrimental. SIFT, PolyPhen-2 and Grantham also disagree with the 
authors and predict a benign mutation. Mutation Leu129Ile is predicted by HOPE as benign because 
leucine and isoleucine have the same properties and isoleucine was observed at this position in the 
HSSP multiple sequence alignment. According to the authors of the original article this residue is 
located close to an allosteric binding site, information that is not available as annotation in any 
database and therefore not known to HOPE.  
 Over the past year, HOPE has analysed hundreds of mutations for users from all over the 
world. Subjectively, HOPE provides very accurate descriptions of the expected effects of mutations. 
These results will be discussed in Chapter 6a. 
 
Conclusion  
In conclusion, we compare HOPE’s performance with that of other popular methods using a  dataset 
of 37 manually analysed disease causing mutations from 15 articles published in 2010 in the 
American Journal of Human Genetics each of which includes a description of the effects on the 3D-
structure and/or function of the affected protein. We find that HOPE performs well compared to 
existing programs such as SIFT and Polyphen-2, but more importantly, HOPE provides more detailed 
mechanistic information that allows scientists to gain deeper insight into the reasons for a particular 
score. 
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Extension of the HOPE validation experiment with 2 more datasets 
We extended the validation of HOPE with two more datasets. Besides the mutations obtained from 
AJHG2010, we also studied 78 mutations described in randomly selected articles in other human 
genetics journals such as Human Genetics and Clinical Genetics. The selection criteria were similar to 
those used for the first dataset (description of at least one point mutation that is linked to a disease, 
and the availability of a 3D-structure or homology model). Another dataset consisted of 66 
mutations that we studied previously in collaborative projects. Again, we used Grantham, SIFT, 
PolyPhen-2, and HOPE to predict the effect of these mutations. The results for these two datasets, 
and the dataset described in chapter 6, are summarized in table 6.3.   
 
Table 6.3: Analysis of pathogenic mutations in 3 different datasets. Dataset 1 corresponds to the dataset 
described in the article in Chapter 6. 15 publications were selected from the 2010 volume of the American 
Journal of Human Genetics. Together, these 15 articles described the effects of 37 mutations using either the 
experimentally solved structure or a homology model. Dataset 2 consists of 78 mutations that were described 
in randomly selected publications in journals such as Human Genetics, Human Mutation, and the New England 
Journal of Medicine. Dataset 3 contains mutations that we studied previously in collaborations with biomedical 
colleagues. Most of these studies have also been published in various journals and many are mentioned in 
chapter 5. The  threshold for Grantham scores (benign < 62 < damaging) was obtained from Bell et al1. SIFT 
predicts either tolerated (does not cause a disease) or not-tolerated (causes a disease). PolyPhen-2 classifies 
mutation as ‘probably damaging’, ‘possibly damaging’, or 'benign'; the best correlation with experiment is 
obtained by considering the first two categories both as damaging. HOPE's decision tree produces rather 
elaborate results that have for this study been compressed onto ‘damaging’ and ‘benign’. 
 
 
 
Mutants Grantham SIFT PolyPhen-2 GH/SIFT/PF
2 agree 
HOPE 
Dataset 1 
(AJHG2010) 
37 59% >62 
 
81% not 
tolerated 
 
89% 
damaging  
(76% is 
“probably 
damaging”) 
59% (5% is 
completely 
wrong)  
92% indicates 
damaging 
mutant (76% 
obviously 
damaging)  
Dataset 2 
(random 
articles) 
78 71% >62  
 
90% not 
tolerated 
 
95% 
damaging  
(94% is 
“probably 
damaging”)  
67% (1% is 
completely 
wrong) 
94% indicates 
damaging 
mutant   (76% 
obviously 
damaging) 
Dataset 3 
(collaborative 
projects) 
66 70% >62  89% not 
tolerated 
 
97% 
damaging  
(95% is 
“probably 
damaging”)  
62%  97% indicates 
damaging 
mutant   
mutant   (82% 
obviously 
damaging) 
Total 181 68% 88% 95% 64% 95% indicates 
damaging 
mutant   
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The extended analysis serves two purposes. First, we wanted to see whether HOPE can 
indeed predict a pathogenic effect for the mutations that were identified as related to disease. 
Indeed, the results in Table 6.3 support the results that were described previously in Chapter 6. 
HOPE performs as good as the best methods with an average of 95% of the disease-causing 
mutations described as damaging. These results once more underline the value of structural 
information for the correct classification of mutations. Second, we wanted to compare the reports 
generated by HOPE with our own manual analyses of the same mutations, and with the analyses 
provided by the original authors. In the ideal situation HOPE should provide the same answer as a 
well-trained structural bioinformatician. A detailed comparison of the automatically generated 
reports with our manual analysis will results in a list of possible future improvements for HOPE. The 
reports and detailed results of this study are collected on the website 
http://www.cmbi.ru.nl/~hvensela/HOPEresults. 
The results showed that about 2/3 of the reports are correct, easily understandable for 
anyone with a limited background in bioinformatics, and provide insight in the effect of the mutation 
on the structure of the protein. The remaining reports are also correct and useful but sometimes 
incomplete and can, in our opinion, be improved in the near future. None of the HOPE reports 
contained errors. We found the following points for improvement: 
 Use the biological protein assembly for the analyses 
 Take multiple conformations of a protein into account 
 Use long-distance residue interactions 
 Include more information such as protein annotations and literature information 
 Analyse more post-mutation interactions 
These points will be discussed in the following paragraphs. 
 
Use the biological assembly  
In the optimal case we want to study a protein in its biological complex, when it is interacting with 
its biological ligand, etc. Unfortunately, due to the nature of the experiments it normally is 
impossible to mimic the exact biological situation in a protein crystal or NMR solution. As a result the 
PDB is filled with protein structures that are, for instance, complexed with unnatural ligands, or 
solved as a monomer while they function as a multimer in vivo. Currently, HOPE decides the 
structure that will be used on the basis of sequence identity, sequence length, experimental 
technique, and resolution. In some cases this does not result in the best choice. For example, almost 
half of the analyzed mutations in the PRPS1 protein occur at the surface of the protein. This protein 
functions as a hexamer, but the PDB file only contains a dimer. HOPE does indeed report the lost 
interactions on the dimer-surface but misses the lost interactions on the other surfaces that will 
disturb the hexameric complex. Instead, it mentions that interactions with other molecules might be 
lost. Technically spoken this answer is correct but it can be improved using the biological assembly of 
this protein. To solve this type of problem, we are planning to use macromolecular assemblies 
stored in the PISA database for our analyses. PISA contains the biological assemblies for each PDB-
file and will as such provide information about the location of interface surfaces on the proteins. 
 
Take multiple conformations of a protein into account 
Another point to consider during template selection is the fact that a protein can change its 
conformation when it fulfils its function. The KRAS protein, for example, adopts a different 
conformation depending on the binding of GTP or GDP. Both complexes are solved as separate PDB-
files. Residues might make essential contacts in one conformation and not in the other. Currently, 
HOPE cannot distinguish between these two forms and will use the one that fits its requirements 
(length, identity, etc) best. We will need to think of an analysis option that includes both 
conformations for these proteins. The heterogeneity of database annotations regarding function-
related conformational changes will make this a difficult problem to solve. 
 
Automated protein structure annotation of human disease variants - Appendix 6 
 
153 
 
Use long-distance-interactions 
In a few cases the mutation does not seem to have a severe effect on the function of the mutated 
residue itself. However, some of these residues are in close contact with other very important 
residues. For instance, HOPE does not (yet) know that the G382 in SPTC2 is one of the residues that 
supports ligand binding pocket residues and therefore HOPE does not use this important piece of 
information in the report. One small check for important functions in residues that surround the 
mutated one could improve the report in this case, but this would come at the risk of producing a 
large number of false-positive warnings. Currently, HOPE can already identify the effects of a 
mutation on a position next to a residue that makes a cysteine-bond, interaction with a metal-ion, 
ligand, or an active site. We are planning to extend this neighbour-analysis to residues that are in 
contact with the mutated residue via hydrogen bonds or ionic interactions. So, when a mutation 
affects a residue that makes, for instance, a salt bridge with an active site residue, this will be listed 
in the report.  
 
Include more information such as protein annotations, and literature information  
Some reports could be improved significantly if HOPE could use information that is currently not part 
of the Swiss-Prot annotation. Useful information includes facts like the location of the active site in 
SPTC2 and YARS2, or the function of the ‘Ig-like’ domains in PVRL4. HOPE cannot use information 
that neither is annotated somewhere in any way nor accessible through a protocol such as DAS. 
Adding new information to the sequence features section of the Swiss-Prot record of that particular 
protein will allow HOPE to access and use the data, thereby improving the predictions. Another 
option would be to use other servers that specialize in a very small but sometimes useful part of 
protein analysis. At this moment we are looking into the possibility to use more servers such as CBS' 
TargetP2 to obtain the location of signal peptides, ProP3 to obtain the location of cleavage sites, or 
TANGO to obtain aggregation properties. We are also planning to include domain-information from 
the InterPro-database4. Knowing the location and possible function of a domain will improve the 
reports for the mutations that destroy either the domain itself or the contacts with that domain. For 
instance, almost half of the analyzed PTPN11 mutations affected the interaction with another part of 
the protein5. As soon as HOPE knows that the other domain is an SH2 domain that has a function in 
regulation, we can add this information to the report.  
 Analyzing the results for almost 200 cases made us realize that an enormous amount of little 
facts is stored in the heads of experts all over the world or otherwise is carefully hidden in the 
literature. We realize that making all this knowledge accessible in databases will take a while, or is, in 
some cases, simply still impossible. 
 
Analyse more post-mutation interactions 
Currently, HOPE reports the effect of the mutations based on the interactions made in the wild-type 
structure. This means that any interaction that is lost will be mentioned in the report. However, 
during our research we found a few examples of mutations that introduced new interactions. These 
new interactions are difficult to predict, but can nonetheless affect the protein function, by locking 
the protein in a certain state. In many proteins, freedom of movement is required to fulfil their 
function and adding a new stabilizing interaction could render the protein less active. In the future, 
we will also study these new interactions that are introduced in the protein structure.  
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Conclusion 
This study resulted in a list of possible improvements for HOPE. Some, of these improvements 
require that scientists change their way of thinking about information and share their data using 
databases, such as Swiss-Prot. Some improvements will require a drastic change in the way data is 
stored in the HOPE database and will therefore take a while before they can be implemented, e.g. 
the addition of post-mutational information. Other improvements, like the use of PISA-assemblies, 
will be implemented soon and will thereby improve the reports. Additionally, we are planning to 
enable HOPE to quantify mutations. In the future, it should be possible to submit a list of candidate 
mutations that were found in a NGS-experiment. HOPE will then perform its analysis for all these 
mutants and sort them by the probability that the mutation at hand is causing the disease. This will 
become a useful option for the field of clinical genetics.  
It may be clear that HOPE is an on-going project that will never be finished, but at this 
moment HOPE can already provide that last piece that is needed to complete the molecular puzzle.   
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Summary 
The majority of all processes in our body are carried out by proteins; from the conversion of food 
into energy to the protection of cells against pathogens, and from growth-regulation to the 
transduction of signals across membranes. We can therefore call proteins the work-horses of our 
body. The function of a protein is enabled by its conformation, or structure, which in turn depends 
on the order of the amino acids, also known as the sequence. The amino acids are linked in a long 
chain which can fold into the final shape of the protein. The order of the amino acids is encoded in 
our DNA. Chapter 1 contains more detailed information about the amino acids and protein 
structures. 
During recent years, lots of research has been aimed at improving and accelerating the 
techniques that can be used to determine DNA sequences. As a result, it is now fairly easy to 
sequence (determine the order of) an individual’s DNA. This DNA sequence can be translated into the 
protein sequences and this is how recently many new protein sequences have been determined and 
stored in databases. Determining the 3D-structure of a protein, for instance by NMR or X-ray 
crystallography, is a more difficult and more time-consuming task. Currently, there is a wide gap 
between the number of known protein sequences and known protein structures, and this gap 
continues to grow. Fortunately, we can predict many of these (yet) unknown protein structures by 
using a technique called ‘homology modeling’. This technique uses the fact that proteins with 
approximately the same sequence will adopt approximately the same 3D-conformation. This means 
that we can predict the structure of one protein by using the structure of another protein that has a 
similar sequence. We describe this homology modeling technique as an 8-step process that is 
extensively discussed in chapter 2. Over the years, this technique has been used a lot, often in 
combination with other methods that can shed light on 3D-structures. More information about the 
developments and improvements in homology modeling and its combination with other 
spectroscopic techniques is provided in chapter 3.  
The use of 3D-structures/homology models can be of great value in (bio)medical research. As 
mentioned before, the technique for DNA-sequencing has greatly improved in recent years. Hospitals 
and research-departments are now routinely using the so-called ‘next generation sequencing’ 
technique to analyze the DNA-sequence of a patient suffering from a hitherto not understood 
disease or syndrome. Diseases caused by an abnormality in the DNA can be discovered by comparing 
the patient’s DNA with reference-DNA obtained from one or more healthy individuals. This is how we 
can discover many of these abnormalities, also known as mutations. Sixty percent of the 
abnormalities are found in the protein coding parts of the DNA, the genes. However, knowing the 
position of a mutation in the sequence is not enough to understand the effect of that mutation on 
the structure and function of the protein. The position in the sequence alone does not tell us 
whether the mutation is disturbing, for instance, the active site, a DNA-binding site, or dimerisation. 
In order to truly understand the effect of a mutation on the function of a protein it is necessary to 
study all available information about the protein in the context of its 3D-structure. Unfortunately, 
not every (bio)medical researcher has the possibility to use hardware and software required for an 
extensive structural analysis. Collaboration between geneticists and bioinformaticians often does not 
only result in a better understanding of the effect of a mutation on the 3D-structure and function of 
the protein, but it can also generate new ideas for future experiments. Eventually, this research 
could form the basis for the development of new medicines to treat the disease.  
During the last 5 years we performed many structural analyses in a series of collaborative 
projects. The development of the ‘next-generation-sequencing’-technique has caused an increase in 
the number of detected disease-causing mutations, and has thereby also increased the demand for 
structural analyses. We have developed an automatic approach for mutational analysis using all our 
knowledge and experiences obtained in these collaborations. The result of this work is HOPE, a web-
server for the automatic analysis of point mutations in proteins. HOPE collects information from 
several information sources, including the 3D-structure or homology model, and combines this into a 
report that describes the effect of the mutation on the structure and function of the protein. The 
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most important source of information will always be the 3D-structure. In case this structure is 
unavailable, HOPE will try to build a homology model using YASARA. The YASARA software was 
developed at the CMBI by my predecessor, Elmar Krieger, and can be used to visualize, analyze and 
predict protein structures. HOPE’s analysis of a model, or existing structure, is done using WHAT IF 
Web services. These analyses result in information about, for instance, the accessibility of the 
residue, the secondary structure, hydrogen bonds, etc. Besides that, HOPE will also collect 
information from other sources. The SwissProt database contains information that cannot directly be 
deducted from the protein structure, like names of protein domains or regions, the location of the 
active site, or known variants in the sequence. It is also interesting to know whether a residue is 
conserved or not and therefore HOPE obtains the conservation-scores from the HSSP database. In 
some cases no protein structure for a protein sequence is known yet and no template for homology 
modeling can be found. In these cases the structural analysis by the WHAT IF Web services cannot be 
performed. Fortunately, several servers exists that can predict properties of the protein based on the 
sequence alone. HOPE uses these servers to predict for instance the transmembrane domains, the 
secondary structure, and the location of phosphorylation sites. On top of that, HOPE will always 
compare the wild-type and mutant residue based on their amino acid properties (size, 
hydrophobicity, and charge). This is how HOPE can always produce a report that describes the effect 
of the mutant on the protein structure.  
HOPE’s interface was designed to be easy to use and understandable for everyone. The user 
only needs to submit the amino acid sequence of the protein of interest. In a next step the user can 
simply click on the mutated residue and indicate the new residue at that position. The complete 
process of choosing the structure for analysis or building the model if possible, collecting the 
information, and generating the report is done without intervention by the user. The report was also 
designed to be understandable for everyone in the (bio)medical field, even if they have no 
bioinformatics background. Bioinformatics and biophysics keywords are linked to our in-house 
bioinformatics dictionary for bio-medical researchers. The HOPE report is illustrated with pictures, 
including an overview of the complete protein as well as close-ups of the mutation. The report also 
contains animations that can be used in presentations or on websites. A more extensive description 
of the technical background of HOPE can be found in chapter 4. 
So far, many (bio)medical researchers have used the knowledge and technology provided by 
our bioinformatics department. Chapter 5 consists of a series of summarized articles that have been 
published about these projects.  Our contribution in these collaborations consisted of the analysis of 
the structural effects of one or more mutations. In a majority of the cases we had to build a 
homology model first. In a few cases homology modeling was not possible and we had to rely on 
methods that only use the protein sequence, such as predicting the transmembrane domains. In 
almost all cases our analysis provided the last little bit of insight that was required to understand the 
effect of the mutation completely. We used the knowledge and experience that we gained by 
participating in these projects to further develop HOPE.  
Chapter 6 describes the validation of HOPE. A large dataset of mutations was selected from 
the 2010 volume of the American Journal of Human Genetics. Both the mutations that were linked to 
a disease and the benign polymorphisms in the same proteins were analysed by HOPE and by three 
other widely used methods; Grantham, SIFT and PolyPhen-2. The results showed that Project HOPE 
can correctly identify 92% of the disease-linked mutations as ‘damaging’, and 67% of the 
polymorphisms as ‘benign’. Comparison of these results with the other 3 methods showed that the 
methods that can use structural information (PolyPhen-2 and HOPE) predict the effect of the 
mutation significantly better than the other methods. The added value of HOPE over PolyPhen-2 lies 
in the fact that the HOPE report not only explains that a mutation is damaging, but also why that 
mutation is damaging. The examples in chapter 6 show that this can be very helpful in cases where 
other methods disagree or in cases where more information is required for follow-up experiments. 
This analysis was extended with mutations from 2 other datasets. One dataset consisted of 
mutations that were collected from randomly selected articles published in journals such as Nature 
Genetics and Human Mutation. The third dataset consisted of mutations that were studied earlier in 
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collaborative projects, most of which are described in the summaries in chapter 5. The HOPE-reports 
generated for these mutations and the predictions provided by Grantham, SIFT, and PolyPhen-2 were 
compared with our own manual analyses and with the predictions by the authors of the articles. The 
results underline our previous findings that Project HOPE performs as good as PolyPhen-2. An 
extensive analysis of all reports revealed several possible points for improvement of HOPE. It is 
impossible to improve each of these points on a short term, for instance, because the required 
database or server simply does not yet exist. We also found that a large part of the information 
known in literature is not yet stored in databases that are accessible to programs such as HOPE. In 
the short term, HOPE will be able to use information about the biological protein-assemblies as 
stored in the PISA database. This is one step in the larger process of improving the choice for 
templates/structures that will be further analyzed in HOPE, and will be the first project of my 
successor. For a significant number of proteins, the structure was solved multiple times, for example 
in different conformations, or in interactions with different substrates. We would like to improve the 
choice for structures/templates so that HOPE can also use the information that is stored in all these 
different structures. Besides that, HOPE will soon be able to think about long-distance effects of 
mutations. A mutation from a small residue into a bigger one in the core of a protein, for instance, 
might affect another residue in its vicinity. When this particular residue has an important task, such 
as substrate binding, that task might be disturbed by this mutation. The current HOPE version only 
takes into account the function of the mutated residue itself and the ones that precede and follow 
the mutated residue in the sequence. The analysis will be extended to those residues that are close 
to the mutated one in the 3D space. Other results and ideas for HOPE’s improvement are discussed 
further in chapter 6 and 6a.  
HOPE could be used to determine the severity of mutations and to rank them based on their 
effect on the protein structure. In the future we would like to adapt HOPE in such a way that each 
effect of a mutation receives a score, and that HOPE can analyse multiple mutations at one go. This 
means that HOPE will be able to score and prioritize candidate mutations. Eventually, HOPE can 
become an essential component in the pipeline for the analysis of next generation sequencing data.  
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Samenvatting  
Verreweg de meeste processen ons lichaam worden uitgevoerd door eiwitten; van het omzetten van 
voedsel in energie tot het beschermen van cellen tegen indringers, en van het reguleren van groei tot 
het doorgeven van prikkels van buitenaf. We kunnen eiwitten daarom de werkpaarden van ons 
lichaam noemen. De functie van een eiwit wordt mogelijk gemaakt door de vorm, ofwel de structuur, 
van dat eiwit en deze structuur wordt weer bepaald door de volgorde van de aminozuren, ofwel de 
sequentie. De aminozuren zijn aan elkaar gekoppeld in een lange keten die opvouwt tot de 
uiteindelijke vorm van het eiwit. De volgorde van deze aminozuren ligt gecodeerd in ons DNA. In 
hoofdstuk 1 wordt ingegaan op de achtergrond van de aminozuren en eiwitstructuren. 
De afgelopen jaren is er veel onderzoek gedaan naar het verbeteren en versnellen van 
technieken om de DNA volgorde te bepalen. Het resultaat is dat het tegenwoordig relatief 
gemakkelijk is om DNA te sequencen (volgorde te bepalen). Wanneer de DNA volgorde bekend is kan 
deze vervolgens vertaald worden naar de aminozuur volgorde van een eiwit. Op deze manier zijn de 
laatste jaren vele nieuwe sequenties van eiwitten bepaald en opgeslagen in databases. Het bepalen 
van de 3D-structuur van deze eiwitten met bijvoorbeeld NMR of X-ray crystallografie is echter veel 
lastiger en duurt daarom ook veel langer. Er zijn op dit moment veel meer eiwit sequenties dan 
structuren bekend en dit verschil wordt alleen maar groter. Gelukkig kunnen we een deel van de 
(nog) onbekende eiwitstructuren bepalen door gebruik te maken van de techniek ‘homologie 
modeleren’. Deze techniek is gebaseerd op het feit dat eiwitten met ongeveer dezelfde sequentie 
ook ongeveer dezelfde structuur hebben. We kunnen dus een eiwitstructuur voorspellen op basis 
van een eiwit waarvan de sequentie enigszins lijkt op de sequentie van het eiwit van interesse. We 
hebben de homologie modeleer techniek onderverdeeld in 8 stappen die uitvoerig beschreven zijn in 
hoofdstuk 2. Door de jaren heen is deze techniek vaak gebruikt, soms in combinatie met andere 
methoden die iets kunnen zeggen over de 3D-structuur. Hoofdstuk 3 gaat dieper in op de 
ontwikkelingen, verbeteringen en het gebruik van homologie modeleren in combinatie met andere 
experimentele methoden. 
Het gebruik van deze 3D-eiwitstructuren en/of homologie modellen kan van grote waarde 
kan zijn voor het (bio)medisch onderzoek. Zoals al eerder vermeld is de techniek om DNA te 
sequencen de laatste jaren sterk verbeterd. Ziekenhuizen en onderzoekscentra gebruiken nu deze 
zogenaamde ‘next generation sequencing’ techniek om snel en gemakkelijk de DNA volgorde van een 
patiënt met een onbegrepen ziekte of syndroom te bepalen. Ziektes die veroorzaakt worden door 
een afwijking in het DNA kunnen ontdekt worden door de DNA volgorde van de patiënt te vergelijken 
met het referentie-DNA van een of meerdere gezonde personen. Op deze manier worden vele 
afwijkingen, ofwel mutaties, ontdekt die een ziekte kunnen veroorzaken. Zestig procent van de 
afwijkingen wordt gevonden in de delen van het DNA die coderen voor eiwitten; de genen. De kennis 
van de locatie van een mutatie in een gen zegt echter nog weinig over het effect hiervan op de 
structuur en dus op de functie van het bijbehorende eiwit. Aan alleen de mutatie in de eiwit 
sequentie is niet te zien of bijvoorbeeld de actieve site, de DNA binding site, of dimerisatie verstoord 
is. Om het werkelijke effect van een mutatie op de functie van het eiwit te begrijpen is het nodig om 
alle beschikbare informatie over het eiwit te bestuderen in het kader van de 3D-structuur. Helaas 
heeft niet elke (bio)medische onderzoeker de beschikking over de hardware en software die nodig is 
voor een uitgebreide structuur analyse. Niet alleen kan samenwerking tussen genetici en 
bioinformatici resulteren in begrip van het effect van een mutatie op de 3D-structuur en functie van 
het eiwit het kan ook nieuwe ideeen voor verder onderzoek opleveren. Uiteindelijk zou al dit 
onderzoek zelfs kunnen resulteren in de ontwikkeling van een medicijn voor de ziekte.  
Gedurende de afgelopen jaren hebben wij de structurele analyse verzorgd in diverse 
samenwerkingsprojecten. De ontwikkeling van de ‘next generation sequencing’ techniek heeft de 
ontdekking van ziekte-veroorzakende mutanten en daarmee de vraag naar structurele analyses doen 
toenemen. De afgelopen jaren hebben wij daarom gewerkt aan de mogelijkheid om deze mutanten 
automatisch te analyseren. Daarbij konden we gebruik maken van de kennis en ervaringen die deze 
samenwerkingsprojecten opleverde. Dit werk heeft geleid tot de ontwikkeling van Project HOPE, een 
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webserver voor de automatische analyse van puntmutaties in eiwitten. HOPE raadpleegt meerdere 
informatie-bronnen waaronder de 3D-structuur of een homologie model, en combineert de 
informatie tot een rapport waarin het effect van de mutant op de structuur en functie beschreven 
staat. De belangrijkste bron van informatie voor HOPE is altijd de 3D-structuur. Als deze niet 
beschikbaar is dan zal HOPE proberen een homologie model te laten bouwen door YASARA. YASARA 
is de software die door mijn voorganger, Elmar Krieger, aan het CMBI ontwikkeld is voor de 
visualisatie, analyse en voorspelling van eiwit-structuren. Voor HOPE wordt de analyse van een 
model, of van een bestaande structuur gedaan door WHAT IF Web services. De analyse resulteert in 
informatie over bijvoorbeeld de toegankelijkheid van het residue, de secundaire structuur, 
waterstofbruggen, enz. Daarnaast raadpleegt HOPE ook informatie uit andere bronnen. Zo bevat de 
SwissProt database informatie die niet rechtstreeks afgelezen kan worden uit een structuur, zoals de 
namen van eiwit-domeinen of regionen, de locatie van de active site of bekende variaties in de 
sequentie. Daarnaast is het interessant om te weten hoe geconserveerd een residue is en daarom 
gebruikt HOPE de conserverings-scores uit de HSSP database. Het komt natuurlijk voor dat de 
structuur bij een bepaalde sequentie nog niet is opgehelderd en dat er ook geen enkele homologe 
structuur bekend is. De structurele analyse door de WHAT IF Web services kan dan niet worden 
uitgevoerd. Er bestaan echter wel servers die op basis van alleen een sequentie bepaalde 
eigenschappen kunnen voorspellen. HOPE gebruikt deze servers voor het voorspellen van o.a. de 
transmembraan domeinen, de secundaire structuur en de locatie van phosphorylatie plaatsen. 
Bovendien zal HOPE altijd het oude en het nieuwe aminozuur, dus het wildtype en de mutant, 
vergelijken op basis van hun eigenschappen (grootte, hydrofobiciteit en lading). Op deze manier kan 
HOPE altijd een rapport produceren dat een beschrijving geeft van het effect van de mutatie op de 
structuur van het eiwit.  
Het interface van HOPE is ontworpen om zo gemakkelijk en begrijpelijk mogelijk te zijn voor 
iedereen. De gebruiker hoeft alleen maar de aminozuur sequentie van het eiwit in te vullen. Daarna 
kan hij/zij op de website het gemuteerde aminozuur aanklikken en het nieuwe aminozuur op die 
locatie aangeven. Het totale proces van het kiezen van de structuur of het eventuele bouwen van het 
model, het verzamelen van informatie en het produceren van het rapport gebeurt zonder 
tussenkomst van de gebruiker. Het HOPE-rapport is zo opgesteld dat het te begrijpen is voor alle 
onderzoekers uit het (bio)medische veld, ook voor hen die maar weinig kennis van structurele 
bioinformatica hebben. Eventuele lastige woorden uit het bioinformatica/biofysica-veld kunnen via 
een help-knop worden doorgelinkt naar ons eigen bioinformatica woordenboek. Het HOPE-rapport is 
geïllustreerd met afbeeldingen van zowel een overzicht van het gehele eiwit als close-ups van de 
mutatie. Daarnaast bevat het rapport ook bewegende animaties die te gebruiken zijn in bijvoorbeeld 
presentaties of op websites. We hopen dat Project HOPE hiermee zo gemakkelijk en 
gebruiksvriendelijk mogelijk is voor iedereen in het (bio)medische onderzoek. Een uitgebreide 
beschrijving van de technische achtergrond van Project HOPE is te vinden in hoofdstuk 4. 
Vele (bio)medische onderzoekers hebben intussen gebruik gemaakt van de kennis en 
technologie die onze bioinformatica afdeling te bieden heeft. Hoofdstuk 5 bestaat uit 
samenvattingen van de hierover gepubliceerde artikelen. Ons aandeel in deze samenwerkings-
projecten bestond uit het analyseren van het effect van een mutatie op de eiwit structuur. In het 
grootste gedeelte van deze gevallen was het nodig om eerst een homologie model te bouwen. In een 
klein aantal projecten was het zelfs niet mogelijk om een homologie model te maken en moesten we 
teruggrijpen op technieken die alleen maar gebruik maken van de sequentie, bijvoorbeeld het 
voorspellen van transmembraan-domeinen. In vrijwel alle gevallen leverde de analyse net het laatste 
stukje begrip dat nodig was om het effect van de mutatie te begrijpen. De kennis en ervaringen die 
wij verkregen uit deze projecten konden worden gebruikt om HOPE te optimaliseren. 
Hoofdstuk 6 beschrijft de validatie van HOPE. Een grote dataset werd samengesteld uit 
mutaties beschreven in de 2010 jaargang van het American Journal of Human Genetics. Zowel de 
ziekte-gerelateerde mutaties als de goedaardige polymorfismes in dezelfde eiwitten werden 
geanalyseerd door HOPE en door 3 andere veelgebruikte methodes; Grantham, SIFT en PolyPhen-2. 
Uit de resultaten bleek dat HOPE 92% van de ziekte-gerelateerde mutaties inderdaad voorspeld als 
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‘negatief effect op het eiwit’ en 67% van de polymorphismes als ‘geen negatief effect op het eiwit’. 
Vergelijking van deze resultaten met de andere 3 methodes wees uit dat methodes die gebruik 
maken van structurele informatie (PolyPhen-2 en HOPE) een significant betere voorspelling 
opleveren dan de andere methoden. De toegevoegde waarde van HOPE ten opzichte van PolyPhen-2 
ligt in het feit dat het HOPE report niet alleen uitlegt dat een mutatie mogelijk een negatief effect 
heeft, maar ook waarom dit zo is. De voorbeelden in hoofdstuk 6 laten zien dat deze kennis erg 
waardevol kan zijn in die gevallen waarbij de andere methodes geen eenduidige antwoorden geven. 
Ook voor bijvoorbeeld het opzetten van vervolg-experimenten is inzicht in het structurele effect van 
een mutatie zeer waardevol.  
De analyse werd uitgebreid met 2 andere datasets van mutaties. Een van deze datasets 
bestond uit mutaties die verzameld werden uit andere willekeurig geselecteerde artikelen 
gepubliceerd in bijvoorbeeld Nature Genetics en Human Mutation. De derde dataset bestond uit 
mutaties die we al eerder bestudeerden in samenwerkingsprojecten. Een deel van deze projecten 
wordt ook beschreven in de samenvattingen in hoofdstuk 5. De HOPE rapporten behorende bij deze 
mutaties en de voorspellingen van Grantham, SIFT en PolyPhen-2 werden vergeleken met onze eigen 
handmatige analyse en met de analyses gedaan door de auteurs van de artikelen. De resultaten zijn 
in overeenstemming met de eerdere bevindingen dat HOPE’s resultaten vergelijkbaar zijn met die 
van PolyPhen-2. Een uitgebreide analyse van alle rapporten onthulde een aantal mogelijke 
verbeterpunten voor HOPE. Het is onmogelijke om op korte termijn aan al deze punten te werken, 
bijvoorbeeld omdat de vereiste database of server nog niet bestaat. Ook bleek dat een groot deel 
van de in literatuur bekende informatie nog niet is opgenomen in databases die toegankelijk zijn voor 
programma’s zoals HOPE. Op korte termijn zal HOPE wel in staat zijn om beter gebruik te maken van 
de informatie over biologische eiwit-complexen zoals deze is opgeslagen in de PISA database. Dit is 
een onderdeel van een grote verbeterstap in het kiezen van de juiste structuur voor verdere analyse 
en zal het eerste project worden van mijn opvolger. Voor een aantal eiwitten is de structuur 
meerdere malen, in verschillende vormen of met verschillende substraten, bepaald. We willen de 
keuze voor de juiste structuur verbeteren zodat HOPE zoveel mogelijk gebruik kan maken van de 
informatie opgeslagen in al deze structuren. Daarnaast zal HOPE binnenkort kunnen kijken naar de 
lange-afstands effecten van mutaties. Het is bijvoorbeeld mogelijk dat een mutatie van een klein 
naar een groot residue in de kern van het eiwit effect heeft op een residue in de buurt. Wanneer dit 
buur-residue een belangrijke taak heeft, zoals bijvoorbeeld het binden van een substraat, zal deze 
functie worden verstoord. Op dit moment kijkt HOPE alleen nog maar naar de functie van het 
gemuteerde residue zelf en naar het voorgaande/volgende residue in de sequentie. Deze analyse zal 
uitgebreid worden met de residuen die in de 3D-omgeving van het gemuteerde residue liggen 
Uitgebreide resultaten van HOPE’s validatie en de daaruit voortkomende ideeën voor verbeteringen 
zijn beschreven in hoofdstuk 6 en 6a.  
HOPE zou gebruikt kunnen worden om de ernst van de structuurverstoring te bepalen voor 
een aantal mutaties en deze vervolgens te rangschikken. In de toekomst willen we dan ook HOPE 
zodanig aanpassen dat elk effect van de mutatie een aparte score krijgt en dat meerdere mutanten 
tegelijk geanalyseerd kunnen worden. HOPE zal dan dus kandidaat mutaties kunnen scoren en 
rangschikken. Op deze manier kan HOPE uiteindelijk een onderdeel worden van de pijplijn voor het 
analyseren van next generation sequencing data.  

Dankwoord - CV - Publicaties 8 
 
164 
 
  
Previous page: 
Crambin – This small plant protein was used 
frequently to test our software systems. (PDB 
file 1crn) 
Dankwoord - CV - Publicaties 8 
 
165 
 
Dankwoord 
Mijn proefschrift had nooit tot stand kunnen komen zonder de hulp en support van een aantal 
mensen die ik hier graag even wil vermelden.  
Ten eerste natuurlijk Prof. dr. G. Vriend, ofwel Gert. Al in het tweede jaar van mijn studie heb je me 
enthousiast gemaakt voor de bioinformatica, al duurde het nog een paar jaar (plus een niet zo'n 
succesvolle poging op het lab) voor ik werkelijk voor het computerwerk durfde te kiezen. Dankzij jouw 
visie op de bioinformatica vs. onderzoekswereld kon dit project tot stand komen. Jij durfde het aan 
om een niet-typische bioinformaticus aan te stellen op een niet-typisch onderwerp, ook al geloofden 
een aantal collega's in eerste instantie niet in het slagen van dit project. Ik ben je dankbaar voor alle 
kansen die ik gekregen heb om mij te kunnen ontwikkelen tot wie ik ben, zowel tijdens als buiten het 
werk. Ik blijf met plezier nog even hangen... 
Prof. dr. H. Brunner, beste Han. Officieel was ik bij jou in dienst, al heb ik nooit helemaal begrepen 
hoe dit boekhoudkundig in elkaar zat. In de praktijk bleek de samenwerking tussen antropogenetica 
en het CMBI heel erg vruchtbaar en heeft verschillende mooie publicaties opgeleverd. Ik hoop dat we 
in de komende jaren nog meer voor elkaar kunnen betekenen. 
Tim en Remko, soms omschrijf ik jullie als 'mijn technische mannen'. Ik besef heel goed dat er weinig 
HOPE was geweest zonder jullie technische kennis. Ik hoop dat jullie dit proefschrift dan ook een 
beetje als jullie eigen verdienste kunnen zien. Mijn 'roomies' voor soms korte, soms lange tijd, 
Maarten, Robbie, Bas en Jules. Naast het feit dat ik jullie altijd lastig mocht vallen met (soms 
stomme) vragen, heb ik jullie ook als zeer prettige collega's leren kennen. Ik ben blij dat er op onze 
kamer naast gesprekken over computers ook aandacht was voor allerlei andere politieke, 
maatschappelijke, culturele, etc, onderwerpen. Robbie/Bas, het deed mij plezier om jullie blijdschap 
te zien toen de gezinsuitbreiding zich aandiende. Veel geluk met jullie gezinnetjes. Jules, wij gaan 
gewoon nog even gezellig verder aan HOPE. En Maarten, jouw hulp en programma's houden voor een 
groot deel HOPE (en nog veel meer) draaiende, dank daarvoor! Prof. Dr. Roland Dunbrack. I've only 
spent a month in your lab in Philly, but it was an experience of a life-time. You gave me the chance to 
see and feel another lab, another country, and another culture, thank you so much for this 
opportunity! Lisa, Annika, Franscesca, Shima en Marlou, om de 1 of andere reden heb ik alleen maar 
vrouwelijke studenten gehad om te begeleiden. Girl-power dus! Jullie hebben allemaal je eigen 
bijdrage geleverd aan HOPE. Vele mutaties en artikelen hebben jullie bestudeerd en deze kennis is 
gebruikt om HOPE nog beter en duidelijker te maken. Ik hoop dat jullie met plezier terugkijken op je 
stage, veel succes in jullie verdere carrière. 
Het CMBI is natuurlijk veel groter dan kamer 0.19. Ik wil al mijn collega's bedanken voor de zeer 
prettige sfeer op onze afdeling, maar een paar mensen verdienen toch echt een aparte vermelding. 
Barbara, stiekem het organisatorische middelpunt van het CMBI, er is niks wat jij niet weet of op kan 
lossen. Bedankt voor al het regelwerk (en het openen van de deur als ik weer eens mijn pasje vergat). 
Wilmar, jij houdt de afdeling technisch gezien draaiende. Bedankt voor al je hulp als mijn pc of de 3D-
beamer weer eens gek deed. Elmar (CMBI-outstation in Austria), where would we be without 
YASARA?? There is no other program that has been so important during my Ph.D, and I cannot 
imagine what the first-year-bioinformatics course would look like nowadays without it. I'd also like to 
thank you for answering my numerous questions about obscure YASARA options. I wish you and your 
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family all the best. Even een aparte vermelding voor NBIC. Ik ben jullie samen met alle bioinformatici 
erg dankbaar voor het organiseren en samenbrengen van bioinformatica in Nederland. Samen met 
mijn mede RSG-leden heb ik van jullie steun mogen genieten.  
Geen enkel proefschrift wordt door een enkel persoon geschreven. Mijn proefschrift is echter een 
extreem geval van vele samenwerkings-projecten. Het gevolg is dat ik vele bladzijdes nodig zou 
hebben om al mijn collega's op andere afdelingen te bedanken. Ik hoop echter dat zij zelf beseffen 
dat HOPE niet alleen voor, maar ook door hen tot stand is gekomen. Ik ben blij dat ik zoveel mensen 
van dienst heb kunnen zijn en dat mijn analyses zo vaak net een laatste beetje extra toe hebben 
kunnen voegen aan hun werk.  
En dan komen we buiten het CMBI, maar niet helemaal buiten de universiteit. Ik wil mijn ex-
studiegenoten bedanken voor de fantastische studententijd die ik heb gehad. Met sommigen van 
jullie heb ik later nog samen mogen werken, anderen zie ik helaas niet zoveel meer. Miriam, Fieke en 
Jordy, vrienden-sinds-de-intro, door drukke schema's zie ik jullie niet zo vaak als ik zou willen, maar ik 
ben dankbaar voor elke minuut dat we samen leuke dingen kunnen doen. Buiten de universiteit heb 
ik door de jaren heen ook vele mensen leren kennen die allemaal om een andere reden speciaal voor 
me zijn. Mijn vrienden in de Poleworld. Met jullie leef ik soms bijna in een parallel universum, wat 
een mooi contrast vormt met de academische wereld. Bedankt voor alle leuke uitjes/shows/ 
evenementen/activiteiten die ik met jullie heb mogen meemaken! Eva, met jou kan ik af en toe een 
laagje dieper, je hebt me een aantal bijzondere dingen geleerd, bedankt voor je steun in voor en 
tegenspoed! En dan natuurlijk Michel: soms zoek je 10 jaar naar iets, en dan ligt het recht voor je 
neus ;-) Ik ben blij dat onze wegen zich toch samengevoegd hebben. Er komen nog vele avonturen die 
we samen aan kunnen gaan!  
En dan als laatste, maar natuurlijk niet het minste: mijn familie.... Je familie is waar het mee begint, de 
mensen die je vormen in je eerste levensjaren en ervoor zorgen dat je de persoon wordt die je bent. 
Matthijs, mijn kleine broertje dat nu ruim een kop groter is dan ik. Ik kan nog steeds niet geloven dat 
dat kleine opdondertje nu studeert, autorijdt en werkt! Ik wens je al het beste in wat er nog komen 
gaat. Marjolein, mijn kleine zusje. Voor mensen is het soms moeilijk te geloven dat we zussen zijn, zo 
verschillend lijken we soms. Toch denken en doen we ook vaak hetzelfde...kijk alleen maar naar het 
feit dat jij nu ook al dr. bent  :-p Ik ben er trots op dat jij mijn zusje bent. Rens, sinds september 2011 
deel van onze familie, en wat ben ik daar blij mee. Je bent een geval apart, super-eigenwijs soms, 
maar dat is ook wat ik in jou waardeer. Zolang het maar geen mainstream is, is het goed! Bedankt dat 
je zo vaak voor me klaar staat.   Pa en ma, de allerbelangrijkste mensen in mijn leven... nu pas zie ik in 
hoe jullie mij gevormd hebben en hoe dankbaar ik mag zijn voor alle zorg en steun die ik altijd van 
jullie heb gehad. Zonder jullie was ik nooit geweest wie ik nu ben. Ik zou nog pagina’s vol kunnen 
schrijven, maar dat zou nog niet genoeg zijn om duidelijk te maken wat een fijne, lieve, maar vooral 
bijzondere familie ik heb ….dank voor alles... 
Liefs, Hanka 
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Curriculum Vitae 
Hanka Venselaar werd geboren op 27 oktober 
1982 in Tilburg en groeide op in Berkel-Enschot. 
In 2001 behaalde zij haar VWO-diploma aan het 
Tilburgse Cobbenhagen College en behoorde 
daarmee tot de eerste lichting 2de-fase 
scholieren. Hierna ging zij Moleculaire 
Levenswetenschappen studeren aan de Radboud 
Universiteit Nijmegen. Zij deed haar eerste stage 
aan het Centrum voor Moleculaire en 
Biomoleculaire Informatica (CMBI) onder leiding 
van Prof. Dr. Gert Vriend en dr. Sander Nabuurs. 
Een tweede stage deed zij op de afdeling 
Antropogenetica onder leiding van dr. Joris 
Veltman en dr. Lisenka Vissers waarna zij in in 
oktober 2006 haar doctoraalexamen behaalde. 
Hierna keerde zij terug naar het CMBI om te 
starten als junior onderzoeker op het onderwerp 
"Toepassingen van Homologie Modeleren". 
Tijdens deze periode bracht zij een maand door 
op het lab van Prof. dr. Roland Dunbrack in 
Philadelphia. Het werk dat verricht is gedurende 
deze jaren heeft geleid tot dit proefschrift en een 
online systeem voor automatische mutant 
analyse genaamd "HOPE". Gedurende haar 
onderzoeksperiode was Hanka ook board-
member van de Regional Student Group (RSG) 
waarmee zij activiteiten voor jonge 
bioinformatica-onderzoekers organiseerde. Naast 
haar werk als onderzoeker is Hanka ook docent 
en artieste (lucht)acrobatiek en sinds januari 2011 
eigenaar van haar eigen bedrijf "Studio Ad Astra".  
Hanka Venselaar was born on October 27th in 
Tilburg and grew up in Berkel-Enschot. She 
attented highschool at the Cobbenhagen 
College in Tilburg where she received her VWO-
diploma in 2001. She was one of the first so-
called  "2nd phase students". She then started 
her studies, Molecular Life Sciences, at the 
Radboud University Nijmegen. She did her first 
internship at the Centre for Molecular and 
Biomolecular Informatics (CMBI) under 
supervision of Prof. Dr. G. Vriend en dr. Sander 
Nabuurs. She did a second internship at the 
department of Human Genetics under 
supervision of dr. Joris Veltman and dr. Lisenka 
Vissers. She obtained here Master's degree in 
October 2006 after which she returned to the 
CMBI. As a PhD student she studied the 
"Applications of Homology Modelling". During 
this period she visited the lab of Prof. dr. Roland 
Dunbrack in Philadelphia for a month. These 
years of research have lead to this thesis and an 
online system for automatic mutant analysis 
called "HOPE". During her time as researcher at 
the CMBI Hanka was also a board member of 
the Regional Student Group. Together with her 
fellow board-members she organized activities 
for young bioinformatics-researchers in the 
Netherlands. Besides her work as PhD student 
Hanka is also an (aerial) acrobat and instructor. 
Since Januari 2011 she is the proud owner of 
her own company "Studio Ad Astra". 
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